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Breast cancer is one of the most prevalent and deadly forms of cancer in women and is 
not restricted by race or ethnicity. Although a wealth of knowledge has been amassed on the 
biology of breast cancer, including its risk factors, diagnosis, prognosis, prevention, and 
treatment, it remains a serious health concern and active area of research. Initial response to 
standard chemotherapeutic and radiotherapeutic regimens is generally strong for many patients, 
yet breast tumors often recur, leading to more aggressive and resistant tumors. Because 
recurrence is such a clinical issue, more effective therapeutic approaches are needed to eliminate 
partial clinical responses and undesirable side effects. 
Molecular chaperones like the heat shock protein 90 (Hsp90) family are regarded as 
ubiquitous, highly conserved proteins that mainly respond upon induction of stress or disruption 
in cellular homeostasis. Chaperones are critically involved in controlling the conformation, 
stability, function, and degradation of many oncogenic client proteins by assisting in trafficking, 
remodeling of improperly folded client proteins, and suppression of protein aggregation. Hsp90-
mediated folding events are an ATP-dependent process that involves the association with various 
co-chaperones and stimulators, including Hsp70, Hsp40, HOP, p23, and Aha1 for client 
stabilization and modification. Notably, Hsp90 seems to be particularly associated with cell 
signaling clientele, such as nuclear hormone receptors, protein kinases, and many other 
oncogenic proteins that directly influence the hallmarks of cancer. 
In order to define the role of chaperones in breast cancer progression, we assessed 
chaperone expression levels in normal and tumor lines. Based on our initial finding of increased 
expression of Hsp90 and p23 in immortal and cancer cell lines, it is possible that this 
phenomenon may be reflected in normal breast tissue as well as breast carcinoma specimens. 
Indeed, we observed high Hsp90 expression in invasive carcinomas, such that high nuclear 
expression correlates with a greater TNM stage, while high cytoplasmic Hsp90 correlates with 
ER negativity, suggesting that elevated Hsp90 may be an indicator or marker of advanced 
disease.  p23 expression also increases appreciably in established breast cancer cell lines with 
invasive breast tissue specimens displaying an opposite trend. Although p23 does not appear to 
have any relationship with TNM stage, significant relationships with ER and PR emerged, with 
higher nuclear p23 correlating to ER positivity and higher total p23 being positively associated 
with PR presence. Due to the differential expression of Hsp90 in normal, DCIS, and invasive 
breast carcinomas, we determined the impact on Hsp90 function, finding that total Hsp90 in 
tumor cells is associated with an increase in both complexed and uncomplexed Hsp90, which is 
in contrast to a previously reported study. 
The intrinsic nature of heat shock proteins makes them especially relevant to a cell’s 
defense against cancer initiation. The preferential accumulation of Hsp90 in cancer cells also 
forms the basis for the unique sensitivity of tumor cells to Hsp90 inhibition. The Hsp90 specific 
inhibitor, radicicol, is more potent in terms of blocking ATPase activity than other Hsp90-related 
compounds like geldanamycin, which is much more toxic. All Hsp90 inhibitors prevent the 
association of the co-chaperone p23 with Hsp90, resulting in destabilization of the client protein. 
For these reasons, it may be possible that Hsp90 inhibition would sensitize breast cancer cells to 
be more responsive to standard chemotherapeutics. We determined that radicicol negatively 
alters cellular proliferation, and in combination with Adriamycin, elicits a more robust decline in 
growth and the expression of Hsp90 client proteins. This finding was associated with an increase 
in senescent cells without a detectable affect on apoptosis. Radicicol in combination with 
cisplatin or Taxol contributed to an increase in cell death (apoptosis) and differentially altered 
the expression of client proteins. Finally, ER negative breast cancer cells do not display altered 
p53 expression upon radicicol and Adriamycin treatment. Blockade of ER activity in ER positive 
cells with tamoxifen induced significant reductions in proliferation and decreased p53 expression 
without a corresponding decrease in p21 levels. In conclusion, these results point to the utility of 
Hsp90 inhibition as a valid form of targeted therapy for breast cancer, and the value of radicicol 
as a potential adjuvant treatment option in combination with standard chemotherapeutics. 
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Chapter 1 
Introduction and Review of Current Literature 
 
1.1 Hallmarks of Cancer 
Breast cancer is one of the most prevalent forms of cancer and cause of mortality in 
women and is not restricted by race or ethnicity.1 Although a wealth of knowledge has been 
amassed on the biology of breast cancer, including its risk factors, diagnosis, prognosis, 
prevention, and treatment, it remains a serious health concern and active area of research. It is an 
especially multifaceted disease with both genetic and environmental factors contributing to its 
layers of complexity. Despite the unpredictable nature of cancer, it still adheres to fundamental 
principles and patterns of transformation, although the pathways and mechanisms may vary 
between cancer types. On a basic level, a collection of genomic alterations need to accrue, 
persist, and bypass defenses in order for normal cells to convert into tumor cells. In doing so, 
homeostasis within the cell and in the surrounding environment is disrupted, leading to a 
malignant phenotype.  
As general features, the hallmarks of any cancer include self-sufficient growth signals, 
insensitivity to anti-growth signals, limitless replication potential, evasion of apoptosis, continual 
angiogenesis, and invasion and metastasis (Figure 1) (Hanahan and Weinberg, 2000). Although 
the mechanisms by which a tumor cell acquires these capabilities may vary, these six alterations 
nevertheless reflect the intricacy of cancer development. In addressing the first capability, 
normal cells require growth signals in order to proliferate, while tumor cells have a reduced 
dependence on such exogenous factors since they produce and respond to their own signals. 
Such autocrine stimulation obviates the need for growth factors from neighboring cells (Fedi et 
                                                 
1 http://www.cancer.gov/cancertopics/types/breast  
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Figure 1: The six hallmarks of cancer. Although the mechanisms by which these 
characteristics are obtained vary, cancer cells fundamentally are armed with the ability to fulfill 
these alterations.  As a reflection of the complexity and intricacy of cancer development, these 
hallmarks include self-sufficient growth signals, insensitivity to anti-growth signals, limitless 
replication potential, evasion of apoptosis, continual angiogenesis, and invasion and metastasis. 
Adapted from Hanahan and Weinberg, 2000. 
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 al., 2000). However, it is important to realize that contributions from surrounding stroma and 
other nearby normal cells may also facilitate tumor progression (Weigelt and Bissell, 2008). 
Additionally, growth factor receptors may be overexpressed in cancer cells, allowing for 
hypersensitivity to such signals, or may become ligand-independent. For example, the HER2/neu 
receptor is overexpressed in mammary cancers and associates with aggressiveness while a 
truncated EGF receptor lacking its cytoplasmic domain remains constitutively active 
(Kurebayashi, 2001; Wiley, 2003; Khazaie et al., 1993). The presence of pro-growth signals is 
balanced by the action of anti-growth signals. Normal cells respond to growth inhibitory factors 
by entering quiescence or a postmitotic state, thereby surrendering their proliferative potential 
(Hanahan and Weinberg, 2000). Mediated mostly by p53, and pRb and its effector TGFβ, anti-
growth signaling pathways are disrupted in cancer cells (Weinberg, 1995). This occurs via 
downregulation or mutation of the TGFβ receptor or detrimental modification of downstream 
signaling factors, cell cycle inhibitors, or cyclin-CDK complexes (Fynan and Reiss, 1993; Chin 
et al., 1998; Zuo et al., 1996). In order to ensure continued cell growth, tumor cells have also 
acquired the potential to propagate indefinitely. In this state of immortalization, normal growth 
boundaries are breached in part by maintaining telomere length (Wright and Shay, 2005). 
In addition to altered growth properties, cancer cells also have deregulated cell death 
processes. Evolutionarily conserved, programmed cell death is mainly mediated by death 
receptors (extrinsic pathway) or the mitochondria (intrinsic pathway), either of which can be 
dysfunctional in tumor cells (Fulda, 2008). As an example, loss of TRAIL (TNF-related 
apoptosis inducing ligand) death receptors from the cell surface attenuates TRAIL-induced 
apoptosis and is associated with TRAIL-resistance in breast cancer cells (Zhang et al., 2009; 
Zhang and Zhang, 2008). Once a tumor has been established with these malignant properties, it 
 4
must further ensure survival and increase in size by gaining angiogenic abilities (Hanahan and 
Folkman, 1996). In breast carcinomas, increased microvascularization was found to be 
associated with metastasis and poorer prognosis (Weidner et al., 1992). Finally, in later stages, 
cells from the primary tumor acquire the capability to invade adjacent tissues and migrate to 
other distant sites. This cascade of events is initiated by the escape of tumor cells from the 
primary mass followed by intravasation, survival in the blood stream, extravasation, and 
colonization and growth at secondary sites (Mazzocca and Carloni, 2009). For breast cancer, 
metastases primarily form in the bone, an environment that contains stromal cells with osteolytic 
properties that facilitate tumor establishment (Suva et al., 2009). The effects of invasion and 
metastasis are ultimately the main factors contributing to cancer mortality, accounting for over 
90% of deaths in breast cancer (Bendre et al., 2003; Couzin J, 2003; Sporn, 1997).  
 
1.2 Role of p53 in Breast Cancer 
One key feature that the hallmarks of cancer share in common is the involvement of the 
tumor suppressor protein, p53. The p53 signaling pathway is essential in preventing malignant 
transformation since malfunction of this regulator is the most common alteration in human 
cancers (Gasco et al., 2002). Furthermore, patients with Li-Fraumeni syndrome, in which a 
germline mutation of p53 exists, are greatly predisposed to tumor development, especially of the 
breast, brain, and soft tissue sarcomas (Akashi and Koeffler, 1998). Upon cellular stress, 
activation of this pathway occurs via ATM, ATR, or DNA-PK, all of which act as sensors in the 
cascade (Figure 2) (McGowan and Russell, 2004). These sensors can then phosphorylate p53 at 
specific serine residues, releasing it from its normal interaction with MDM2 and stabilizing it. 
The subsequent increase in p53 levels results in upregulation of p21Waf1/Cip1, a cyclin-dependent 
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Figure 2: p53 mediates the DNA damage response. A variety of insults can lead to activate 
checkpoint mechanism and trigger a DNA damage response. Signaling occurs mainly via ATM 
and ATR, which in turn stimulates a cascade of events, including activation of p53. The 
culmination of these activities contributes to cell cycle arrest followed by resolution of the 
damage via DNA repair, or other cellular fates, including senescence and apoptosis. Replicative 
senescence may have evolved as part of an anti-tumor protective mechanism, whereby bypassing 
this checkpoint may lead to neoplastic transformation. Apoptosis may have evolved as a 
mechanism of ensuring survival of only undamaged cells and thus maintaining genomic 
integrity. Adapted from Diehl et al., 2009. 
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kinase inhibitor that acts to suppress the kinase activity of cyclinE/cdk2 (Bartek and Lukas, 
2001). Activation of p53 ultimately triggers its sequence-specific DNA binding to target genes, 
allowing for their transcription. 
The role of p53 has been extensively studied in breast carcinogenesis and it is now 
known that inactivation of p53 occurs through a variety of mechanisms (Gasco et al., 2002). The 
p53 gene is the most commonly mutated gene, occurring in approximately 50% of all human 
cancers. Most mutations, about 85%, are missense mutations that generate mutant p53 that lacks 
the ability to bind target gene DNA in a sequence-specific manner, either through mutation of the 
codons within this region or alteration of p53 conformation (Wong et al., 1999). The mutations 
in DNA binding domains of p53, but not in non-conserved domains, were found to be associated 
with more aggressive mammary cancers (Alsner et al., 2000). Specifically for breast cancer, 
coding mutations create somatic changes, but the generation of these mutant p53 proteins occurs 
only about 20% of the time (Pharoah et al., 1999). This percentage increases in patients with 
concurrent germline mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2 
(Greenblatt et al., 2001). In addition to mutations of p53 itself, modification of p53 interactors 
may occur. For instance, reduced protein expression of the upstream kinase, ATM, or of Chk2, 
which also activates p53, is apparent in sporadic breast cancer (Angele et al., 2000; Sullivan et 
al., 2002). The role of p21Waf1/Cip1 in modulating breast cancer is less clear, but the general 
consensus indicates that this CDK inhibitor is associated with poorer prognosis and drug 
resistance (Abukhdeir and Park, 2008). Finally, p53 inactivation may be due to cytoplasmic 
sequestration in which wild-type p53 is excluded from the nucleus, thus prohibiting its 
transcriptional activity (Moll et al., 1992). 
In all, descriptive and mechanistic studies of p53 have produced abundant data on the 
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biology and function of wild-type and mutant p53, including the compilation of a growing list of 
its target genes and protein interactors (Vousden and Lu, 2002).2 Since its first description in 
1979, it is clearly evident that this tumor suppressor protein is involved in the pathways 
contributing to the classic cancer hallmarks (Lane and Crawford, 1979; Lacroix et al., 2006). 
Upon DNA damage, p53 induces cell cycle arrest to allow for DNA repair or apoptosis when 
damage is beyond repair, but this process malfunctions when p53 is mutated, thus leading to loss 
of growth regulation. In this manner, normally latent genes controlling cell proliferation and 
survival are transcriptionally activated, thus increasing tumorigenic potential. Negative cell cycle 
regulation by wild-type p53 primarily occurs via p21Waf1/Cip1 (CDK inhibitor family member), 
which, in concert with p16 (member of INK4 family specific to Cdk4 and Cdk6) inhibits cyclin-
cdk complexes (Sherr, 1996). These actions thereby prevent phosphorylation (inactivation) of 
pRb and subsequent G1/S phase cell cycle arrest (Cadwell and Zambetti¸ 2001). Similar to mice 
that are p21 null, mice deficient in p53 fail to induce p21Waf1/Cip1 upon UV exposure and cannot 
properly arrest (Deng et al., 1995). Upon ionizing radiation (IR) exposure, wild-type 53 also 
frequently induces Gadd45α (growth arrest and DNA damage-inducible), which normally 
associates with Cdc2/cyclin B1 and exerts control over the G2/M transition (Zhan, 2005). This 
role is reflected in p53-/- mouse embryonic fibroblasts that show undetectable Gadd45α 
induction in response to IR (Kastan et al., 1992). Along these lines, siRNA-mediated silencing of 
Gadd45 alleviated the G2/M blockade upon zinc toxicity in normal bronchial epithelial cells and 
was associated with reduced phosphorylation of p53 (Shih et al., 2008).  
The process of immortalization also requires the deregulation of growth promoting and 
inhibiting genes. In general, p53 levels are drastically elevated in transformed cells as compared 
to normal cells due to increased stability of the protein (Finlay, 1992). In other cases, the lack of 
                                                 
2 http://www.hprd.org/interactions?hprd_id=01859&isoform_id=01859_1&isoform_name=  
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functional p53, represented as mutant p53, was found in lymphoid transformed cells and in 
tumors (Wolf et al., 1984; Masuda et al., 1987). One study compared mortal and parentally-
derived immortal chick embryo fibroblasts (CEF) in terms of p53 and Rb status (Ulrich et al., 
1992). In this instance, they found that all immortal cell lines demonstrated loss of wild-type p53 
RNA expression, without any concurrent change in Rb levels. In another instance, spontaneously 
immortalized CEFs were found to have abundant p53 mRNA levels, but no corresponding 
functional activity, as measured by p21Waf1/Cip1 levels, was detectable (Christman et al., 2006). 
These data suggest that p53 must be inactivated in order for immortalization to ensue. Since 
indefinite proliferation requires the maintenance of telomere length, the interaction of telomerase 
with p53 has also become an area of interest. Telomerase reactivation occurs in approximately 
98% of immortal cell lines and in over 90% of invasive breast carcinomas (Kim et al., 1994; 
Herbert et al., 2001). In light of this phenomenon, elevated telomerase activity has been found to 
be loosely associated with p53 expression (Mueller et al., 2002). 
 In addition to cell cycle control, wild-type p53 also modulates the apoptotic response.  
For example, p53 inactivation leads to a loss of repression of Bcl-2 (anti-apoptotic protein), 
which subsequently abrogates apoptosis (Cadwell and Zambetti, 2001). Maspin, an inhibitor of 
angiogenesis that is transcriptionally activated by p53, serially decreases as DCIS progresses to 
invasive carcinomas and then onto lymph node metastases (Maass et al., 2001). All this evidence 
highlights the essential function of the p53 pathway in maintaining the balance between survival 
and death.  
 
1.3 Telomere Biology and Function  
From initial work with yeast and Tetrahymena to the more recent trend of studying
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mammalian telomeres, a wealth of information has been amassed on telomere biology and 
function. The protection provided by chromosome ends is essential for maintaining chromosomal 
and genomic stability. Telomeres are specialized structures found at the ends of linear 
chromosomes that are distinct from the remainder of the genomic chromatin in many ways, both 
structurally and functionally. These nucleoprotein complexes contain non-coding DNA 
distinguished by the highly conserved 5’-(TTAGGG)-3’ sequence in humans. The presence of 
multiple guanine residues allows the telomere to inherently form G-quadruplex structures under 
physiological conditions (Rhodes, 2006). The telomeric region consists of an area of double-
stranded DNA followed by a stretch of single-stranded DNA to produce a G’-overhang at the 3’ 
end. Telomeres exist in variable lengths among different organisms or cells of different origins. 
Telomeric DNA is maintained at a defined equilibrium, although repeats vary in number between 
different chromosomes, and so telomeric length is quite heterogeneous. In mammalian cells, 
telomere-binding proteins establish this equilibrium (Hemann et al., 2000). For instance, the 
average length ranges from 3 to 20 kb in humans, while inbred strains of mice have been shown 
to have telomeres as long as 150 kb (Matulić et al., 2007). 
 As dynamic structures, the primary function of telomeres is to provide a capping 
mechanism, and to this end, telomeres fulfill three such roles (Baykal et al., 2004). First, intact 
telomeres protect natural DNA ends from being recognized as double-stranded breaks and 
consequently activating a DNA damage response (Deng and Chang, 2007). In other words, 
telomeres assure that the ends of normal linear chromosomes are not subjected to unwarranted 
mechanisms of repair. Second, telomeres provide protection from inappropriate exonuclease 
degradation, and third, telomere structure prevents formation of end-to-end fusions (Deng and 
Chang, 2007; Bhattacharyya and Lustig, 2006). Normal cells without a capping mechanism are 
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also vulnerable to recombination due to their highly repetitive sequence (Baykal et al., 2004). 
Other downstream chromosomal instabilities including translocations, non-disjunction, and 
aneuploidy may occur at later rounds of cell division, which likely contribute to tumorigenesis 
(Karlseder, 2003). Thus, maintaining telomere integrity and avoiding dysfunction are critical for 
genomic stability. 
 A host of telomere binding proteins assure that telomeres do not trigger a DNA damage 
response, since an unfolded telomere could be sensed as a double strand DNA break (Figure 3). 
Some of these capping proteins include telomeric repeat binding protein factor 1 and 2 (TRF1 
and 2), TIN2 (TRF1-interacting nuclear factor 2), POT1 (protection of telomeres), RAP1 
(repressor/activator protein), MRE11 complex, Ku, PTOP/PIP1, and tankyrase 1/2 (Shay and 
Bacchetti, 1997). These proteins cooperatively establish the telomere loop, or T-loop, in which 
the single-stranded 3’overhang folds back and invades duplex DNA (de Lange, 2005; Kanoh and 
Ishikawa, 2003). The region of double strand invasion is referred to as the displacement loop, or 
D-loop (de Lange, 2005; Neidle and Parkinson, 2003). The existence of apparently 
evolutionarily conserved T-loops supports the presence of higher-order structure in telomeres 
(Rhodes, 2006; Neidle and Parkinson, 2003).  
Of these telomere binding proteins, six integral proteins, TRF1, TRF2, TIN2, RAP1, 
TPP1, and POT1, constitute the Shelterin complex. Unlike other telomere-associated proteins, 
this complex is abundant only at chromosome ends and remains associated at the telomere 
throughout the cell cycle (de Lange, 2005). Two of the shelterin components, TRF1 and TRF2, 
contain DNA-binding domains that recognize the double-stranded portion of telomeric DNA, 
and thus are necessary for the proper formation and stabilization of the T/D-loop (Rhodes, 2006). 
TRF2 is also found at the junction of duplex DNA invasion, around the D-loop (Wai, 2004).
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Figure 3: Telomere binding- and associated-proteins localize on the telomeric structure. 
Formation of the T-loop and D-loop require the assistance of several telomere-binding proteins. 
Of these, the shelterin complex, consisting of TRF1, TRF2, TIN2, TPP1, RAP1, and POT1, 
collectively contains five DNA-binding domains (two each in TRF1 and TRF2 and one in 
POT1), thus making it uniquely suited to recognize telomeric DNA. The role of other telomere 
associated proteins in homologous recombination or non-homologous end joining implicates 
DNA damage sensing and repair to be intimately connected to telomere biology. The absence or 
deficiency in telomere-based or DNA damage and repair proteins may lead to telomere 
dysfunction and ultimately, genomic instability. Taken from Diehl et al., 2009. 
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These proteins bind as preformed homodimers and are able to form higher order oligomers (de 
Lange, 2005). Homodimerization of TRF1 and TRF2 is essential to their proper functioning 
since loss of this ability results in a failure to localize to the telomere (Rhodes, 2006).  
Although TRF1 and TRF2 localize to the same region of the telomere, they serve 
different functions. TRF1 mainly acts as a negative regulator of telomere length, partially 
through inhibition of telomerase. Overexpression of TRF1 results in gradual telomere shortening, 
while dominant-negative TRF1 causes elongation in the presence of telomerase (Matulić et al., 
2007). In contrast, TRF2 has emerged as the major protective factor at chromosome ends, acting 
as a positive regulator of telomere length (Karlseder, 2003). In support of this role, 
overexpression of TRF2 results in increased telomere shortening, without an associated increase 
in replicative senescence rate (Karlseder et al., 2002), indicating that TRF2 acts to stabilize and 
protect shortened telomeres and prevents the induction of senescence. Functional inactivation of 
TRF2 via a dominant-negative mutant results in a loss of T-loop formation, leading to the 
production of non-homologous end joining (NHEJ)-mediated end-to-end fusions. These fusions 
presumably arise from the cell’s inability to distinguish natural ends and broken DNA 
(Karlseder, 2003; Karlseder et al., 1999). Additionally, recent data indicate that TRF2 may 
assume other (non-telomeric) cellular roles. For instance, TRF2 has been implicated in sensing 
and responding to irradiation-induced non-telomeric interstitial DNA damage (Bradshaw et al., 
1999). In this context, the interaction of TRF2 with numerous mediators of DNA repair 
implicates this protein in serving multiple functional roles. 
Other factors involved in telomere capping include TIN2 and tankyrase (a poly (ADP-
ribose) polymerase), which act as negative and positive regulators of telomere length, 
respectively (Neidle and Parkinson, 2003). TIN2 is believed to provide a scaffolding unit for 
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other proteins to dock and modulate TRF1 function (Matulić et al., 2007).  Tankyrase is required 
for resolution and complete separation of sister telomeres during mitosis. Tankyrase is recruited 
by TRF1 to the telomere where it interacts with the acidic N-terminal domain of TRF1 (Kanoh J 
and Ishikawa, 2003; Hsiao and Smith, 2008). Human RAP1 indirectly binds to the telomere via 
TRF2 and has been reported to have both negative and positive roles (Matulić et al., 2007; 
Neidle and Parkinson 2003). POT1 specifically binds single-stranded telomeric sequences of 
both the 3’ overhang portion of the telomere and internally displaced regions in order to regulate 
telomere elongation (de Lange, 2005; Loazya and de Lange, 2003). Loss of POT1 results in loss 
of telomeric sequences and the appearance of fusions that may solicit a damage response. TPP1 
negatively regulates length by interacting with POT1 and TIN2 using different domains (Matulić 
et al., 2007), and in doing so, it apparently holds all the components of the shelterin complex 
together (de Lange, 2005).  
In addition to members of the shelterin complex, the lariat T-loop structure is also 
associated with proteins involved in DNA repair, DNA processing, and proteins that specifically 
bind single-stranded DNA. The many DNA repair factors that localize to chromosome ends 
include ATM, DNA-PKcs, RAD51, Ku70, Ku86, and the RAD50-MRE11-NBS1 complex 
(Figure 3) (Matulić et al., 2007). Furthermore, additional DNA processing enzymes interact at 
the telomere, including WRN, BLM, ERCC1-XPF1, and Apollo (Matulić et al., 2007). 
Interestingly, the normal localization of these DNA damage and repair proteins does not trigger a 
DNA damage response or cell cycle arrest (Karlseder, 2003). The fact that these DNA damage 
response proteins and telomere-binding proteins reside at chromosome ends and their 
involvement in both telomere maintenance and the damage response suggests interdependency 
for ensuring genomic integrity (Slijepcevic, 2006; Slijepcevic and Al-Wahiby, 2005). Loss of 
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any telomere binding or telomere-localized proteins could lead to compromised structure, 
function, and protective failure. Given that many of these proteins participate in repair 
mechanisms, the convergence of the coexistence of the DNA damage response and telomere 
homeostasis has been a subject of great interest. A global picture is emerging that intrinsically 
implicates repair mechanisms as contributors of telomere maintenance. 
Taken together, information about both linear and three-dimensional structure and 
associated proteins has provided valuable insight into telomere biology and function. The 
plethora of mediators that aid in preserving this function and the complexity of the telomeric 
structure indicate that telomere dysfunction is intolerable and must be prevented. Therefore, 
ensuring the presence of a protected state at chromosome ends is necessary for upholding 
chromosomal and genomic integrity. 
 
1.4 Maintenance of Telomeres by Telomerase 
During normal replication, the discontinuous property of lagging-strand synthesis 
produces a stretch of unreplicated DNA between the final RNA priming event and the terminus 
of the chromosome due to DNA polymerase inaccessibility. This phenomenon, termed the “end 
replication problem”, effectively shortens telomeres in somatic cells by 20-200 bases with each 
round of cell division until a critically short length is reached (Neidle and Parkinson, 2003). The 
progressive accumulation of short telomeres directs cells with functional tumor suppressors into 
senescence, characterized as an irreversible G1 growth arrested state (Figure 4) (Feldser et al., 
2003; Shay et al., 1991). In rare cases, immortal and tumor cells are able to spontaneously 
reactivate the processive ribonucleoprotein enzyme, telomerase, in an attempt to counteract the 
end replication problem and extend or maintain these shortened ends. This activation leads to the
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Figure 4: Telomerase reactivation in cancer cells could be therapeutically targeted. 
Telomerase activity is upregulated in more than 85% of all malignant human cancers, making it a 
logical therapeutic target and practicable molecular marker for human tumorigenic conversion. 
Proliferative cells, such as germ and stem cells, normally express telomerase and so maintain 
telomeres at longer lengths even with many population doublings. The progressive accumulation 
of short telomeres directs normal cells with functional tumor suppressors into senescence, 
characterized as an irreversible G1 growth arrested state. In rare cases, a subset of these cells is 
able to spontaneously reactivate telomerase, in an attempt to counteract the end replication 
problem. This occurrence leads to immortalization and risk of accumulation of mutations that 
predispose the cell to tumorigenesis. Continued proliferation and shortening of telomeres in these 
escaped cells eventually leads to crisis or mortality stage II. Taken from Holt et al., 1996. 
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formation of immortal cells that may accumulate further mutations to predispose the cell to 
tumorigenesis. Continued proliferation and shortening of telomeres in these escaped cells 
eventually leads to crisis or mortality stage II (Herbert et al., 2001). In contrast, proliferative 
cells, such as germ and stem cells, normally express telomerase and therefore maintain telomeres 
at longer lengths even after many population doublings. 
First identified in Tetrahymena by Greider and Blackburn (Greider and Blackburn, 1985), 
telomerase consists of an internal RNA template (hTR in humans) that recognizes the single 
stranded overhang produced as a result of DNA replication and a catalytic reverse transcriptase 
(hTERT in humans) that uses the template to add on telomeric DNA (Holt et al., 1999; Lin and 
Yan, 2005). As mentioned above, normal somatic human cells lack telomerase activity beyond 
the developmental period, while tumor, stem, and germ cells have reactivated telomerase activity 
(Neidle and Parkinson, 2003; Shay and Bacchetti, 1997; Holt and Shay, 1999). Proper 
telomerase assembly requires the association of various proteins including the heat shock protein 
90 multichaperone complex, consisting of Hsp90, p23, Hsp70, p60, and Hsp40/ydj (Holt et al., 
1999). However, only Hsp90 and p23 have been shown to stably associate with active enzyme 
(Forsythe et al., 2001).  
Telomerase activity has been detected in more than 85% of all malignant human cancers, 
making it a logical therapeutic target and practicable molecular marker for human tumorigenic 
conversion. For breast cancer, the percentage of tumors with telomerase is closer to 95%, 
including 75% of in situ carcinomas, 88% of ductal and lobular carcinomas, and 5% of adjacent 
tissue (Carey et al., 1998; Shay and Bacchetti, 1997). Furthermore, more severe breast cancers as 
determined by histologic alterations, tumor size, lymph node status, and staging are associated 
with increased telomerase activity (Yashima et al., 1998; Hoos et al., 1998). The telomerase 
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mRNA transcript (hTERT) is also upregulated in more aggressive breast carcinomas (Bieche et 
al., 2000). However, despite high levels of telomerase activity in cancer cells, telomeres are 
nevertheless maintained at a relatively short length. In fact, telomere length abnormalities occur 
early in the initiation of epithelial carcinogenesis (Meeker et al., 2004b), for example, in ductal 
carcinoma in situ (DCIS) of the breast (Meeker et al., 2004a). The mechanism for shortened, 
stable telomeres in tumors is likely related to access of telomerase to the telomere, which may be 
regulated by telomeric structure as determined by the presence of telomere binding proteins (Lei 
et al., 2005). 
The association of telomerase with severity in breast cancer has implicated this protein as 
a potential prognostic marker. In support of this notion, a significant association has been 
determined between positive telomerase activity and lymphovascular invasion, an important step 
in breast cancer metastasis and indicator of prognosis (Mokbel et al., 2000). Clinical studies have 
also demonstrated that high telomerase activity correlates with reduced disease-free survival in 
patients (Clark et al., 1997). For these reasons, telomerase inhibition may be an appropriate 
adjuvant anticancer approach to treating breast cancer. Treatment would be specific since only 
telomerase-positive (i.e. cancer) cells would be susceptible, thereby limiting toxicity to normal 
cells. A variety of inhibitors exist, including those that target hTR and hTERT, compounds that 
stabilize the G-quadruplex, and immunotherapeutics (White et al., 2001). 
The lack of telomerase reactivation in a small fraction of cancers points to the existence 
of secondary mechanism of proliferation and survival. Approximately 10% of human tumors, 
immortalized human cell lines, and telomerase-null mouse cell lines employ the alternative 
lengthening of telomeres (ALT) pathway (Bryan et al., 1997; Niida et al., 2000; Reddel and 
Bryan, 2003). ALT cells display telomere dynamics in which telomeres with various critically 
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short lengths are targeted and elongated to various lengths, which is suggestive of an inter-
telomeric recombination method in mammalian cells (Henson et al., 2002). Recombinatorial 
proteins characteristically found in cells with undetectable telomerase activity, but exhibiting 
ALT activity, include RAD51, RAD52, MRN, RPA, WRN, and BLM (Henson et al., 2002), all 
of which localize to the telomere. Additionally, poly(ADP-ribose) polymerase (PARP), which 
binds single and double-stranded breaks and interacts with p53 to modulate base excision repair, 
may also be involved in ALT since loss of PARP induces an ALT-like telomere phenotype 
(Tong et al., 2001). Moreover, PARP binds with high affinity to TRF2, making the telomere 
connection to DNA repair even more sound (Neidle and Parkinson, 2003). 
 
1.5 Cellular Fates 
When cell cycle checkpoint mechanisms are intact, cells respond to damage by 
undergoing senescence or apoptosis. In the absence of such checkpoints, cells continue to 
proliferate leading to increased genomic instability (Callén and Surrallés, 2004). Functional 
checkpoints ensure cellular integrity by allowing time for the damage to be repaired. In the case 
of DNA damage, successful DNA repair drives the cells to either undergo checkpoint recovery 
or adaptation (Bartek and Lukas, 2007). In recovery, progression into M phase is associated with 
inactivation of Chk1 via the ubiquitin/proteasome-mediated degradation of Claspin and Wee1, a 
mitosis inhibiting kinase (Bartek and Lukas, 2007), which is closely followed by accumulation 
of Cdc25A, subsequent activation of Cdc25C, and entry into mitosis. Recovery may be mediated 
by the removal or dephosphorylation of γH2AX, a phosphorylated histone tightly associated with 
DNA damage-induced foci (Keogh et al., 2006). Adaptation, on the other hand, involves entering 
mitosis even in the presence of unaddressed checkpoints and unrepaired DNA damage (Harrison 
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and Haber, 2006). This mechanism is not completely understood and may entail elimination of 
damaged cells via mitotic catastrophe (Castedo et al., 2004). Regardless of the final cellular 
outcome, it is evident that cell cycle checkpoints ensure that appropriate signals are elicited and 
transduced in response to DNA damage. 
Progressive telomere shortening destabilizes the T-loop structure and predisposes the 
chromosome to deleterious uncapping events and dysfunction (Griffith et al., 1999). Although 
other forms of senescence exist, loss of protection from telomeres can lead to replicative 
senescence in which cell growth is irreversibly arrested after a certain amount of population 
doublings, i.e. once the cell has reached the Hayflick limit (Hayflick and Moorhead, 1961; 
Hayflick 2000; Shay and Roninson, 2004; von Zglinicki et al, 2005). This supports the thought 
that cellular senescence may have evolved as part of an anti-tumor protective mechanism, and 
that bypassing this checkpoint leads to neoplastic transformation (Wright and Shay, 1992). In 
addition to telomere-dependent growth arrest, stress-induced senescence is triggered by DNA 
damaging agents, such as irradiation, chemicals, and oxidative stress, all generating double-
strand breaks, some of which occur at the telomere (Herskind and Rodemann, 2000; Robles and 
Adami, 1998; von Zglinicki et al., 1995). In this way, DNA damage responders can sense 
aberrations in telomeres and halt proliferation to avoid the accumulation of detrimental mutations 
(Artandi and Attardi, 2005). 
As an alternative to senescence, short unprotected telomeres and DNA or cellular damage 
may also trigger apoptosis (Matulić et al., 2007; Verdun and Karlseder, 2007). p53-dependent 
apoptosis is mediated by cell cycle checkpoints and the transcriptional activation of DNA repair 
factors and pro-apoptotic proteins, such as Apaf1 and Bcl-2 (Su, 2006). On the other hand, p53-
independent mechanisms of apoptosis also exist. The transcription of the p53 family member, 
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p73, is stimulated by the transcription factor, E2F1, which is implicated in inducing cell death in 
the absence of p53 (Irwin et al., 2000). In support of the role of p73 in apoptosis, high levels of 
this protein are found in cells with inactivated pRb (or unrepressed E2F1) as well as cells 
undergoing malignant transformation (Kaelin, 1999). Furthermore, reactivation of telomerase or 
inactivation of p53 and pRb (or aberrant expression of p16) allows continued proliferation by 
bypassing senescence (Karlseder, 2003; Narita et al., 2003). In this scenario, cells continue to 
divide beyond their normal replicative capacity, producing telomeres that lack a protective 
structure. At this point, the cell enters a crisis stage marked by severe chromosomal instability 
and cell death (Artandi and Attardi, 2005; Verdun and Karlseder, 2007). Cells that achieve 
immortalization, most likely via reactivation of telomerase, also display properties of 
transformation, regardless of whether telomerase is activated (Seger et al., 2002). The decision to 
follow the apoptotic route has most likely evolved as a way to preserve genomic integrity via 
selective killing of damaged cells (Su, 2006). In summary, cellular responses to DNA damage, 
including telomeric damage, are triggered by various signals, but ultimately contribute to cell 
cycle arrest, repair, and replicative senescence or apoptosis. 
 
1.6 Molecular Chaperones, Heat Shock Proteins, and Hsp90 
Protein assembly is not a simple, spontaneous process, but rather entails a multistep 
series that requires assistance from a class of proteins termed molecular chaperones. These 
proteins have evolved in response to the highly flexible and unstable nature of higher order 
structures that are held together via non-covalent interactions (Chang, 2009). In aiding in 
accurate folding, chaperones effectively prohibit improper associations with other proteins as 
they assist in the maturation of their substrates or clients. Chaperones generally are not 
 21
components of the final structure of their clients, but rather associate with substrates in a 
transient manner. Otherwise referred to as heat shock proteins (HSPs), these proteins were 
discovered based on their ability to induce a heat shock response upon chemical or physical 
stress to the cell or a disruption in cellular homeostasis (Lindquist and Craig, 1988; Ritossa, 
1962). These stresses include proteotoxic stressors, such as high heat, heavy metals presence, or 
hypoxia. Although these stimuli trigger dramatic upregulation of HSPs in times of stress, normal 
conditions also require their assistance in protein folding (or refolding), translocation across 
membranes, preventing aggregation or self-association, maintaining complexes in an activation 
competent state, and directing misfolded or otherwise non-functional proteins towards 
degradation (Figure 5) (Mosser and Morimoto, 2004; Whitesell and Lindquist, 2005). Thus, the 
presence and action of HSPs is akin to an adaptive response that is needed more during 
unfavorable conditions to ensure cell survival. 
Heat shock protein 90 (Hsp90) is uniquely distinguished from other chaperones since it 
behaves in the most passive manner. While chaperones like Hsp70 are involved in nascent 
protein folding, Hsp90 appears to specifically hold client proteins in an intermediate activation-
primed state, not just in unfolded states (Mosser and Morimoto, 2004). The Hsp90 family 
consists of multiple members found in different locations within the cell. The two main 
cytoplasmic isoforms share 85% sequence identity and include Hsp90α, which is inducible upon 
cellular stress or shock, and Hsp90β, which is constitutively expressed (Hickey et al., 1989). 
Additionally, GRP94 is mainly found in the endoplasmic reticulum while TRAP1 (TNF 
receptor-associated protein) is located in the mitochondria (Argon and Simen, 1999; Felts et al., 
2000). Homologous members in mice include Hsp86 and Hsp84 in mice, Hsp83 in Drosophila, 
Hsc82 and Hsp82 in yeast, and HtpG in bacteria (Young et al., 2001). Collectively, they are
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Figure 5: Heat shock proteins have multifunctional responsibilities on client protein 
maturation. Molecular chaperones such as heat shock proteins aid in accurate folding and 
maturation of their substrates, effectively prohibiting improper associations with other proteins. 
HSPs are dramatically upregulated by a variety of chemical and physical stressors, but are also 
needed under normal conditions. In addition to their assistance in protein folding (or refolding), 
HSPs also participate in translocation of clientele across membranes, preventing protein 
aggregation or self-association, maintaining complexes in an activation competent state, and 
directing misfolded or otherwise non-functional proteins towards degradation.  
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regarded as ubiquitous, highly conserved proteins that are critically involved in controlling the 
conformation, stability, function, and degradation of many oncogenic client proteins, thus 
determining their cellular fate (Beliakoff and Whitesell, 2004; Csermely et al., 1998). The 
essentiality of this protein for cell viability is evident since genetic knockdown of Hsp90 proves 
to be lethal in eukaryotic cells (Chiosis, 2006). Furthermore, Hsp90 is abundantly found in the 
cell, comprising 1-2% of total protein content even under non-stressed conditions. In tumor cells, 
this percentage increases to approximately 4-6% (Chiosis and Neckers, 2006).  
Recent advances in determining the structure of Hsp90 has led to important advances in 
elucidating its function. As shown in Figure 6, the Hsp90 protein consists of three main 
conserved domains, as this structural arrangement is shared across species (Young et al., 2001). 
Hsp90 exists as an obligate homodimer, whose protomers consists of an N-terminal domain, a 
middle domain, and a C-terminal dimerization domain (Nemoto et al., 1995). The 24-28 kDa N-
terminus contains the primary binding site of client proteins and a separate, distinct ATP-binding 
site. These binding pockets include highly conserved residues, indicating that the specificity 
between the client and Hsp90 interaction is structure-dependent (Pearl and Prodromou, 2006). 
Crystallography has also indicated that the N-terminus contains a nucleotide-binding cleft where 
specific Hsp90 inhibitors bind (Stebbins et al., 1997). A shorter linker region tethers the N-
terminal domain to the 38-44 kDa middle domain. This linker is highly susceptible to proteolysis 
and contains charged residues such as Asp, Glu, and Lys (Prodromou and Pearl, 2003). It is 
possible that the linker regulates Hsp90 function by increasing substrate affinity at the N-
terminus and mediating cross-talk between protein and ATP binding (Scheibel et al., 1999). 
However, this linker is not essential for ATPase activity, since its removal still allows for ATP 
hydrolysis (Meyer et al., 2003). Deletion of this linker region has also been shown to cause
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Figure 6: Schematic of the domains of the Hsp90 monomer. Hsp90 is a highly conserved 
protein that consists of three main domains, of which, the structural arrangement is shared across 
species. A short linker region tethers the 24-28 kDa ATP-binding N-terminal domain (“N”, 
green) to the flexible 38-44 kDa middle domain (“M”, dark blue). This linker is highly 
susceptible to proteolysis and contains charged residues such as Asp, Glu, and Lys. The final 12 
kDa C-terminal domain (“C”, orange) contains the obligate dimerization site and contains an 
MEEVD motif that recruits select co-chaperones that recognize this sequence. Numbers indicate 
amino acid position. Adapted from Young et al., 2001. 
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defects in the heat shock response and a decrease in Aha1-stimulated ATPase activity and loss of 
p23 binding, suggesting that this region imparts a regulatory function (Hainzl et al., 2009).  The 
flexible 35 kDa middle domain contains a series of α-β-α sandwiches and α-helical coils 
(Prodromou and Pearl, 2003). Client protein and ATP binding induces a conformational change 
in structure such that the N-terminal and middle domains act in concert to form a lid that clamps 
down over the open pocket (Figure 7). This action induces twisting of the middle domains 
around each other, subsequent transient N-terminal dimerization in Hsp90 protomers, and ATP 
hydrolysis (Dollins et al., 2007). The middle domain also contains a hidden recognition site for 
nuclear localization signals in the interior of the protein that is activated upon heat shock (Daniel 
et al., 2008). The final 12 kDa C-terminal domain is the obligate dimerization site and contains 
an MEEVD motif that recruits select co-chaperones that recognize this sequence (Young et al., 
1998). This domain has also been implicated in binding client proteins and may also contain a 
secondary ATP binding site, although this is still controversial (Csemerly et al., 1998; Young et 
al., 1997; Scheibel et al., 1998; Soti et al., 2002).  
Functionally, the Hsp90 multiprotein machinery assists in cellular trafficking, the 
remodeling of improperly folded client proteins, and the suppression of protein aggregation 
(Whitesell and Lindquist, 2005; Sarto et al. 2000). This machinery is a cytosolic multiprotein 
complex that is supplemented with a variety of cochaperones, whose interactions are dependent 
upon the binding state of ATP. Accordingly, the association of Hsp90 and client proteins 
behaves in a cyclic manner such that the ADP-bound state is amenable to binding of clientele 
while the ATP-bound state leads to clientele stabilization and modification (Figure 8). In the 
initial step, an immature client protein associates with Hsp70, Hsp40, and heat shock organizing 
protein (HOP) (Hernandez et al., 2002). This complex then transfers the client to the open form 
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Figure 7: Structure and features of the Hsp90 homodimer. As an obligate homodimer, Hsp90 
protomers consists of an N-terminal domain, a middle domain, and a C-terminal dimerization 
domain. The N-terminus contains the primary binding site of client proteins, and the co-
chaperone, p23, and a separate, distinct ATP-binding site. It is also region where Hsp90 
inhibitors are targeted. These binding pockets include highly conserved residues, indicating that 
the specificity between the client and Hsp90 interaction is structure-dependent. The flexible 
middle domain contains a series of α-β-α sandwiches and α-helical coils that induces a 
conformational change in Hsp90 structure upon client binding. A region for the recognition of 
nuclear localization signals (NLS) is located within the interior of the middle domain and is 
activated upon heat shock. The C-terminus has also been implicated in binding client proteins 
and may also contain a secondary ATP binding site. Adapted from Pearl and Prodromou, 2006. 
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Figure 8: Hsp90 ATP-driven chaperoning cycle. The Hsp90 cycle is supplemented with a 
multitude of cochaperones, whose interactions are dependent upon the binding state of ATP. 
Accordingly, the association of Hsp90 and client proteins behaves in a cyclic manner such that 
the ADP-bound state is amenable to binding of clientele while the ATP-bound state leads to 
clientele stabilization and modification. An immature client protein initially is presented by 
Hsp70, Hsp40, and heat shock organizing protein (HOP). This complex then transfers the client 
to the open form of Hsp90, creating an intermediate chaperone assembly. Following the 
dissociation of Hsp70/40 and displacement by the introduction of co-chaperones (p23) and 
immunophilins, the client-bound complex accepts ATP. This triggers N-terminal dimerization of 
Hsp90 such that the middle domains intersect, resulting in the formation of the closed or clamped 
state. Upon ATP hydrolysis in the presence of Aha1, a mature client protein is released. Adapted 
from Bracher and Hartl, 2006. 
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of Hsp90, creating an intermediate chaperone assembly. Following the dissociation of Hsp70/40 
and displacement by the introduction of co-chaperones (p23) and immunophilins, the complex is 
then able to accept ATP. Binding of ATP triggers N-terminal dimerization of Hsp90 such that 
the middle domains intersect, resulting in the formation of the closed or clamped state. Upon 
ATP hydrolysis in the presence of Aha1, a mature client protein is released (Bracher and Hartl, 
2006). It is notable from kinetic studies that Hsp90 has a very slow ATPase activity that is 
dramatically accelerated in the presence of Aha1 (Hessling et al., 2008). The ADP generated in 
this reaction is unfavorable for the closed conformation, which promotes Hsp90 to resume the 
open conformation. In this manner, client proteins achieve stability, allowing them to bind to 
ligands or undergo post-translational modifications to activate signaling pathways (Sharp and 
Workman, 2006).  
Regulation of Hsp90 activity occurs through a variety of mechanisms. In one mode, heat 
shock factor 1 (HSF1) is sequestered by an Hsp90 monomer under basal conditions. Upon stress, 
client proteins compete with HSF1 for Hsp90 binding and thus displace HSF1, which 
subsequently timerizes to initiate the heat shock response (Zou et al., 1998). Another mechanism 
of regulation occurs allosterically via the binding of nucleotides (i.e. ATP or ADP) at sites 
distinct from active sites. These effectors cause a change in conformation in Hsp90, which 
subsequently affects its activity level (Prodromou et al., 1997). On a second level, regulation of 
Hsp90 ATPase and client binding activities occurs through binding of essential co-chaperones, 
many of which are chaperones themselves (Riggs et al., 2004). Co-chaperones are not considered 
client proteins, but may impart specificity to Hsp90 by recognizing certain clientele and 
presenting it to Hsp90 (Caplan, 2003). In addition to client protein selection, co-chaperones aid 
in other Hsp90 functional aspects, including client protein activation and degradation, Hsp90-
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client stabilization, and ATP hydrolysis. Hsp90 enlists the aid of the largest number of co-
chaperones, and these can be classified into two broad groups. One type contains a 
tetratricopeptide (TRP) motif that recognizes the EEVD domain in Hsp90 and includes Hop and 
immunophilins, while the second type does not contain this domain and includes Cdc37, Aha1, 
and p23, which is able to act independently of Hsp90 (Buchner, 1999; Freeman and Yamamoto, 
2002). The p23 co-chaperone has been studied for its role in breast cancer, although the majority 
of studies involving p23 focus on the relationship of this protein with steroid hormone receptors. 
Specifically, overexpression of p23 positively regulates the activity of the estrogen receptor, 
resulting in enhanced invasiveness of breast cancer cells without an effect on proliferation 
(Knoblauch and Garabedian, 1999). Furthermore, p23 expression increases accordingly as tumor 
grade increases (Oxelmark et al., 2006). Finally, the third level of regulation involves the 
reversible covalent modification of Hsp90. Hsp90 has been shown to undergo S-nitrosylation at 
endothelial nitric oxide synthase (eNOS) specific cysteine residues, resulting in inhibition of 
ATPase and eNOS activities (Martínez-Ruiz et al., 2005). 
Currently, Hsp90 has been found to interact with over 200 client proteins and the list is 
continually expanding.3 Many client proteins, such as kinases, transcription factors, hormone 
receptors, and telomerase, undergo post-translational maturation via the Hsp90 chaperone cycle 
to determine their cellular fate (Csermely, et al., 1998; Dai and Whitesell, 2005; Holt and Shay, 
1999; Sharp and Workman, 2006). It is notable that Hsp90 seems to selectively associate with 
cell signaling clientele, such as nuclear hormone receptors and protein kinases (Pratt and Toft, 
2003; Brown et al., 2007). Furthermore, many Hsp90 client proteins directly influence the six 
hallmarks of cancer (Figure 9). For example, oncoproteins and proteins involved in cell 
signaling, such as Akt, HER2, Bcr-Abl, and EGFR, require Hsp90-mediated stability and 
                                                 
3 http://www.picard.ch/downloads/downloads.htm  
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Figure 9: Hsp90 client proteins are involved in the hallmarks of cancer. Currently, Hsp90 
has been found to interact with over 200 clientele proteins and the list is continually expanding. 
Many oncogenic client proteins, such as kinases, transcription factors, hormone receptors, and 
telomerase, undergo post-translational maturation via the Hsp90 chaperone cycle. Hsp90 seems 
to particularly associate with cell signaling clientele, such as nuclear hormone receptors and 
protein kinases. Many of these Hsp90 client proteins directly influence the establishment of the 
six hallmarks of cancer. The interaction of Hsp90 with these clientele clearly implicates this 
chaperone in transformation and tumorigenesis. Adapted from Neckers, 2006. 
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functional activation (Zhang and Burrows, 2004). Thus, the role of Hsp90 in signal transduction 
inherently implicates this chaperone in transformation and tumorigenesis. 
         
1.7 Hsp90 inhibition  
Cancer is clearly not a simple disease, but rather employs the involvement of multiple 
pathways and a variety of abnormalities. Even when the targeting of a malignant cell is specific 
and induces less cytotoxicity, non-responsive cells eventually emerge due to their highly plastic 
and adaptive nature. Hormone-dependent cells become hormone-independent, chemotherapeutic 
resistance develops, and survival persists even in unfavorable environments (Neckers, 2006). In 
the face of such obstacles in successful cancer treatment, it may be more effective to assume a 
multi-nodal approach by simultaneously targeting a common factor. Namely, by blocking the 
Hsp90 machinery, it is possible to inhibit many of those pathways and mechanisms of survival.   
The intrinsic nature of heat shock proteins makes them especially relevant to cellular 
defense against cancer initiation.  Previous studies have reported an overexpression of Hsp90 in 
human breast cancer; however, only tumor specimens and breast cancer cell lines were examined 
(Pick et al., 2007). The stress-inducible isoform Hsp90α has also been reported to be 
preferentially increased in cancer tissues compared to non-cancerous tissues (Yano et al., 1996, 
1999). In addition to significantly elevated total levels in cancer cells, Hsp90 has been found 
predominantly in a form that is bound to its client proteins, while most normal cells have 
uncomplexed Hsp90 (Kamal et al., 2003; Ferrarini et al., 1992). Despite the higher Hsp90 levels 
in cancer cells, Hsp90 inhibitors negatively affect tumor growth even though only a small 
fraction of available binding sites are occupied (Banerji et al., 2005; Eiseman et al., 2005; 
Vilenchik et al., 2004). These observations suggest that Hsp90 in stressful conditions (as in 
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tumor cells) exists in a highly activated state as a multiprotein complex capable of supporting the 
transformed phenotype (Chiosis and Neckers, 2006). As a corollary, normal cells must maintain 
Hsp90 in an inactive state that undergoes more dynamic interactions with client partners. Thus, 
the balance between activated and latent Hsp90 must be tipped in favor of multichaperone 
assembly in order for transformation to occur or progress. 
The preferential accumulation of Hsp90 in cancer cells also forms the basis for the unique 
sensitivity of tumor cells to Hsp90 inhibition. In particular, Hsp90 in cancer cells has a higher 
affinity for anti-Hsp90 compounds compared to that in normal cells, thus providing tumor 
selectivity via, as yet, an unknown mechanism (Kamal et al., 2003). In light of this finding, it is 
possible that malignant cells are more dependent on Hsp90-mediated stability and activation of 
oncogenic pathways than normal cells, and so are more sensitive to Hsp90 inhibitors (He et al., 
2006; Vilenchik et al., 2004; Whitesell et al., 1992). In addition to its tumor selectivity, Hsp90 
inhibitors also act in a specific manner. Since Hsp90 inhibition is tailored against one specific 
protein, it has been considered a targeted therapy for cancer. Because of the dependence of 
Hsp90 function on ATP hydrolysis, many Hsp90 inhibitors interfere with this intrinsic activity 
by binding at the N-terminal ATP site.  In this way, Hsp90-dependent client proteins bound at 
the N-terminus can be tagged for ubiquitination and subsequently directed toward proteasomal 
degradation (Eleuteri et al., 2002; Pearl et al., 2008). Thus, Hsp90 inhibition has earned great 
interest as a promising approach for cancer therapy since many oncogenic client proteins can be 
simultaneously targeted and disrupted (Goetz et al., 2003; Sharp and Workman, 2006). 
From the first Hsp90 inhibitor to be discovered and developed, a multitude of derivatives 
and additional classes of inhibitors have been identified. These inhibitors do not necessarily 
interfere with binding of client proteins; rather, they prevent their maturation. Two of the most 
 33
potent naturally occurring Hsp90 inhibitors identified thus far are geldanamycin and radicicol. 
Initially discovered in 1970 as an antimicrobial agent, geldanamycin (GA, Figure 10A) is a 
benzoquinone ansamycin antibiotic that has exhibited antigrowth properties (DeBoer et al., 
1970). Originally believed to operate via direct inhibition of v-Src, a tyrosine kinase involved in 
proliferation in tumor cells, GA was later shown to actually bind a 90 kDa protein that directed 
its activity (Whitesell et al., 1994). Although GA binds with higher affinity to Hsp90 than ATP, 
it displayed high in vivo hepatotoxicity in preclinical studies due to the unstable nature of the 17-
methoxy group (Supko et al., 1995).  For this reason, GA analogues were created, of which 17- 
allylamino, 17-demethoxy geldanamycin (17-AAG, Figure 10B), developed at Kosan 
Biosciences, showed the most promise. This agent is less hepatotoxic, more stable, and has more 
inhibitory activity than its parent compound, even in animal models (Schulte and Neckers, 
1998b; Pacey et al., 2006). For instance, it has demonstrated anticancer activity at nontoxic doses 
in prostate cancer xenografts as measured by the dose-dependent degradation of androgen 
receptor, HER2, and Akt expression (Solit et al., 2002). As such, it was the first Hsp90 inhibitor 
to enter clinical trials and has now progressed to phase II trials for melanoma, breast, prostate, 
and thyroid cancers (Sausville, 2003). The success of this inhibitor is evidenced by the 
formulation of an injectable version of the drug labeled tanespimycin (KOS-953, Kosan 
Biosciences), which shows antitumor activity in HER2 (+) metastatic breast cancer, and 
retaspimycin (IPI-504, Infinity Pharmaceuticals), which is currently undergoing trials for breast 
cancer (Taldone et al., 2008; Modi et al., 2007; Sydor et al., 2006). 
Despite the advantages of 17-AAG, drug solubility remained problematic. To circumvent 
this issue, the second generation 17-(2-dimethylaminoethyl) amino-17-demethoxygeldanamycin 
(17-DMAG, Figure 10C) was synthesized and showed greater physiologic solubility (Tian et al., 
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Figure 10: Hsp90 inhibitors. Geldanamycin (A) is a benzoquinone ansamycin antibiotic and 
radicicol is a non-ansamycin macrocyclic agent, and both have exhibited antigrowth properties. 
Derivatives of geldanamycin, 17-AAG (B) and 17-DMAG (C), have shown less cytotoxic effects 
and are currently in clinical trials for a variety of cancers. The radicicol parent compound (D) 
lacks in vivo activity due to its chemical structure, so derivatives have been synthesized that 
show greater antitumor promise. These Hsp90-specific inhibitors competitively bind at the N-
terminal ATP-binding site, effectively blocking Hsp90 chaperoning function. 
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2004). It has also demonstrated activity in mice with MDA-MB-231 xenografts as evidenced by 
a greater retention of 17-DMAG in tumor tissue than normal, as well as a reduction in Hsp90 
levels (Eiseman et al., 2005). Also known as alvespimycin (KOS-1022, Kosan Biosciences), it 
has entered phase I clinical testing and also shows activity against hormone refractory HER2 (+) 
metastatic breast cancer (Miller et al., 2007). Thus, HER2 is an especially sensitive target of 
Hsp90 inhibition, undergoing degradation in response to exposure to both 17-AAG and 17-
DMAG (Neckers, 2000). A variety of other synthetic GA derivatives with a mixture of side 
chains and conjugated moieties is reviewed in Hadden et al., 2006, but is beyond the scope of 
this introduction.  
Similar to GA, radicicol (RAD, Figure 10D) is also an antifungal antibiotic that was 
originally identified in Monosporium bonorden based on its ability to inhibit growth of mold and 
bacteria (Delmotte and Delmotte-Plaque, 1953). This non-ansamycin macrocyclic agent was also 
believed to exert inhibitory effects on v-Src and was later realized to be an Hsp90 inhibitor 
(Kwon et al., 1992b). It is able to revert the transformed phenotype, such that transformed 
fibroblast cells treated with RAD undergo morphologic changes to resemble normal cells (Kwon 
et al., 1992). Like GA, RAD binds in the N-terminal ATP binding site of Hsp90 and exerts its 
anticancer effect through inhibition of the Hsp90 machinery. In fact, RAD has a higher affinity 
for Hsp90 and competes with GA for binding in the N-terminal domain (Schulte et al., 1998a). 
Furthermore, RAD is more potent in terms of blocking ATPase activity and prevents the 
association of the co-chaperone p23 with Hsp90 (Roe et al., 1999). In breast cancer cells, RAD 
has been shown to affect the level of Hsp90 client proteins (Schulte et al., 1998a). Other 
advantages of RAD include activity in GA-resistant cells and a lack of hepatotoxicity (Chiosis et 
al., 2003; Yamamoto et al., 2003). However, RAD lacks in vivo activity since its electrophilic 
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structure undergoes modifications that render it biologically inactive when injected into the 
bloodstream (Geng et al., 2004). Thus, the native RAD molecule is still in preclinical 
development, but RAD derivatives (KF25706 and KF58333) are showing greater promise since 
they exhibit antiproliferative abilities while maintaining in vivo activity in tumor xenograft 
models (Soga et al., 1999; Soga et al., 2001). 
In addition to benozquinone ansamycins and radicicol, more recently identified Hsp90 
inhibitors include pyrazoles, purines, and novobiocin. All exhibit inhibitory effects on Hsp90 
chaperoning function, although their potency and mechanisms vary. Pyrazoles, exemplified by 
CCT018159, are able to induce Hsp70 expression while reducing levels of client proteins c-raf, 
Cdk4, and ErbB2 in melanoma cells (Cheung et al., 2005; Sharp et al., 2003). Treatment with 
small molecule purines, specifically PU3 and PU24F-Cl, also affects ErbB2, AKT, and c-raf 
levels in breast cancer cells and in in vivo xenograft tumors (Chiosis et al. 2002: Vilenchik et al., 
2004). Coumarin antibiotics such as novobiocin are believed to bind in a secondary ATP binding 
site located within the C-terminus of Hsp90 (Marcu et al., 2000a). Although it also negatively 
affects ErbB2, c-raf, v-Src, and mutant p53, its action is not as potent as other inhibitors (Marcu 
et al., 2000b; Yun et al., 2004). The putative C-terminal ATP site is also the reported binding site 
for cisplatin, whose presence prevents Hsp90 from interacting with hormone receptors (Itoh et 
al., 1999; Rosenhagen et al., 2003). However, no significant effects on client protein levels were 
detected nor any cellular response, suggesting that cisplatin alone cannot induce anticancer 
reactions (Sharp and Workman, 2006). 
Although the exact mechanism by which inhibition of Hsp90 disrupts the stability of its 
client proteins is unclear, it most likely involves the ubiquitin-proteasome system. In this 
pathway, destabilized client proteins are covalently tagged for degradation by the three-step 
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transfer of multiple ubiquitin molecules from ubiquitin-related enzymes (Marques et al., 2006). 
Ubiquitin is initially bound and activated by ubiquitin-activating enzyme (E1). An ubiquitin-
conjugatin enzyme (E2) then transfers this ubiquitin from E1 to the damaged protein, which is 
sequestered by a ubiquitin-ligase enzyme (E3). The polyubiquitinated protein is then degraded 
by the 26S proteasome, which entails recognition by the 19S regulatory subunit of the 
proteasome and subsequent entry into the interior 20S core subunit (Schwartz and Ciechanover, 
2009). In the presence of ATP, unfolding of proteins occurs, which leads to proteolysis that 
produces short polypeptide fragments. 
In summary, a vast amount of information has been amassed on Hsp90 biology and 
function, yet much remains to be elucidated in terms of mechanism. Although Hsp90 has 
previously been shown to be moderately uninformative on a diagnostic level, it is clear that 
Hsp90 plays a role in tumor progression and response to therapy. Continuing progress in 
identifying clientele and understanding Hsp90 inhibition will surely contribute to advancing the 
global Hsp90 story.  
 
1.8 Current Breast Cancer Therapeutics 
While breast cancer patients now have a wide range of therapeutics available to them, 
occurrence of the disease is still common and treatment challenges still remain. Although many 
patients initially respond to standard chemotherapeutic regimens, breast tumors may redevelop 
leading to localized, regional, or distant recurrence that may be more aggressive and resistant to 
further treatment. Clearly, more effective approaches are needed since conventional therapy is 
typically associated with partial clinical responses and undesirable side effects, including the 
destruction of normal non-cancerous surrounding cells. For this reason, there is a great need for 
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the identification of new therapeutic options that specifically target tumor cells. With the current 
trend for early breast cancer detection, there is also a growing demand for discovering markers to 
assist in the risk stratification of patients.  
Breast cancer treatments can generally be categorized into groups of surgical 
intervention, radiotherapy, chemotherapy, hormone therapy, or targeted therapy.4 Depending on 
the type and stage of the cancer, different treatment options are more suitable than others. 
Removal of the lump (lumpectomy) or of the entire breast (mastectomy) are established and 
appropriate options in less advanced forms of breast cancer (Benson et al., 2009). With these 
procedures, assessment of the resected tissue may be used in a diagnostic as well as therapeutic 
capacity. Radiation therapy is most successful when combined with surgical options; however, 
long-term side effects due to off-target effects remain major concerns (Fisher et al., 2002). For 
this reason, two new techniques have been developed to reduce normal tissue toxicity and non-
uniform irradiation dosage. Accelerated partial breast irradiation (APBI) refers to a collection of 
methods that targets the primary region of the affected breast for a shorter duration of time, thus 
eliminating the need for whole-breast treatment (Van Limbergen and Weltens, 2006). APBI is 
recommended for patients with smaller tumors and with low risk of developing multifocal 
recurrence (Van Limbergen and Weltens, 2006). The second technique, intensity modulated 
radiation therapy (IMRT), addresses dose homogeneity by attempting to improve delivery (Yu et 
al., 2008). Although long-term clinical outcome data is scarce, these methods nevertheless have 
enhanced the radiotherapy option. 
Chemotherapy refers to the range of anti-cancer compounds that are used to treat 
inoperable breast cancer and either pre- or post-operatively as part of a breast conserving surgery 
regimen. Since this type of treatment destroys both tumor and normal cells, it is not especially 
                                                 
4 http://www.mayoclinic.com/health/breast-cancer/DS00328/DSECTION=treatments-and-drugs  
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selective in killing and is thus associated with significant side effects.  By the 1980’s, 
anthracycline antibiotics were developed and continue to be used as first-line treatments or in 
combinations with other chemotherapeutics (Fisher et al., 1989). Specifically, doxorubicin 
(Adriamycin®) has been a mainstay in the treatment of various solid tumors, including breast, 
ovary, liver, lung, and soft tissue sarcomas, and has been used as both a single agent and in 
combination therapies (Figure 11A) (Murphy et al., 1995; DeVita et al., 1993). A variety of 
mechanisms of action have been proposed that are based on the ability of this antineoplastic drug 
to intercalate into DNA and induce apoptosis (Gewirtz, 1999). In this manner, doxorubicin can 
block macromolecular DNA biosynthesis by inhibiting DNA polymerase (Zunino et al., 1975; 
Gewirtz, 1999). Another mechanism involves free radical formation, in which the electron 
accepting quinone structure in the presence of electron donors allows for the generation of free 
radicals, which then cause DNA damage (Feinstein et al., 1993). The addition of Adriamycin has 
also been shown to create drug-DNA adducts in a dose-dependent manner (Cullinane et al., 
2000). These covalently tethered adducts serve as interstrand cross-links that impart exceptional 
stabilization in the DNA (Fornari et al., 1994). This stability may reflect the drug’s preferential 
binding to GC sites, which contributes to obstruction of duplex strand separation or unwinding 
and subsequent interference with helicase activity (Bachur et al., 1993).  Finally, Adriamycin has 
been shown to exert its activity via the induction of DNA strand breaks due to inhibition of 
topoisomerase II (Tewey et al., 1984). Accepted as the primary target of Adriamycin, this 
enzyme exhibits reduced or altered activity in Adriamycin-resistant cells that have 
correspondingly fewer DNA breaks (Son et al., 1998). 
Despite its frequent application and efficacy in breast cancer treatment, Adriamycin 
resistance is a major clinical concern. Response rates average between 40-60%, but development 
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Figure 11: Current anticancer drugs for breast cancer. The chemotherapeutics, Adriamycin 
(A) and Taxol (C), have been a mainstay in treatment of various cancers. Adriamycin acts as a 
DNA damaging agent by forming DNA cross-links and inhibiting topoisomerase II, while Taxol 
acts as a microtubule stabilizing agent. Cisplatin (B) is a novel platinum-based chemotherapeutic 
that creates DNA adducts which effectively block transcription. Tamoxifen (D) is a selective 
estrogen receptor modulator (SERM) that antagonizes ER activity. However, its mode of action 
is limited to those breast cancers that have retained expression of the ER. Resistance is a serious 
concern for all current therapies, but further advancement in the field of drug development shows 
promise in overcoming these challenges. 
 41
of resistance leads to complete treatment failure (Ta et al., 2008). One proposed mechanism of 
breast cancer resistance towards anthracyclines occurs via the overexpression of plasma 
membrane transporter proteins, such as breast cancer resistance protein (BCRP), which is 
expressed at low levels in parental MCF7 cells but higher in MCF7/AdrVp cells that have 
multidrug resistance (Faneyte et al., 2002; Doyle et al., 1998). Furthermore, alterations in 
apoptosis-mediating proteins, such as those in the Bcl-2 pro- and anti-apoptotic family, or in 
drug targets, such as topoisomerase II, may lead to a resistant phenotype (Pommier et al., 2004; 
Prost, 1995). 
Although antitumor drugs like Adriamycin have garnered much attention and use as 
standard chemotherapeutics, novel platinum-based compounds are rapidly gaining research 
interest as cancer combatants. Initially described in E.coli as a cell division inhibitor in response 
to an electric current applied to the growth medium, cisplatin (cis-diamminedichloroplatinum (II) 
or cis-DDP) has exhibited anticancer activity in solid tumors such as those of testicular, ovarian, 
and advanced breast cancers (Rosenberg et al., 1965; Jordan and Carmo-Fonseca, 2000; Muggia, 
2009; Martín, 2001). The reactivity of cisplatin is based on its platinum and chlorine containing 
chemical structure, which is conducive for the formation of DNA adducts (Figure 11B). In an 
aqueous environment, the chlorine ions are displaced, allowing for amino acid side chains or 
purine bases within DNA to pair with platinum (Jordan and Carmo-Fonseca, 2000). 
Subsequently, DNA adducts form, of which intrastrand 1,2-d(GpG) and -d(ApG) cross-links are 
the most common. This platinum-modified structure creates bends in the DNA which results in 
the recruitment of high mobility group (HMG) proteins (Gelasco and Lippard, 1998). The 
presence of HMG proteins shields the adducts from being recognized by nucleotide excision 
repair (NER) proteins, and consequently, are poorly repaired (Huang et al., 1994).  
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In this manner, the mechanism of action of cisplatin lies in its ability to inhibit 
transcription and trigger apoptosis. In particular, cisplatin-induced cross-links do not interfere 
with priming events but block further elongation by RNA polymerase II, resulting in a stalled 
complex (Corda et al., 1991). Since rRNA synthesis is elevated in rapidly proliferating cells like 
cancer cells, cisplatin may preferentially affect only these cells only (Moss and Stefanovsky, 
1995). Furthermore, cisplatin may induce cell death by triggering G2 cell cycle arrest in a p53-
dependent manner since p53 deficient cells are less responsive to cisplatin treatment (Allday et 
al., 1995; Anthoney et al., 1996). Alternatively, apoptosis may be mediated by a p53-
independent pathway, namely that of p73, since cisplatin activates c-Abl, which induces the p73 
cascade (Gong et al., 1999). Intrinsic cisplatin resistance exists, but advancement of the 
understanding of the platinum-DNA interaction will aid in overcoming these challenges. 
In addition to DNA damaging agents, microtubule stabilizing agents have been successful 
as chemotherapeutic compounds, especially in the treatment of breast cancer. Namely, by the 
1990’s, taxanes, including paclitaxel (Taxol®) and docetaxel (Taxotere®), were developed as 
viable options and are now widely recognized as being extremely active against advanced breast 
cancer as well as a promising initial line of treatment for early breast cancer (Figure 11C) (Ring 
and Ellis, 2005).  Besides their role in cell division and chromosome separation in mitosis, 
microtubules are also essential for other cellular activities, including maintenance of cell shape, 
intracellular transport, and cell signaling (Jordan and Wilson, 2004). As components of the 
cytoskeleton, microtubules are highly dynamic structures that are characterized by dynamic 
instability and treadmilling, which refer to processes of tubulin polymerization that is regulated 
by microtubule-associated proteins (Mitchison and Kirschner, 1984; Honore et al., 2005). 
Electron crystallography has shown that Taxol binds to β-tubulin on the inside of the cylindrical 
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core, thus preventing polymer disassembly (Downing and Nogales, 1999). In this case, the 
mechanism of action lies within the ability to stabilize microtubules and effectively block the 
metaphase to anaphase transition, resulting in apoptosis or mitotic catastrophe (Jordan and 
Wilson, 2004; Castedo et al., 2004).  
Similar to anthracyclines, natural and acquired resistance to taxanes is multifaceted and 
not uncommon (McGrogan et al., 2007). Mutations in β-tubulin or changes in β-tubulin isotype 
composition, alterations in microtubule-associated proteins, or cell cycle anomalies can all 
contribute to the development of resistant cells (Berrieman et al., 2004; Burkhart et al., 2001; 
Goncalves et al., 2001; Villeneuve et al., 2006). Despite this hurdle, many clinical studies have 
reported that Taxol in combination with other antimitotics or anthracyclines is more effective 
and associated with a better outcome (Henderson et al., 2003; Jordan and Wilson, 2004). It is 
clear that rational design of chemotherapeutic combinations will enhance antitumor activity and 
possibly overcome multidrug resistance. 
Since breast cancer initiation and progression are dependent on the production of 
endocrine factors and sex hormones, hormone or endocrine therapy has also been developed as 
another therapeutic option. Not only does it regulate reproductive processes in hormone-
dependent cancers such as those of the breast or prostate, estrogen participates in the 
advancement of disease. Three natural forms of estrogen exist, including 17β-estradiol (E2), 
which is most predominant and has the highest affinity for its receptors, and estrone (E1) and 
estriol (E3), both of which are estradiol metabolites (Chen et al., 2008). Part of the nuclear 
receptor superfamily, two isoforms of the estrogen receptor (ER) exist, ERα , which is the more 
prevalent form in breast cancer and promotes proliferation, and ERβ, found mainly in normal 
breast tissue (Pearce and Jordan, 2004; Herynk and Fuqua, 2004). In the classical pathway of ER 
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signaling, E2 binds to ligand-binding domains on estrogen receptors in the nucleus while 
mitogen-actived protein kinase (MAPK)-related growth factors bind in a secondary coactivation 
domain, in turn triggering receptor dimerization (Shiau et al., 1998; Kato et al., 1995). This 
estrogen-ER complex then binds to estrogen response elements within the promoter region of 
target genes involved in cell growth, stimulating their transcription (Björnström and Sjöberg, 
2005). 
 It has long been known that reducing endogenous estrogen levels can ameliorate the 
progression of breast cancer. Limiting estrogen production can reduce the frequency of breast 
cancer emergence as well as induce remission in patients with advanced cancer (Dorssers et al., 
2001). Furthermore, about 60% of breast cancers are positive for ER and are therefore responsive 
to estrogen-mediated growth signals (Putti et al., 2005). These findings have resulted in the 
development of a new promising category of chemotherapeutics. Specifically, selective estrogen 
receptor modulators (SERMs) have gained immense interest for its antitumor and cancer 
prevention capabilities. The unique quality of SERMs lies in its ability to act as both antagonists 
and agonists in select tissues. Indeed, SERMs display antagonistic properties in the breast and 
brain, while they behave agonistically in the bone, liver, and cardiovascular system (Lewis and 
Jordan, 2005). 
One of the most well known and studied SERM is the nonsteroidal ER antagonist, 
tamoxifen (Figure 11D). The mechanism of action of this drug lies in its ability to interrupt the 
ER signaling cascade. Tamoxifen serves as a competitive inhibitor of estrogen binding by 
occupying the normal ligand-binding site on ER and altering its conformation (Shiau et al., 
1998). Once tamoxifen binds the ER, dimerization of receptors still occurs; however, subsequent 
transcriptional activation of target genes is obstructed (Lønning and Lien, 1995).  Consequently, 
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inhibition of tumor cell proliferation may occur, as shown by an accumulation of MCF7 cells in 
G1 phase due to their inability to transition through the cell cycle (Osborne et al., 1983). 
Induction of cell death also occurs since ER(+) MCF7 cells treated with tamoxifen display 
apoptotic morphology and DNA cleavage at a lower dose and more rapidly than ER(-) MDA-
MB231 breast cancer cells (Perry et al., 1995). Furthermore, although it lacks activity in a 
portion of ER-positive cancers, tamoxifen acts as an effective antiestrogen by targeting ERα for 
degradation in ER-positive breast cancer cells (Wu et al., 2009).  
Mechanisms of acquired and intrinsic resistance to tamoxifen are not completely 
elucidated; however, three possibilities have been proposed that address the metabolism of the 
drug, including alterations in ER, interaction with the tumor environment, and involvement of 
alternative signaling pathways. In the body, tamoxifen is metabolized into the primary 
compounds, 4-hydroxy-tamoxifen and N-desmethyl-tamoxifen, followed by secondary 
metabolism of both into the active metabolite, 4-hydroxy-N-desmethyl-tamoxifen (endoxifen) 
(Algeciras-Schimnich, et al., 2008). If alternative metabolic pathways emerge, tamoxifen may be 
converted instead into ER agonists and thus stimulate tumor growth (Crewe et al., 2002). In the 
second mechanism, although mutations in ERα are rare, splice variants are more common 
(Karnik et al., 1994; Dowsett et al., 1997). Surprisingly, acquired resistance is usually not 
concurrent with loss of ER expression or ineffective DNA binding to estrogen-response elements 
(Johnston et al., 1995; 1997). Signaling between the tumor mass and neighboring cells may 
promote tumor progression. For example, high levels of stromal cell-secreted proteolytic factors, 
such as urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 are associated with a 
poorer response to tamoxifen (Meijer-van Gelder ME et al., 2004). Finally, phosphorylation of 
ER by MAPK or Akt, which are activated by the HER-2 receptor, may stimulate tumor 
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proliferation. Indeed, an inverse correlation exists between Her-2/neu and ER expression, in 
which patients with high Her-2/neu are less responsive to tamoxifen treatment (Lewis and 
Jordan, 2005). 
As an alternative or possible solution to tamoxifen resistance, another hormonal therapy 
employing aromatase inhibitors was developed to treat women with ER(+) breast cancer. 
Aromatase inhibitors (AIs) function by inhibiting the aromatase enzyme responsible for the 
conversion of androgens into estrogens, thereby reducing physiologic levels of circulating 
hormone (Pietras, 2006). Unlike tamoxifen, AIs lack agonist activity and so are more effective in 
this respect as an adjuvant therapy. Current third-generation AIs are extremely potent and 
selective and show less toxicity as compared to the first-generation drug, and thus are the 
standard first-line therapy for hormone-dependent metastatic breast cancer (Samphao et al., 
2009). 
In addition to the standard chemo- and hormonal-therapeutics previously described, 
improved understanding of the molecular events in carcinogenesis has spurned the discovery of 
targeted therapies for breast cancer. Due to the specific nature of their action, these novel drugs 
are limited to the subset of tumors that display dependence on the target in question. A key 
pathogenic feature of breast cancer is the contribution of the epidermal growth factor receptor 
(EGFR) in disease progression (Normanno et al., 2006). The advent of gefitinib (Irresa®) was 
initially promising, but phase II clinical trials proved that it was ineffective for metastatic breast 
cancer, even when combined with chemotherapy (Agrawal et al., 2005; Ferrer-Soler et al., 
2007). Currently, trastuzumab (Herceptin®), which targets the HER2/ErbB2 receptor, a member 
of the epidermal growth factor receptor (EGFR) family, is designated as one of the most well 
used targeted inhibitors (Di Cosimo and Baselga, 2008). Activation of this tyrosine kinase 
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receptor leads to stimulation of signaling pathways involved in cellular proliferation, including 
the Akt, MAPK, and Jak/Stat pathways (Schlessinger, 2004). Overexpression of Her-2/neu 
occurs in about 30% of breast cancers and is associated with poor survival outcome (Slamon et 
al., 1989; Muller et al., 2004). Moreover, elevated Her-2/neu leads to a greater metastatic 
potential and resistance to p53-mediated apoptosis (Dittmar et al., 2002; Huang et al., 2002). 
Lepatinib (Tykerb®) is another targeted therapy that is dually directed towards EGFR and HER2. 
Treatment with either trastuzumab or lepatinib in combination with chemotherapy in patients 
with HER2 amplification improves disease-free survival (Slamon et al., 2001; Geyer, et al., 
2006). Although described briefly here, the list of viable targets in scientific and clinical 
development is continually expanding and will ultimately lead to the advancement of patient-
tailored therapies. 
 
1.9 Aims and Rationale for Study 
Due to the development of acquired drug resistance with single agents as well as with 
current combination treatments, there is a need to identify therapeutic regimens able to overcome 
this limitation. Despite numerous studies in a variety of solid tumors (Becker et al., 2004; Kato 
et al., 1995; Kurahashi et al., 2005; Ogata et al., 2000; Romanucci et al., 2006), the roles of 
Hsp90 and p23 during mammary carcinogenesis and progression and particularly how inhibiting 
these proteins may influence breast tumor biology remains unclear. Our laboratory has 
previously shown that in an experimental model for prostate cancer, Hsp90 and p23 are 
upregulated during malignant progression (Akalin et al., 2001). This study was then extended to 
clinical prostate specimens, in which normal tissue and benign prostatic hyperplasia (BPH) 
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demonstrate relatively low levels of both Hsp90 and p23 while carcinomas consistently express 
high levels (Elmore et al., 2008).  
Based on these studies, we assessed expression levels and cellular localization of Hsp90 
and p23 in normal and malignant breast tissues. Although examining Hsp90 expression in cancer 
cells is not a novel undertaking, current literature lacks comprehensive studies that assess Hsp90 
in normal tissue or in stages of breast cancer development, as well as its association to clinical 
variables. The present study assesses chaperone expression during the advancement of 
malignancy. We conjectured that chaperone expression would increase according to malignancy 
in breast tissue, as was observed for prostate specimens. This initial assessment was used to 
determine whether chaperone expression and localization patterns correlate with stage or 
advancement of disease.  
Based on the positive findings in the first study, it proved necessary to characterize the 
effects of Hsp90 inhibition in breast cancer cells. This entailed the characterization of this 
inhibition by pharmacologic methods using the Hsp90 specific drug, radicicol, which specifically 
targets the essential ATP binding site at the N-terminus of Hsp90 and binds with higher affinity 
to this pocket than client proteins, effectively blocking its ATPase activity. The rationale behind 
pharmacologic inhibition is based on the idea that lack of functional Hsp90 may cause telomere 
erosion and/or dysfunction, leading to apoptosis in breast tumor cells. In addition to the Hsp90 
inhibitor alone, various combinations of radicicol with other chemotherapeutics provided insight 
into the possibility of sensitization of breast cancer cells. Because nonspecific cytotoxicity is 
associated with these standard regimens, we speculated that inhibiting Hsp90 before initiating 
conventional therapy would help reduce the amount of exposure, drug dose, or duration of 
treatment, potentially leading to a better response with fewer side effects. In other words, we 
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hypothesized that Hsp90 inhibition would be an effective means to sensitize tumor cells to be 
more responsive to standard treatments. Chemotherapeutic and hormonal drugs used in 
combination treatments included Adriamycin, Cisplatin, Taxol, and Tamoxifen, all of which are 
currently used to treat both early and advanced breast cancer. The goal of the following 
experiments was to define and characterize the consequences of Hsp90 inhibition specifically on 
cellular proliferation, telomerase stability and function, telomere length, expression of client 
proteins, and ultimately on senescence or apoptosis in breast cancer cells.  
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Chapter 2 
Materials and Methods 
 
Drug Reagents 
Radicicol and cisplatin were purchased from Sigma and solubilized in DMSO (St. Louis, MO). 
Adriamycin, taxol, and tamoxifen were suspended in DMSO and were kindly provided by Dr. 
David Gewirtz, Pharmacology and Toxicology, VCU. All drugs were stored at -20oC until ready 
for use, at which time stock reagents were diluted in culture media. 
 
Cell Culture and Protein Extraction 
BJ fibroblasts were cultured in DMEM medium supplemented with 10% cosmic calf serum 
(HyClone Laboratories, Logan, UT), 0.36% 10x medium 199 (Invitrogen, Carlsbad, CA), and 
0.03 mg/ml gentamicin (Invitrogen). Human mammary epithelial MCF10A cells were cultured 
in DMEM/F12 (Invitrogen) supplemented with 10 µg/ml insulin (Sigma), 0.5 µg/ml 
hydrocortisone (Sigma), 20 ng/ml EGF (BD Bioscience, San Jose, CA,), 5% horse serum 
(Invitrogen), 100 ng/ml cholera toxin (Calbiochem, Gibbstown, NJ), and 1% pen/strep 
(Invitrogen). Breast cancer cell lines, MCF7 (obtained from American Type Culture Collection), 
MDA-MB 231, and ZR75-1 were grown in RPMI 1640 medium supplemented with 0.03 mg/ml 
gentamicin (Quality Biologicals, Gaithersburg, MD) and 10% fetal bovine serum (Fisher 
Scientific, Pittsburgh, PA). All cells were maintained as monolayers and cultured at 37oC in 5% 
CO2 and 100% humidity, as previously described (Elmore et al., 2002). Upon near confluence or 
conclusion of drug treatments, cells were washed with 1x phosphate-buffered saline (PBS) and 
briefly treated with trypsin-EDTA (Invitrogen). Cells were harvested for lysing in a standard 
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radioimmune precipitation assay buffer (RIPA: 1% Nonidet-P40, 1% sodium deoxycholate, 
150mM Tris, 50mM NaCl, 1mM EDTA) and a protease inhibitor cocktail (EMD Chemicals, 
Gibbstown, NJ). Lysates were cleared by centrifugation at 11,000 rpm for 20 min. Extracted total 
protein content in the supernatant was quantified using a Lowry-based colorimetric assay (Bio-
Rad, Hercules, CA) according to manufacturer’s protocol. Li-Fraumeni human mammary 
epithelial (HME) cell protein lysates were prepared as above and generously provided by Dr. 
Lauren Gollahon of Texas Tech University (Lubbock, TX). 
 
Western Blot Analysis and Quantitation 
A 15 µg (for Hsp90, p23, and β-actin proteins) or 50 µg (for all other proteins) aliquot of total 
cell protein was separated in a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose 
membrane. Standard blotting protocol included blocking of non-specific reactions by incubation 
in 5% dry milk (Bio-Rad), followed by washing three times for 10 min each in 1x PBS/0.1% 
Tween 20 and incubation with primary antibody. Antibodies used include anti-Hsp90 
monoclonal (recognizes both α and β isoforms), anti-p23 monoclonal, and anti-Hsp70 
monoclonal (1:5000, all kindly provided by Dr. David Toft, Mayo Clinic); anti-p53 pantropic 
(1:1500, Calbiochem); anti-Cip1/WAF1 (1:1500, BD Transduction Laboratories); anti-Cdk4 
(1:1500, Santa Cruz Biotechnology, Santa Cruz, CA); anti-Hsp27 (1:1500, Stressgen, Ann 
Arbor, MI); and anti-c-abl (1:1000, Santa Cruz Biotechnology). Anti-β-actin monoclonal 
(1:5000, Sigma) antibody was included as a loading control. The membrane was then washed 
again three times and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG 
secondary antibody (1:3000, Bio-Rad). Transferred proteins were detected by 
chemiluminescence reaction (Pierce Super Signal West Pico, Rockford, IL) according to 
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manufacturer’s protocol. Quantitation was performed via densitometry using the ChemiImager 
4400 software program (Alpha Innotech, San Leandro, CA). 
 
Design of Tissue Microarrays (TMAs) 
Breast tissue arrays were obtained from the National Cancer Institute’s Cooperative Breast 
Cancer Tissue Resource (CBCTR) (http://cbctr.nci.nih.gov). The second generation case sets 
were created from 679 breast tissue specimens divided into six non-overlapping sets (Figure 12). 
Each tissue specimen was arrayed in quadruplicate to address possible tissue heterogeneity, such 
that four cores were taken from each breast tissue specimen, with one core per specimen 
appearing in each of the four replicate paraffin tissue microarray (TMA) blocks. A collection of 
these blocks is referred to as a case set. A complete array set, representing the minimum number 
of cores recommended for an experiment, includes sections from three case sets. We have 
obtained sections from three individual case sets (#3, #5, and #7). Assembled TMA blocks were 
cross-sectioned, formalin-fixed, and paraffin-embedded onto slides (one section per slide). Each 
slide contains between 133-135 cores, including 79-80 invasive breast cancer, 23 normal, and 
10-11 ductal carcinoma in situ (DCIS) breast specimens. Also included are 21 control cores, with 
normal spleen arrayed in triplicate, breast cancer cell lines selected based on expression of 
several mammary cancer-associated proteins, and non-breast specific cell lines. A total of six 
slides each were stained for Hsp90, p23, and TRF2 (two slides each from three case sets). One 
slide from case set #3 served as a PBS negative control, in which no primary antibody was 
applied, yet was processed in exactly the same manner as the experimental slides. Relevant 
clinical data provided for each case included age at diagnosis, estrogen receptor (ER) and 
progesterone receptor (PR) status, and tumor-node-metastasis (TNM) stage.  
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Figure 12: Design of Tissue Microarrays. Second generation breast tissue arrays were obtained 
from the National Cancer Institute’s Cooperative Breast Cancer Tissue Resource. Each tissue 
specimen was arrayed in quadruplicate to address possible tissue heterogeneity, with one core 
per specimen appearing in each of the four replicate paraffin tissue microarray (TMA) blocks. A 
collection of these blocks is referred to as a case set. A complete array set, representing the 
minimum number of cores recommended for an experiment, includes sections from three case 
sets. Sections were sliced from each paraffin block and embedded onto slides. 
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Immunohistochemistry (IHC) / Immunocytochemistry (ICC) 
 
A standard immunohistochemical staining procedure (Akalin et al 2001) was used to detect 
Hsp90 and p23 in breast tissue arrays. A VectaStain ABC immunoperoxidase IgG detection kit 
(Vector Labs, Burlingame, CA) was used according to the manufacturer’s recommendations, 
using diaminobenzidine (Vector Labs) as the substrate. Slides were deparaffinized in CitriSolv 
(Fisher Scientific), rehydrated in graded ethanol series, and steamed for antigen retrieval in a 
modified citrate buffer (pH 6.1) (Dako Cytomation, Carpinteria, CA). Endogenous peroxidase 
activity was quenched, followed by blocking in horse serum, overnight incubation with primary 
Hsp90 or p23 antibody (provided by Dr. David Toft, Mayo Clinic) or primary TRF2 antibody 
(Upstate, Charlottesville, VA), 1 hr incubation with biotinylated secondary antibody, 30 min 
incubation with avidin-biotin complex, and 10 min incubation with DAB substrate. Slides were 
then lightly counterstained with Gill’s Hematoxylin (Poly Scientific, Bay Shore, NY) prior to 
dehydration in increasing ethanol gradients, clearing, and permanent mounting with Permount 
(Fisher Scientific). 
 
Immunoprecipitation 
Sub-confluent untreated cells were harvested and lysed as described above. A 100 µg or 300 µg 
aliquot of lysate was precleared with protein G agarose (Roche, Indianapolis, IN) or protein L 
agarose (Santa Cruz Biotechnology) beads, respectively. Following primary antibody incubation 
with complexed Hsp90 (Stressgen, SPA-845) or uncomplexed Hsp90 (Stressgen, SPA-830) for 2 
hr, prewashed protein G (for uncomplexed Hsp90) or L (for complexed Hsp90) beads were 
added to the sample and agitated overnight. Bead-protein mixtures were spun down and 
supernatant collected as the unbound fraction. Bead-bound fraction was washed three times with 
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TRAP lysis buffer (0.1% Nonidet-P40, 1 M Tris-Cl pH 7.5, 0.5 M KCl, 1 M MgCl2, 1 M 
dithiothreitol, 20% glycerol). All samples were heat denatured at 95oC for 10 min and bead-
bound fraction was briefly spun down prior to being electrophoresed on a 10% SDS-
polyacrylamide gel.  
 
Drug Treatments  
To determine the optimal RAD concentration to use for chronic drug studies, approximately 1 x 
105 MCF7 cells were plated in 6-well dishes. The next day, cells were treated with a range of 
RAD concentrations including 0.01 µM, 0.03 µM, 0.1 µM, 0.3 µM, 1 µM, 3 µM, and 10 µM for 
4 hr, 24 hr, or 48 hr. For chronic drug treatments, approximately 5 x 105 MCF7 cells were plated 
in 100 cm2 dishes or 5 x 104 cells were plated in 6-well dishes. The next day, cells were either 
not treated (Adr only cells) or treated with 0.03 µM RAD for 48 hr (for RAD+Adr cells), 
followed by acute treatment for all cells with Adr for 2 hr.  The range of Adr used included 
0.0075 µM, 0.025 µM, 0.075 µM, 0.25 µM, and 0.75 µM. For combination treatments with CIS 
and TAX, cells were either not treated (for CIS or TAX only cells) or treated with 0.03 µM RAD 
(for RAD+CIS or RAD+TAX cells) for 48 hr beginning the day after original plating. All cells 
were then washed with 1x PBS, and treated with either 0.1 µM CIS or 100 nM TAX, 
respectively, for 24 hr. For combination treatments with TAM, all cells were treated with 1 µM 
TAM for 24 hr beginning the day after original plating. The next day, cells were either not 
treated (TAM+Adr only cells) or treated with RAD (TAM+RAD+Adr cells) for 48 hr. This was 
followed by acute treatment with Adr for 2 hr. The concentrations of Adr used included 0.075 
µM and 0.75 µM. Upon completion of treatments for each drug series, cells were washed with 1x 
PBS (Invitrogen) and fresh media was added. 
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Cell Growth Assays 
MCF7 cells were plated and treated with various drug combinations as described above. At the 
conclusion of each treatment period, cells were washed once in 1x PBS and harvested using 
trypsin-EDTA (Invitrogen). Cell growth was measured by counting in triplicate using a 
hemocytometer (Hausser Scientific, Horsham, PA). Population doubling was calculated using 
the formula [log10(cell count post treatment/original cell count)]/0.3. 
 
Telomere Repeat Amplification Protocol (TRAP) Assay 
After drug treatment, telomerase activity was measured using the TRAPeze® telomerase 
detection kit (Chemicon/Millipore, Billerica, MA) according to the manufacturer’s 
recommendations, as previously described (Forsythe et al., 2001). Each 100,000 cell sample was 
lysed in 1x CHAPS lysis buffer (Chemicon/Millipore) with protease inhibitor cocktail (EMD 
Chemicals). TS primer was labeled with [γ-32P]ATP (Perkin Elmer, Boston, MA) for 30 min, 
followed by telomerase-mediated extension incubation with cell extract equivalent to 1000 cells 
for 25 min. Extended products were then amplified by PCR via a two-step process (94°C for 30 s, 
60°C for 30 s) for 27 cycles. Amplified products were separated on a 10% polyacrylamide gel, 
which was subsequently fixed and exposed to a PhosphorImager screen (Molecular Dynamics, 
Sunnyvale, CA) overnight. Relative telomerase activity was quantified using ImageQuant 5.2 
software (Molecular Dynamics) by determining the ratio of the sample telomerase ladder activity 
to the standard internal 36 bp ladder. 
 
Terminal Restriction Fragment (TRF) Assay 
Telomere length was determined via the terminal restriction fragment (TRF) assay.  Genomic 
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DNA was isolated from cells using Blood and Cell Culture Midi Kit and columns (Qiagen, Santa 
Clarita, CA) according to manufacturer’s instructions. Following quantitation using the 
NanoDrop 100 Spectrophotomer (Thermo Scientific, Waltham, MA), 8-10 µg of DNA was 
digested with a mixture of AluI, HaeIII, HinfI, MspI, and RsaI restriction enzymes (New England 
BioLabs, Ipswich, MA) for 4 hr and resolved on a 0.7% agarose gel that included a 1 kb 
(Invitrogen) and HindIII DNA digest ladder (New England Biolabs). These ladders, as well as a 
G-rich telomere specific (TTAGGG)4 probe (IDT, San Diego, CA), were labeled with [γ-
32P]ATP for 30 min at 37oC. Unincorporated radioactive ATP was removed using the QIAquick 
nucleotide removal kit (Qiagen). The gel was then denatured in 1.5 M NaCl, 0.5 M NaOH for 30 
min, dried until thin (Gel Dryer 583, BioRad), and neutralized in 1.5 M NaCl, 0.5 M Tris for 15 
min. Following this series, the dried gel was hybridized with labeled probe overnight, washed at 
least three times in 0.1X SSC, 0.1% SDS, and exposed on a PhosphorImager cassette (Molecular 
Dynamics) overnight. 
 
Senescence associated β-Galactosidase Staining and Quantitation 
MCF7 cells were plated in 6-well dishes and treated with RAD alone or RAD and Adr. At 4 d 
post-treatment, cells were washed twice in 1x PBS, followed by fixation in 2% formaldehyde, 
0.2% glutaraldehyde for 5 min at room temperature. After washing twice in PBS, cells were 
incubated for 4 h in the dark at 37oC with 1 mg/ml β-galactosidase substrate (X-gal, Gold 
BioTechnology, St. Louis, MO) prepared fresh in 40 mM citric acid/NaP buffer, pH 6.0, 5 mM 
potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl, as 
previously described (Elmore et al., 2002). After two washes in PBS, the percentage of 
positively stained cells was quantified by counting three random fields. 
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Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) Assay 
Upon completion of drug treatments, both floating and adherent fractions of MCF7 cells were 
collected and approximately 2 x 104 MCF7 cells were cytospun (Shandon Cytospin 4, Thermo 
Scientific). Cells were fixed in 4% formaldehyde for 10 min, washed twice in 1x PBS, postfixed 
in -20oC cold glacial acetic acid:ethanol (1:2) for 5 min, and washed twice again. Subsequent 
steps were performed in a covered humidifying chamber in the dark. These steps included 
blocking in 1 mg/ml bovine serum albumin (New England Biolabs) for 30 min and incubation 
with terminal transferase (Roche) in the presence of fluorescein 12-dUTP (Roche) for 60 min at 
37oC in the dark. Cells were washed with 1x PBS and mounted in Vectashield with DAPI 
(Vector Labs). 
 
Fluorescence in situ hybridization (FISH). To assess telomere length, a pantelomeric, FITC-
labeled peptide nucleic acid (PNA) probe was used to detect telomeres on TMAs. The probe 
hybridization followed standard procedures that have been shown to be successful in breast 
cancer cell lines and adapted to test the TMAs (Bradshaw et al., 2005; Jones et al., 2005). Each 
slide was pretreated with heat incubation overnight at 60oC, followed by deparaffinization and 
rehydration in a graded ethanol series. Slides were microwaved in citric acid (pH 6.0) and 
digested in pepsin solution (4 mg/ml in 0.9% NaCl, pH 1.9). After immersion in 3:1 fix of 
methanol:acetic acid for 1 hr and fixation in 4% formaldehyde in PBS (pH 7.2), tissue cores and 
FITC-labeled telomeric probe (C3TA2)3  and PNA probe were codenatured for 3 min at 80oC. 
Hybridization overnight at 37oC was followed by washing in denaturation solution (70% fo 
rmaldehyde/2x SSC for 15 min at 31oC) to remove excess probe. After washing in 2x SSC and 
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2x SSC with 0.1% NP-40, slides were air dried and counterstained with DAPI (Cytocell, 
Windsor, CT). 
 
Scoring of Slides  
For IHC, mounted slides were semi-quantitatively scored by two independent pathologists in 
terms of reactivity (positive if >10% of the cells are immunostained), intensity based on an 
ordinal scale (negative/very weak = 0, weak = 1, moderate = 2, strong = 3), and cellular 
localization (nuclear or cytoplasmic). Inter-rater agreement was measured using a weighted 
kappa test. For FISH, one slide was scored by Dr. Colleen Jackson-Cook, Director of 
Cytogenetics Diagnostic Laboratory at VCU, and the rest by Kristi Turner, Cytogenetics 
Research Specialist at VCU. Relative telomeric DNA lengths are assessed by visual inspection of 
telomere-specific hybridization probe fluorescent intensities between pre-malignant and 
malignant breast tissue and their normal counterparts. A semi-quantitative assessment of 
telomere signals was performed. Lesions categorized as “normal” are scored “2” and have 
telomeric signals comparable to those of normal stromal fibroblasts, endothelial cells, and 
normal mammary epithelial cells. Lesions categorized as “short” are scored “1” and have signal 
intensities dimmer than the normal stroma, but are still readily detectable and within the normal 
range of normal cells. Lesions categorized as “very short” are scored “0” and have such low 
telomeric signal that they are barely detectable and dimmer than any normal cell. Lesions 
categorized as “long” are scored “3” and have signal stronger than that found in normal cells.  
 
Statistical Analysis  
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For western blot analysis, changes in population doublings, and telomerase activity, a student’s t-
test was performed to assess statistical significance of mean sample differences. For IHC, 
rigorous statistical analysis was performed using R version 2.9.1 to definitively assess Hsp90, 
p23, and TRF2 expression differences across all disease types using analysis of variance methods 
with significance set at p<0.05. Analyses that involved prediction of intensity scores were 
handled using a mixed effects modeling approach (Faraway, 2006) to handle the presence of 
both fixed and random effects. Pearson’s correlations were calculated to assess the relationship 
between protein expression and TNM stage, ER/PR, or age, with significance set at p<0.05. 
Intensity scores were treated as ordered categorical values while localization was a nominal 
outcome. The design of the TMA further identifies multiple cores from the same case and 
replicate sections. Student’s t-test was used to determine significance for changes in cellular 
localization. 
 
Image Acquisition 
All images of Hsp90, p23, and TRF2 immunostained tissue microarrays were magnified by 
Nikon Eclipse E600 and captured by Nikon Digital Camera DXM1200F, using the Nikon ACT-1 
image editing program. FISH images were obtained using a Zeiss AxioScope2, equipped with 
DAPI, FITC and dual color filters. All phase contrast, β-Galactosidase, and TUNEL images were 
obtained by a Zeiss Axiovert 40 microscope, maintained by the microscopy facility of VCU’s 
Anatomy and Neurobiology. All TRAP and TRF images were scanned on a Typhoon 9410 
Variable Mode Imager (GE, Piscataway, NJ), maintained by the Massey Cancer Center of VCU. 
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Chapter 3 
Differential expression of Hsp90 and its co-chaperone, p23, in human breast tissue 
 
3.1 Introduction and Rationale 
 
Molecular chaperones, like the heat shock protein 90 (Hsp90) family, are regarded as 
ubiquitous, highly conserved proteins that mainly respond upon induction of stress or disruption 
of cellular homeostasis. Chaperones are involved in controlling the conformation, stability, 
function, and degradation of many oncogenic client proteins, thus determining their cellular fate 
(Beliakoff and Whitesell, 2004; Csermely et al., 1998). Functionally, the Hsp90 multiprotein 
machinery assists in trafficking, the remodeling of improperly folded client proteins, and the 
suppression of protein aggregation (Whitesell and Lindquist, 2005; Sarto et al. 2000). Kinases, 
transcription factors, hormone receptors, and certain polymerases, like telomerase, all undergo 
post-translational maturation via the Hsp90 chaperone cycle (Dai and Whitesell, 2005; Holt and 
Shay, 1999).  
The intrinsic nature of heat shock proteins makes them especially relevant to a cell’s 
defense against cancer initiation.  Previous studies have reported an overexpression of Hsp90 in 
human breast cancer; however, only tumor specimens and breast cancer cell lines, but not normal 
and pre-malignant specimens, were examined (Pick et al., 2007). The stress-inducible isoform 
Hsp90α has also been reported to be preferentially increased in cancer tissues compared to non-
cancerous tissues, but this study did not assess total Hsp90 levels in normal tissues (Yano et al., 
1996, 1999). Because upregulation of Hsp90 was reported in these previous findings, Hsp90 
inhibition has attracted great interest as a promising approach for cancer therapy since many 
client proteins can be simultaneously targeted and disrupted (Goetz et al., 2003; Sharp and 
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Workman, 2006), which would likely result in tagging of client proteins with polyubiquitin 
molecules and subsequent proteasomal degradation (Pearl et al., 2008). As such, the Hsp90 
inhibitor, 17-allyamino, 17-demethoxy geldanamycin (17-AAG), is in phase II clinical trials and 
is a promising anticancer drug, since it is less hepatotoxic and more stable than its parent 
compound, geldanamycin (Pacey et al., 2006). 
The co-chaperone p23 has also been studied for its role in breast cancer, although the 
majority of studies involving p23 focus on the relationship of this protein with steroid hormone 
receptors. Specifically, overexpression of p23 positively regulates the activity of the estrogen 
receptor, which regulates growth-promoting gene transcription, resulting in enhanced 
invasiveness of breast cancer cells without any effect on proliferation (Björnström and Sjöberg, 
2005; Knoblauch and Garabedian, 1999; Oxelmark et al., 2006). The expression of p23 in breast 
cancer cell lines also increases according to tumor grade (Oxelmark et al., 2006), with higher 
expression in high-grade tumors. Furthermore, p23 has been shown to be significantly increased 
in mammary tumors and metastatic lung carcinomas and very weak in normal tissue (Krebs et 
al., 2002; Mollerup et al., 2003). These findings implicate p23 in cancer cell growth, and may 
suggest a novel role for this co-chaperone in tumor cell invasion or metastasis and breast cancer 
progression. 
Despite these studies and others in a variety of solid tumors (Becker et al., 2004; Kato et 
al., 1995; Kurahashi et al., 2005; Ogata et al., 2000; Romanucci et al., 2006), the role of Hsp90 
and p23 during mammary carcinogenesis and progression remain unclear, particularly how 
inhibiting these proteins may influence breast tumor biology. Our laboratory has previously 
shown that in an experimental model for prostate cancer, Hsp90 and p23 are upregulated during 
malignant progression (Akalin et al., 2001). This study was then extended to clinical prostate 
 63
specimens, where we demonstrated that normal tissue and benign prostatic hyperplasia (BPH) 
express relatively low levels of both Hsp90 and p23 while carcinomas consistently express high 
levels (Elmore et al., 2008).  
We now assess expression levels and localization of Hsp90 and p23 in normal and 
malignant breast tissues, which will then be used to determine whether chaperone expression 
correlates with stage or advancement of malignancy, with particular attention on subcellular 
localization and tumor grade. The results obtained in this study will provide the rationale behind 
whether inhibition of chaperones is an appropriate means to sensitize tumor cells to be more 
responsive to traditional cancer therapeutics. 
 
3.2 Results 
3.2.1 Hsp90 and p23 protein levels are elevated in breast cancer cells.  
Since little is known about the roles of Hsp90 and its co-chaperone, p23, in mammary 
carcinogenesis and progression, we initially assessed their expression in human cell lines. Total 
cellular levels of Hsp90 and p23 were examined in normal human mammary epithelial cells 
(HMEs) at various population doublings, as well as in established human breast cancer cell lines.  
Pre-immortal HMEs at lower population doublings displayed significantly lower levels of both 
Hsp90 and p23 as compared to their isogenic immortal HME (PD>100) cell line and breast 
cancer cell lines (Figure 13A). Western analysis of Hsp90 shows relatively equal levels of this 
chaperone, however, upon quantitation, it is evident that Hsp90 is moderately elevated 1.2-fold 
in immortal HMEs, 1.4-fold in MCF7, 1.6-fold in MDA-MB231, and 1.3-fold in ZR75-1 (Figure 
13B). Compared to HMEs at PD 11.8, p23 is almost two-fold greater in immortal HMEs, 3.2-
fold greater in MCF7, 2.4-fold greater in MDA-MB231, and 2.1-fold greater in ZR75-1. It is 
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Figure 13. Hsp90 and p23 protein levels increase with population doubling in normal cells 
and are high in established breast cancer cell lines. (A) 15 µg of total cellular lysate from pre-
immortal Li-Fraumeni human mammary epithelial cells (HMEs) at low passage numbers, 
isogenic immortal HMEs, and breast cancer cell lines (MCF7, MDA-MB231, ZR75-1) was 
subjected to western analysis. Immunoblots were probed with antibodies against Hsp90, p23, and 
β-actin, which served as a loading control. (B) Quantitation of western blot by densitometry. All 
experiments were performed in triplicate, unless other wise noted. Significance was set at p < 
0.05. HME 50-5 PD 34.2 was only analyzed once and so was not able to be assessed for 
significance.  
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notable that within the HME cells, p23 protein expression increases as cells progress toward 
immortality with high passage cells displaying higher levels.  
In order to confirm the increased expression of Hsp90 and p23 in these cancer cell lines, 
immunostaining was performed on live cells, including immortalized human mammary epithelial 
MCF10A cells, breast cancer MCF7 and MDA-MB231 cells, and prostate cancer PC-3 cells. All 
immortal and cancer cells lines tested display extremely high levels of Hsp90 and p23 that 
appear in both nuclear and cytoplasmic locations (Figure 14). 
 
3.2.2 Established cancer cell lines on TMA consistently express higher Hsp90 and p23 levels.  
As an extension of the in vitro finding of increased Hsp90 and p23 in cancer cells, we 
wanted to determine whether cell lines included in the tissue arrays also reflect an upregulation 
of these chaperones. Each array contained cores of the established cell lines MCF10A, MCF7, 
T47D, PC-3, and the human colon adenocarcinoma cell line HT-29. For Hsp90 and p23 
expression, a total of 106 and 104 cell line cores, respectively, were examined. Representative 
images of Hsp90 and p23 immunostaining for these cell lines (data not shown for HT-29) reveal 
that these proteins are localized to both the nucleus and cytoplasm, although to varying degrees 
(Figure 15). For Hsp90, expression of this chaperone is always greater in the cytoplasm than in 
the nucleus, such that cytoplasmic scores indicate consistently strong staining (Table 1). When 
assessing average Hsp90 scores, it is again clear that this chaperone is abundantly expressed in 
the cytoplasm, with the majority of cell line cores (75.8%) staining very strongly (Table 2). 
Nuclear Hsp90 expression is only moderately reduced with the majority of cores staining either 
+1 or +2 in intensity (71.3%) (Table 2). 
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Figure 14: High Hsp90 and p23 expression in established immortal and cancer cell lines. 
Immunocytochemical staining of immortalized breast epithelial MCF10A cells, breast cancer 
MCF7 and MDA-MB231 cells, and prostate cancer PC3 cells show abundant Hsp90 and p23 
expression. Bottom panel represents PBS-incubated negative control cells, in which no primary 
antibody was added. 
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Figure 15. Cell lines of TMA consistently express high levels of both Hsp90 and p23. 
Established cell lines included in the TMAs were also subjected to immunohistochemical 
processing. Representative images of the immortalized breast epithelial cell line MCF10A (B); 
breast cancer cell lines MCF7 (E) and T47D (H); and the prostate cancer cell line PC3 (K), are 
shown stained with an antibody against Hsp90. MCF10A (C), MCF7 (F), T47D (I), and PC3 (L) 
cores were also stained with an antibody for p23. PBS-treated MCF10A (A), MCF7 (D), T47D 
(G), and PC3 (J) served as a negative control (no primary antibody). Total numbers of cores 
stained for Hsp90 and p23 was n = 106 and n = 104, respectively. All images shown are at 40x.  
moderately intense in the cytoplasm (41.7% ± 0.04%) and a greater proportion of moderately 
intense nuclear p23-staining cell lines (45% ± 0.03%) as compared to Hsp90. Taken together, 
our data reveal that Hsp90 and p23 protein expression in detectable in both cellular locations, 
although to different extents, in established immortal and cancer cell lines. 
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Table 1: Summary of chaperone intensity of established cell lines on TMAs.  
Mean Hsp90 Score  Mean p23 Score 
Cell Line Nuclear Cytoplasmic  Nuclear Cytoplasmic 
MCF10A 1.04 2.67  1.95 1.82 
MCF7 0.63 2.79  1.54 1.25 
T47D 1.75 2.96  1.78 1.35 
PC3 1.42 3.00  1.54 1.63 
HT-29 1.46 3.00  0.82 1.09 
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Table 2: Cell Line cytoplasmic and nuclear immunostaining 
  Hsp90  p23  
    Intensity Nuclear % 
(stdev) 
Cytoplasmic % 
(stdev) 
Nuclear % 
(stdev) 
Cytoplasmic % 
(stdev) 
0 24.1 (0.02) 1.4 (0.004) 19.8 (0.01) 8.4 (0.01) 
1 40.6 (0.03) 1.4 (0.004) 29.2 (0.03) 47.3 (0.04) 
2 30.7 (0.02) 21.4 (0.01) 45.0 (0.03) 41.7 (0.04) 
3 4.6 (0.02) 75.8 (0.02) 6.0 (0.01) 2.6 (0.007) 
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As a group, it appears that the levels of p23 in nuclear and cytoplasmic locations are 
comparable to each other (Table 1). Interestingly, immortalized breast epithelial and breast 
cancer cell lines have less intense cytoplasmic p23 than nuclear, while the opposite situation is 
found in prostate and colon cancer cells (higher cytoplasmic and lower nuclear). A comparison 
of average p23 scores reveals that the expression of cytoplasmic p23 in cell lines is simply not as 
strong as that of Hsp90, with only 2.6% staining very strongly (compare to 75.8% for Hsp90, 
Table 2). Rather, the majority of cell lines express relatively lower cytoplasmic p23 levels 
(47.3%). Furthermore, there is a greater proportion of cell lines staining moderately intense in 
the cytoplasm (41.7%) and a greater proportion of moderately intense nuclear p23-staining cell 
lines (45%) as compared to Hsp90. Taken together, our data reveal that Hsp90 and p23 protein 
expression is detectable in both cellular locations, although to different extents, in established 
immortal and cancer cell lines. 
 
3.2.3 Hsp90 expression in clinical tissues is predominantly cytoplasmic.  
Based on the finding in tumor cell lines, we wanted to determine whether Hsp90 
expression is also relatively higher in malignant breast tissue specimens. Tissue arrays 
containing the three disease states, normal, ductal carcinomas in situ (DCIS), and invasive breast 
carcinomas, were immunohistochemically stained for Hsp90. Briefly, clinical samples including 
each of these three tissue types were obtained and arrayed (tissue cores punched out) in 
quadruplicate to address tissue heterogeneity. Each of these four cores was then paraffin-
embedded onto separate slides such that a group of six slides constitutes a case set. We have 
obtained three case sets and have used two slides from each case set to assess Hsp90 and p23 
levels, while the remaining two slides were treated as negative controls. Each slide thus contains 
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hundreds of representative cores that can be processed and analyzed simultaneously. For Hsp90 
and p23 expression, a total of 107 and 111 normal cores; 55 and 56 DCIS cores; and 457 and 426 
invasive breast carcinomas, respectively, were examined.  
As shown in Figure 16A and 16B, normal breast tissues predominantly show lower 
Hsp90 staining intensity, with the majority of cores staining very weakly for Hsp90 in the 
nucleus (68.3%) (Table 3). Similarly, approximately 69.1% of DCIS (Figure 16C, D) and 72.9% 
of invasive breast carcinomas (Figure 16E, G) also stained weakly in the nucleus for Hsp90 
(Table 3). Representative images of invasive carcinomas show that Hsp90 expression is variable, 
ranging from very weak nuclear staining (or mainly cytoplasmic) to very strong (Figure 16F, G). 
Based on this data, we therefore conclude that nuclear Hsp90 staining does not appear to vary 
between the disease types. 
Unlike nuclear Hsp90 expression, cytoplasmic staining is moderately strong in all clinical 
specimens in these tissue arrays. Namely, the majority of normal cores (38.7%), DCIS (59%), 
and invasive carcinomas (51.2%) all express moderate levels of Hsp90 in the cytoplasm (Table 
3). Interestingly, over half of the DCIS and invasive carcinomas show moderately intense Hsp90 
staining while this intensity is observed in just over a third of normal cores. As a corollary, a 
small fraction of normal tissue (2.4%) express very strong Hsp90 staining, while DCIS and 
invasive tissues have ~8.4-fold (20.2%) and ~6.3-fold (15.1%) more, respectively (Table 3). 
Thus, cytoplasmic Hsp90 expression is generally greater in malignant tissue. 
 
3.2.4 p23 nuclear expression differs between disease types.  
Since p23 protein levels were shown to be significantly elevated in tumor cell lines, we 
wanted to assess p23 expression and localization in breast tissue counterparts. Normal, DCIS,
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Figure 16. Hsp90 cytoplasmic expression is elevated in invasive breast carcinomas as 
compared to normal and DCIS tissues. Immunohistochemical analysis of negative control (no 
primary antibody) PBS-treated normal (A), DCIS (C), and invasive (E) breast tissues and Hsp90-
stained normal (B), DCIS (D), and invasive (F, G) breast carcinomas. Six slides were processed 
for Hsp90 that included an overnight incubation with primary antibody, 10 min. DAB 
incubation, and light hematoxylin counterstain. Total numbers of cores stained was n = 107 for 
normal, n = 55 for DCIS, and n = 457 for invasive carcinomas. Myoepithelial and epithelial cells 
are denoted by the arrow and arrowhead, respectively. All representative images shown are at 
40x. Overall weighted kappa = 0.8358. 
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Table 3: Hsp90 cytoplasmic and nuclear immunostaining 
 Cytoplasmic Score % (stdev)  Nuclear Score % (stdev)  
Intensity Normal DCIS Invasive Normal  DCIS Invasive 
0 24.3 (0.05) 3.9 (0.01) 12.4 (0.03) 68.3 (0.07) 69.1 (0.04) 72.9 (0.03) 
1 34.6 (0.02) 16.9 (0.02) 21.3 (0.02) 29.7 (0.04) 30.0 (0.03) 22.5 (0.02) 
2 38.7 (0.04) 59.0 (0.03) 51.2 (0.03) 2.0 (0.006) 0.9 (0.003) 4.1 (0.007) 
3 2.4 (0.008) 20.2 (0.03) 15.1 (0.01) 0 0 0.5 (0.001) 
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and invasive breast carcinoma sections were processed for p23 immunoreactivity in the same 
manner as Hsp90. Based on tissue array data, nuclear p23 immunostaining noticeably differs 
among the disease types. Similar to the finding for Hsp90, it is evident that p23 expression is 
variable among invasive carcinomas. Additionally, p23 expression also shows differences 
between clinical tissues and established cell lines. Specifically, the majority of normal breast 
tissue (47.2%, Figure 17A, B) displays moderately strong nuclear staining while most DCIS 
(38.8%, Figure 17C, D) cores stain relatively weakly and invasive carcinomas (53.5%, Figure 
17E, G) stain very weakly (Table 4). This is in contrast to the cancer cell line finding, in which a 
greater proportion of established cell line cores stained moderately intense and very strong in the 
cytoplasm and a larger percentage score moderately intense in the nucleus (Table 2). This data 
suggests that a trend exists wherein p23 nuclear expression decreases with advanced malignancy, 
which is opposite of our in vitro cell strain/line results. 
An initial assessment of p23 immunostaining in cytoplasmic fractions reveals no apparent 
difference in the intensity of the majority of disease types. Specifically, normal (53.5%), DCIS 
(46.1%), and invasive (41.8%) cores all stain relatively weakly (Table 4).  However, it is 
noteworthy that a greater proportion of normal cores but a smaller proportion of invasive cores 
stain at this intensity. As an extension of this finding, fewer invasive cores stain moderately 
intense (24.4%) compared to normal tissue, while more invasive cancers stain very weakly 
(33.2%) compared to normal tissue (9.0%) (Table 4). Hence, these data also suggest reduced p23 
levels in more advanced cancers. 
 
3.2.5 Hsp90 and p23 expression differs between disease types but not between locations.  
In order to assess disease group-specific differences, normal, DCIS, and invasive
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Figure 17. Level of p23 is higher in normal breast tissue than in invasive breast 
carcinomas. Immunohistochemical analysis of negative control (no primary antibody) PBS-
treated normal (A), DCIS (C), and invasive (E) breast tissues and p23 primary antibody-stained 
normal (B), DCIS (D), and weakly staining invasive (F) and strongly staining invasive (G) breast 
carcinomas. Six slides were processed for p23 in the same manner as Hsp90. Total numbers of 
cores stained was n = 111 for normal, n = 56 for DCIS, and n = 426 for invasive carcinomas. All 
images shown are at 40x. Overall weighted kappa = 0.4957. 
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Table 4: p23 cytoplasmic and nuclear immunostaining 
 Cytoplasmic Score % (stdev)  Nuclear Score % (stdev)  
Intensity Normal DCIS Invasive Normal  DCIS Invasive 
0 9.0 (0.02) 19.8 (0.03) 33.2 (0.05) 12.9 (0.02) 26.2 (0.03) 53.5 (0.05) 
1 53.5 (0.04) 46.1 (0.03) 41.8 (0.03) 27.3 (0.02) 38.8 (0.04) 26.2 (0.01) 
2 37.1 (0.05) 34.1 (0.04) 24.4 (0.03) 47.2 (0.03) 28.8 (0.04) 18.4 (0.02) 
3 0.4 (0.002) 0 0.6 (0.002) 12.6 (0.02) 6.2 (0.01) 1.9 (0.004) 
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carcinomas were analyzed as separate groups. On a scale of 0 to 3, observed average scores for 
Hsp90 nuclear expression is fairly consistent between the disease types with normal tissues 
scoring 0.35, DCIS scoring 0.32, and invasive carcinomas scoring 0.32 (Table 5). These results 
do not suggest any significant differences in nuclear Hsp90 staining as cells progress from a 
normal to invasive state (p = 0.7468). In contrast, cytoplasmic Hsp90 expression does 
significantly differ between the disease types with normal breast tissue generally scoring lower 
(1.19) than both DCIS (1.95) and invasive carcinomas (1.69) (p<0.0001, Table 5). Although 
Hsp90 expression increases with advanced malignancy, there is no apparent change in cellular 
localization patterns (p>0.05) with cytoplasmic Hsp90 nearly always greater than nuclear levels. 
In the case of p23, both nuclear and cytoplasmic fractions exhibit the same trend in which 
higher p23 levels are associated with benign states and lower p23 levels with invasiveness. 
Again, disease specific differences exist in which normal, DCIS, and invasive carcinomas on 
average have significantly varied scores (p<0.0001, Table 5). Similar to the finding for Hsp90, 
no localization changes were noted for p23 (p>0.05). 
 
3.2.6 Breast cancer related clinical parameters are significantly associated with chaperone 
upregulation.  
Due to the variability in Hsp90 and p23 immunoreactivity within the invasive carcinoma 
group, we sought to determine whether this variability correlated with TNM stage and/or steroid 
hormone receptor status. Clinical data was provided by the CBCTR on the status of ER and PR, 
which are both Hsp90 client proteins. Breast cancers can be broadly grouped according to disease 
progression by assigning TNM scores, which takes into account the tumor-node-metastasis stage 
of a particular cancer, wherein a higher score is associated with greater severity. Invasive breast 
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Table 5:  Summary of disease type-specific differences 
  Observed means (s.e.)  
Chaperone Location Normal DCIS Invasive p-value* 
Hsp90 Nuclear 0.3480 (0.5171) 0.3235 (0.4907) 0.3191 (0.5702) 0.7468 
Hsp90 Cytoplasmic 1.1921 (0.8310) 1.9515 (0.7327) 1.6932 (0.8731) <0.0001 
p23 Nuclear 1.6099 (0.8465) 1.1892 (0.8583) 0.7214 (0.8395) <0.0001 
p23 Cytoplasmic 1.2870 (0.6354) 1.1441 (0.7242) 0.8607 (0.7746) <0.0001 
*p<0.05 are significant 
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carcinomas included in our case sets represented various levels of TNM stages. In our study, we 
found that a positive correlation exists between nuclear Hsp90 and TNM stage, in which higher 
Hsp90 expression is directly associated with a higher TNM score (p = 0.0023, Table 6). The co-
chaperone p23 does not appear to have any relationship with TNM stage (Table 6). Likewise, ER 
and PR negativity typically signify poorer prognosis since most available therapeutics depend on 
the presence of these receptors. Cytoplasmic Hsp90 expression has an inverse correlation with 
ER status, such that higher expression is associated with ER negativity (p = 0.0112, Table 7). 
Significant relationships between p23 and ER/PR also emerged, with higher nuclear p23 
correlating to ER positivity (p = 0.0003) and higher total p23 being positively associated with PR 
presence (nuc: p = 0.0044; cyto: p = 0.353, Table 7). 
Finally, in addition to significant relationships with chaperone expression, TNM stage 
also displays an inverse, or negative correlation with both ER and PR presence (p<0.0001 for 
both, Table 8), which is to say that a higher TNM stage, corresponding to a higher grade breast 
cancer, is significantly associated with ER and PR negativity. Collectively, these data suggest the 
involvement of the chaperones, Hsp90 and p23, in participating in breast cancer progression. 
Their influence on clinical parameters of prognosis are specifically observed in that nuclear 
Hsp90 is associated with more advanced breast cancer, while elevated p23 correlated with 
ER/PR positive tumors. 
 
3.2.7 Total Hsp90 in tumor cells is associated with an increase in both complexed and 
uncomplexed Hsp90.  
 Due to the differential expression of Hsp90 in normal, DCIS, and invasive breast 
carcinomas, we wanted to determine whether these changes in protein levels impacted the activity 
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Table 6: Correlations between TNM stage and average chaperone 
scores in invasive cores 
Chaperone Location Correlation p-value* 
Hsp90 Nuclear + 0.0023 
Hsp90 Cytoplasmic None 0.6018 
p23 Nuclear None 0.4690 
p23 Cytoplasmic None 0.2323 
*p<0.05 are significant 
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Table 7: Correlations between ER/PR status and chaperone expression in 
invasive cores 
Receptor Chaperone Location Correlation p-value* 
ER Nuclear None 0.1441 
 
Hsp90 
Cytoplasmic - 0.0112 
PR Hsp90 Nuclear None 0.6706 
  Cytoplasmic None 0.0933 
ER p23 Nuclear + 0.0003 
  Cytoplasmic None 0.0506 
PR p23 Nuclear + 0.0044 
  Cytoplasmic + 0.0353 
*p<0.05 are significant 
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Table 8: Relationship between TNM stage and hormone 
receptor status in invasive cores 
Receptor Correlation p-value* 
ER - <0.0001 
PR - <0.0001 
*p<0.05 are significant 
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state of Hsp90. As a rationale for Hsp90 as a viable therapeutic target for breast cancer, previous 
data reports that the Hsp90 found in tumor cells is nearly all in a complex with its client proteins, 
while Hsp90 in most normal cell types remains predominantly in an unbound state (Kamal et al., 
2003). Our results suggest differential expression of Hsp90 in normal, DCIS, and invasive breast 
carcinomas based on the cancer staging, rather than alterations in Hsp90/client protein binding 
status. In an effort to recapitulate the study by Kamal et al., we compared normal fibroblasts, 
MCF10A cells, and MCF7 breast cancer cells for the presence of bound (active) and free 
(inactive) forms of Hsp90 (Figure 18).  Our results show that while there is an increase in the 
client-complexed form of Hsp90 in immortal and tumor cell lines pulled down by protein G 
beads compared to fibroblast cell strains, there is considerably detectable complexed Hsp90 in 
normal cells. It is significant, in contrast to previous results, that there is also an abundance of the 
uncomplexed form of Hsp90 in immortal and tumor cells. Furthermore, there is a significant 
portion of Hsp90 protein that is not at all bound to protein G beads, suggesting that the 
immunoprecipitation may have been inefficient. 
In the course of troubleshooting these experiments, we discovered that the complexed 
Hsp90 form used in the Kamal et al., 2003 paper was actually an IgM antibody and that protein 
G beads were ineffective in recognition of this immunoglobulin type. For this reason, a modified 
immunoprecipitation technique was implemented in which we compared the ability of protein G 
and L beads to pull down uncomplexed Hsp90 (IgG antibody) and complexed Hsp90 (IgM) 
(Figure 19). For both the protein G and L beads, a variety of lysate concentrations were tested to 
determine the optimal concentrations – 100µg of lysate for G beads because lesser amounts 
failed to precipitate sufficient detectable Hsp90, which is consistent with previous report (Kamal 
et al., 2003), and a maximal recommended concentration of 300µg for L beads. In this procedure,  
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Figure 18.  Hsp90 in cancer cells exists in both a complexed and uncomplexed state. Normal 
BJ fibroblasts, MCF10A immortal mammary epithelial cells, and MCF7 breast cancer cells were 
subjected to immunoprecipitation using antibodies against the client-bound and client-free forms 
of Hsp90. Immunoprecipitation utilizing protein G beads was performed on 100 µg of total 
protein lysate. Left panels show fraction bound to beads (immunoprecipitated), while the right 
panels show the supernatant fraction (non-immunoprecipitated). Following IP, immunoblot was 
probed for total Hsp90 (Toft, recognizes both complexed and uncomplexed and both isoforms of 
Hsp90). 
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Figure 19: Schematic of modified immunoprecipitation technique. Total cell lysate was 
subjected to immunoprecipitation using two different agarose beads that recognize different 
immunoglobulins. Either 100 µg (for protein G) or 300 µg (for protein L) of lysate was 
precleared, followed by incubation with primary antibody, either complexed Hsp90 (IgM) or 
uncomplexed Hsp90 (IgG). Prewashed G or L beads were then added to each precleared G or L 
mixture, respectively, and incubated overnight with agitation. Each sample was spun down and 
supernatant collected as the “unbound” fraction, while bead-bound protein was labeled the 
“bound” fraction. In theory, protein G beads do not recognize IgM antibodies, and so complexed 
Hsp90 in the IgM form would be found in the “unbound” fraction (A). These G beads 
preferentially bind IgG antibody, so the uncomplexed Hsp90 form would be found in the 
“bound” fraction (B). Similarly, protein L beads have a distinct affinity for IgM antibodies, and 
so the “bound” fraction would only contain complexed Hsp90 (C, D). 
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optimal amounts of protein lysate from normal fibroblasts and breast cancer cells were 
precleared with either G or L beads, followed by incubation with primary antibody (complexed 
or uncomplexed Hsp90). Protein G or L beads were then added to the lysate-antibody mixture, 
incubated together, and bead-bound fractions separated from unbound fractions. Protein G beads 
do not recognize IgM antibodies, and so complexed Hsp90 would be found in the supernatant or 
“unbound” fraction (Figure 19A). Since G beads preferentially bind IgG antibody, the 
uncomplexed Hsp90 form would be found in the “bound” fraction (Figure 19B). Similarly, 
protein L beads have a distinct affinity for IgM antibodies, and the unbound fraction would 
contain uncomplexed Hsp90 (Figure 19C) while the bound fraction would only contain 
complexed Hsp90 (Figure 19D). 
Given the number of technical issues with immunoprecipitation-type assays in general, 
experiments employing this modified method were repeated a minimum of 10 times with 
differing protein concentrations, antibody types, incubation periods, and lysis conditions, with 
representative results shown (Figure 20) and compiled (Table 9). Indeed, protein G beads do not 
pull down IgM antibodies, as evidenced by the lack of complexed Hsp90 in the bound fraction. 
We again show that there is clearly detectable uncomplexed Hsp90 in cancer cells. However, 
upon immunoprecipitation with L beads, we do not detect either complexed or uncomplexed 
Hsp90 in the bead-bound fractions. The results presented here are in significant contrast with that 
reported by Kamal et al, as shown by the abundance of the uncomplexed form of Hsp90 in 
immortal and tumor cells. While they report detectable complexed Hsp90 with G bead 
incubation, we consistently could not repeat this finding. We are confident that our 
immunoprecipitation technique accurately represents biologically relevant findings, indicating
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Figure 20: Method of immunoprecipitation affects detection of Hsp90 complexes. Normal 
BJ fibroblasts and MCF7 breast cancer cells were compared for differential presence of client-
bound or free form of Hsp90.  A 100 µg or 300 µg aliquot of total cell lysate was 
immunoprecipitated for uncomplexed Hsp90 (SPA-830, IgG) and complexed Hsp90 (SPA-845, 
IgM) using protein G or protein L beads, respectively. Left panels show fraction bound to beads 
(immunoprecipitated), while the right panels show the supernatant fraction (non-
immunoprecipitated). Following IP, immunoblot was probed for total Hsp90 (Toft). 
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Table 9: Summary of complexed vs. uncomplexed Hsp90 in normal and cancer cells 
  Present Study  Kamal et al., 2003 
 Uncomplexed Hsp90 (830 IgG) 
Complexed  
Hsp90 (845 IgM)  
Uncomplexed 
Hsp90 (830 IgG) 
Complexed  
Hsp90 (845 IgM) 
B
ea
ds
 
 BJ MCF7 BJ MCF7  Normal Cancer Normal Cancer 
Bound + ++ − −  + − + + G 
Free + ++ ++ ++  − + − − 
Bound − − − −  ND ND ND ND 
L 
Free − + ++ ++  ND ND ND ND 
*representative of at least 10 separate experiments; ND = not done 
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that the Kamal et al.’s result is an artifact of inappropriate method. Taken together, our data may 
suggest that the differences between normal and immortal or cancer cells in terms of functional 
Hsp90 levels may be related to either its overall expression level or its subcellular location, 
rather than the client-binding status of Hsp90. 
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Chapter 4 
Effect of Hsp90 Inhibition on Breast Cancer Sensitization 
 
4.1 Introduction and Rationale  
While breast cancer patients now have a wide range of therapeutics available to them, 
occurrence of the disease is still common and treatment challenges still remain. Chemotherapy 
and hormonal therapy have been valuable therapeutic options that are widely used to treat 
inoperable breast cancer and either pre- or postoperatively as part of a breast conserving surgery 
regimen. Since this type of treatment destroys both tumor and normal cells, it is not especially 
selective in killing and is thus associated with significant side effects. 
Doxorubicin (Adriamycin®) has been a mainstay in the treatment of various solid tumors, 
including breast, ovary, liver, lung, and soft tissue sarcomas, and has been used as both a single 
agent and in combination therapies (Murphy et al., 1995; DeVita et al., 1993; Gewirtz, 1999). 
Additionally, novel platinum-based compounds are rapidly gaining research interest as cancer 
combatants. Cisplatin has exhibited anticancer activity in solid tumors such as those of testicular, 
ovarian, and advanced breast cancers (Rosenberg et al., 1965; Jordan and Carmo-Fonseca, 2000; 
Muggia, 2009; Martín, 2001). In addition to DNA damaging agents, microtubule stabilizing 
agents such as paclitaxel (Taxol®) have been successful as chemotherapeutic compounds, 
especially in the treatment of both early and advanced breast cancer. Since breast cancer 
initiation and progression are dependent on the production of estrogen, hormone therapy targeted 
against the estrogen receptor has also been developed as another therapeutic option. About 60% 
of breast cancers are positive for ER and so are responsive to estrogen-mediated growth signals 
(Putti et al., 2005). As a selective ER modulator, tamoxifen has been shown to inhibit tumor cell 
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proliferation by blocking the G1 to S phase transition in (ER+) MCF7 cells, which also display 
apoptotic morphology and DNA cleavage at a lower dose more rapidly than ER(-) MDA-231 
breast cancer cells when treated with tamoxifen (Osborne et al., 1983; Perry et al., 1995). 
Furthermore, although it lacks activity in a portion of ER-positive cancers, tamoxifen acts as an 
effective antiestrogen by targeting ERα for degradation in ER-positive breast cancer cells (Wu et 
al., 2009). 
As is evident from basic research and clinical studies, intrinsic and acquired resistance 
via a variety of mechanisms to these chemotherapeutic and anti-hormonal drugs is a major 
concern. Hence, more effective approaches are necessary since conventional therapy is typically 
associated with partial clinical responses and undesirable side effects, including the destruction 
of normal non-cancerous surrounding cells. Rational design of chemotherapeutic combinations 
may thus enhance antitumor activity and possibly overcome multidrug resistance, providing new 
therapeutic options that specifically target tumor cells. 
Molecular chaperones aid in accurate protein assembly by prohibiting improper 
associations with other proteins as they assist in the maturation of their substrates or clients. 
These proteins are dramatically upregulated in times of stress, but are also present under normal 
basal conditions, thus highlighting their essential nature in cell viability. Heat shock protein 90 
(Hsp90) is unique from other chaperones since it is critically involved in controlling the 
conformation, stability, function, and degradation of many oncogenic client proteins, thus 
determining their cellular fate (Beliakoff and Whitesell, 2004; Csermely et al., 1998). This 
chaperone is abundantly found in the cell, comprising 1-2% of total protein content even under 
non-stressed conditions, while in tumor cells, this percentage increases to approximately 4-6% 
(Chiosis and Neckers, 2006). Functionally, the Hsp90 multiprotein machinery, assists in cellular 
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trafficking, the remodeling of improperly folded client proteins, and the suppression of protein 
aggregation (Whitesell and Lindquist, 2005; Sarto et al. 2000). In this manner, client proteins 
achieve stability, allowing them to bind to ligands or undergo post-translational modifications to 
activate signaling pathways (Sharp and Workman, 2006). Currently, Hsp90 has been found to 
interact with over 200 clientele proteins, many of which are associated with cell signaling, 
including kinases, transcription factors, and hormone receptors. Thus, the role of Hsp90 in 
affecting the maturation of client proteins involved in signal transduction inherently implicates 
this chaperone in transformation and tumorigenesis. Hsp90 acts in conjunction with co-
chaperones and other cofactors that stimulate or enhance its activity. The p23 co-chaperone has 
been studied for its role in breast cancer, although the majority of studies involving p23 focus on 
the relationship of this protein with steroid hormone receptors. Specifically, overexpression of 
p23 is associated with increased tumor grade and positively regulates the activity of the estrogen 
receptor, resulting in enhanced invasiveness of breast cancer cells without any effect on 
proliferation (Knoblauch and Garabedian, 1999; Oxelmark et al., 2006).  
The intrinsic nature of heat shock proteins makes them especially relevant to a cell’s 
defense against cancer initiation.  Previous studies have reported an overexpression of Hsp90 in 
human breast cancer; however, only tumor specimens and breast cancer cell lines were examined 
(Pick et al., 2007). The preferential accumulation of Hsp90 in cancer cells also forms the basis 
for the unique sensitivity of tumor cells to Hsp90 inhibition. In particular, Hsp90 in cancer cells 
have a higher affinity for anti-Hsp90 compounds compared to that in normal cells, thus 
providing tumor selectivity via, as yet, an unknown manner (Kamal et al., 2003). In light of this 
finding, it is possible that malignant cells are more dependent on Hsp90-mediated stability and 
activation of oncogenic pathways than normal cells, and so are more sensitive to Hsp90 
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inhibitors (He et al., 2006; Vilenchik et al., 2004; Whitesell et al., 1992). The tumor selectivity 
of Hsp90 inhibitors allows it to act in a specific manner, and is thus considered a targeted therapy 
for cancer. Because of the dependence of Hsp90 function on ATP hydrolysis, Hsp90 inhibitors 
like radicicol interfere with this intrinsic activity by binding at the N-terminal ATP site. In this 
way, Hsp90-dependent client proteins can be tagged for ubiquitination and subsequently directed 
toward proteasomal degradation (Eleuteri et al., 2002; Pearl et al., 2008). Thus, Hsp90 inhibition 
has earned great interest as a promising approach for cancer therapy since many client proteins 
can be simultaneously targeted and disrupted (Goetz et al., 2003; Sharp and Workman, 2006). 
Radicicol is also an antifungal antibiotic that is able to revert the transformed phenotype, 
such that transformed fibroblast cells treated with RAD undergo morphologic changes to 
resemble normal cells (Kwon et al., 1992). In fact, RAD has a higher affinity for Hsp90 and 
competes with GA for binding in the N-terminal domain (Schulte et al., 1998a). Furthermore, 
RAD is more potent in terms of blocking ATPase activity and prevents the association of the co-
chaperone p23 with Hsp90 (Roe et al., 1999). In breast cancer cells, RAD has been shown to 
affect the level of Hsp90 client proteins (Schulte et al., 1998a). Other advantages of RAD 
include activity in GA-resistant cells and a lack of hepatotoxicity (Chiosis et al., 2003; 
Yamamoto et al., 2003).  
Based on the findings in our first study, it is necessary to characterize the effects of 
Hsp90 inhibition in breast cancer cells. This entails the characterization of this inhibition by 
pharmacologic methods using radicicol. Studies utilizing radicicol as a means to examine the 
role of Hsp90 in cancer progression are far fewer in comparison to those employing 
geldanamycin. Pharmacologic inhibition is partly based on the idea that lack of functional Hsp90 
may cause telomere erosion and/or dysfunction, leading to apoptosis in breast tumor cells. 
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Previous work in our lab has shown that M12 metastatic prostate cancer cells show a decline in 
cell growth upon Hsp90 inhibition that coincides with a transient reduction in telomerase activity 
and telomere erosion (Compton et al., 2001). However, it remains to be determined whether 
breast cancer cells also behave in a similar manner.  
In addition to the Hsp90 inhibitor alone, various combinations of radicicol with other 
chemotherapeutics will provide insight on the possibility of sensitization of breast cancer cells. 
Because nonspecific cytotoxicity is associated with these standard regimens, inhibiting Hsp90 
before initiating conventional therapy may help reduce the amount of exposure, drug dose, or 
duration of treatment, potentially leading to a better response with fewer side effects. 
Chemotherapeutic and hormonal drugs utilized in the combination treatments include 
adriamycin, cisplatin, taxol, and tamoxifen, all of which are currently used to treat breast cancer. 
The goal of the following experiments is to define and characterize the consequences of Hsp90 
inhibition specifically on cellular proliferation, telomerase stability and function, telomere 
length, expression of client proteins, and ultimately on senescence or apoptosis. 
 
4.2 Results  
4.2.1RAD affects cellular proliferation and telomerase activity in breast cancer cells.  
Since Hsp90 inhibition in breast cancer progression is not well defined, we wanted to 
begin our assessment of the effect of radicicol (RAD) on the ability of tumor cells to 
continuously proliferate. The human breast adenocarcinoma MCF7 cell line was used for the 
majority of studies because it is an established, well-characterized cell line that is routinely used 
as an in vitro breast cancer model. MCF7 cells were initially treated with RAD at 0.1 µM, 0.3 
µM, 1 µM, 3 µM, and 10 µM for either 24 hr or 48 hr. Upon completion of treatment at each time 
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point, cells were harvested and cell growth was assessed. It is evident that MCF7 cells display a 
dose-dependent growth effect upon RAD treatment, such that cellular proliferation begins to 
display a reduction even at the lowest concentration tested (Figure 21).  At each time point, 24 
hrs or 48 hrs, there is a steady decline in population doubling as the RAD concentration 
increases, with the highest concentrations of RAD eliciting the greatest effect on growth. 
Specifically, at 0.3 µM, 1 µM, 3 µM, and 10 µM, MCF7 cells are undergoing cell death, reflected 
as significant negative population doublings.  Interestingly, MCF7 cells begin to display aberrant 
growth effects at 0.1 µM RAD, whereas M12 prostate cancer cells require a higher dose (0.3 
µM) to elicit an Hsp90 inhibition-mediated growth reduction (Compton et al., 2001).  
 The assembly of the active form of the ribonucleoprotein enzyme telomerase has been 
shown to require the assistance of various chaperones. Hsp90 and p23 specifically aid in this 
process by mediating the joining of the hTERT catalytic subunit and its internal RNA template, 
hTR. As telomerase is folded into the active state, Hsp70, Hsp40, and HOP dissociate from the 
initial complex while Hsp90 and p23 remain stably associated with the final product (Figure 22). 
Because this association is necessary for efficient and functional telomerase assembly, we 
wanted to determine whether inhibition of Hsp90 adversely affected its activity. MCF7 cells 
were treated with various RAD concentrations as just described above and harvested at 4 hr, 24 
hr, and 48 hrs post-treatment.  
As shown in Figure 23, telomerase activity, as measured by the TRAP assay, shows a 
steady decline over time with RAD treatment as compared to non-treated cells. At each RAD 
concentration, the intensity of the laddering effect progressively decreases with increasing post 
treatment time. This decrease in telomerase activity is not dose-dependent (i.e. activity does not 
decrease or increase according to RAD dose), but rather, it appears that the effect on 
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Figure 21: Cell growth decreases with increasing RAD concentrations. Breast cancer MCF7 
cells were treated for 48 hrs with RAD at varying concentrations, including high doses of 3 µM 
and 10 µM. For each RAD concentration, cells were treated and harvested at 24 hr or 48 hr post-
treatment. Cells at each time point were counted in triplicate and population doubling (PD) 
calculated as described in the Methods section. Untreated MCF7 cells served as the negative 
control and this PD was set to a value of 1, to which all other PDs were normalized. Results 
represent at least 3 individual experiments. Asterisks (*) denote significant reduction (p < 0.05) 
in PD as compared to untreated cells. 
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Figure 22: Assembly of telomerase. The assembly of the active form of the ribonucleoprotein 
enzyme telomerase has been shown to require the assistance of various chaperones. Hsp90 and 
p23 specifically aid in this process by mediating the joining of the hTERT catalytic subunit and 
its internal RNA template, hTR. As telomerase is folded into the active state, Hsp70, Hsp40, and 
HOP dissociate from the initial complex while Hsp90 and p23 remain stably associated with the 
final product. Adapted from Forsythe et al., 2001. 
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Figure 23: Radicicol-responsive telomerase activity. Breast cancer MCF7 cells were treated 
for 48 hrs with RAD at varying concentrations, including higher doses of 3 µM and 10 µM. For 
each RAD concentration, cells were harvested at 4 hr, 24 hr, and 48 hr post-treatment and 
subjected to analysis of TRAP activity. The PCR-based TRAP assay measures telomerase 
activity in comparison to the amplification of the 36 bp internal standard. The characteristic 
laddering effect reflects the variability in size of TRAP products. TRAP activity was quantitated 
and average values were normalized to untreated cells. Results representative of 3 individual 
experiments. Asterisks (*) denote significant changes (p < 0.05) in telomerase activity compared 
to no treatment. 
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activity is time-dependent. In general, 4 h post-treatment is associated with erratic telomerase 
activity, with only relatively lower RAD concentrations (0.1 µM and 0.3 µM) and the highest 
concentration (10 µM) eliciting significant changes. At 24 h post-treatment, middle range RAD 
concentrations produce significant reductions in TRAP activity, while at 48 h post-treatment, all 
RAD doses lead to considerable decreases in activity. It is important to note that although cell 
death is evident after treatment, only adherent cells were harvested for the TRAP assay (i.e. no 
floating cells). 
Because MCF7 cells displayed great sensitivity in terms of growth inhibition and 
downregulation of telomerase activity to RAD treatment in the range of 0.1 µM to 10 µM, it is 
possible that these concentrations were too toxic for cell viability. In this case, long-term 
treatment with RAD may instead induce non-specific effects on cellular proliferation. In order to 
identify a working RAD concentration for future chronic studies, MCF7 cells were treated with 
lower doses of RAD, specifically, 0.01 µM and 0.03 µM. At these concentrations, MCF7 cells 
again display a dose-dependent growth decline at 24 h and 48 h post-treatment (Figure 24). 
Although cells are still in the log phase of growth (positive population doubling), proliferation 
rate nevertheless appreciably decreases in this lower RAD range. This is in contrast to the 
predominantly negative population doubling (death) at high RAD concentrations. Treatment with 
lower RAD doses also affects telomerase activity. At 0.03 µM, telomerase activity progressively 
declines over time, while treatment with 0.01 µM shows a transient effect on activity (Figure 25). 
Importantly, only treatment with 0.03 µM RAD significantly causes both a decline in cell growth 
without inducing toxicity-related cell death and a reduction in telomerase activity at all post-
treatment times. Based on these collective negative effects, the RAD concentration of 0.03 µM 
was designated for chronic and combinational studies. 
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Figure 24: RAD-dependent cell growth at low RAD doses. Breast cancer MCF7 cells were 
treated with lower RAD concentrations for 48 hrs and harvested at 24 hr or 48 hr post-treatment. 
Even at very low concentrations, proliferation of MCF7 cells are negatively affected. Cells at 
each time point were counted in triplicate and population doubling (PD) calculated as described 
in the Methods section. MCF7 that were not treated served as the control and this PD was set to a 
value of 1, to which all other PDs were normalized. Results representative of 3 individual 
experiments. Asterisks (*) denote significant reduction (p < 0.05) in PD as compared to untreated 
cells. 
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Figure 25: Telomerase activity declines at lower RAD concentrations. Breast cancer MCF7 
cells were treated for 48 hrs with RAD at varying concentrations, including lower doses of 0.01 
µM and 0.03 µM. For each RAD concentration, cells were harvested at 4 hr, 24 hr, and 48 hr 
post-treatment and subjected to analysis of TRAP activity. Again, the characteristic laddering 
effect was quantitated against the 36 bp internal standard and average values normalized to 
untreated cells. Results representative of 3 individual experiments. Asterisk (*) denotes 
significant changes (p < 0.05) in telomerase activity compared to no treatment. 
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 4.2.2 RAD and Adr in combination more than additively alters growth properties. 
Although effective in modulating cancer cell proliferation, Hsp90 inhibition alone may 
not be a practical course of treatment in combating breast cancer. The ability of RAD to act as an 
adjuvant or supplementary form of therapy was determined in combination studies with the 
established chemotherapeutic, Adriamycin. MCF7 cells were pretreated with 0.03 µM RAD for 
48 hr, followed sequentially by acute treatment with a range of Adr concentrations, including 
0.0075 µM, 0.025 µM, 0.075 µM, 0.25 µM, and 0.75 µM. At 2 d and 4 d after completion of this 
treatment series, cell growth was determined to be differentially affected.  
For those cells treated with Adr alone, mean cell count decreases with increasing Adr 
concentration at both collection time points (Figure 26, black bars). MCF7 cells pretreated with 
0.03 µM RAD display an even greater decline in average cell counts at both time points when 
compared to singly Adr-treated cells (Figure 26, grey bars). At 2 d post-treatment, cells display a 
significant reduction in cell number when pretreated with RAD in combination with Adr at 0.025 
µM, 0.075 µM, and 0.25 µM (Figure 26A), while at 4 d, significant growth defects occur at 
0.0075 µM, 0.025 µM, and 0.075 µM Adr, when compared against Adr only treated cells (Figure 
26B). A comparison of growth at each concentration tested shows that 4 d cell counts are always 
less than 2 d cell counts. Interestingly at 4 d, the significant decreases in cell numbers upon RAD 
pretreatment at a given Adr concentration is greater than the effect of either agent acting 
independently, suggesting a more than additive response.  
Examination of population doubling supports the observed change in cell numbers. For 
those cells treated with Adr only, population doubling generally decreases with increasing Adr 
concentration at both 2 d and 4 d post-treatment (Figure 27, black bars). Cells pretreated with 
RAD prior to initiation of Adr exposure display an even more pronounced growth reduction  
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Figure 26: Average cell counts decrease in the presence of RAD pretreatment. MCF7 cells 
were either treated with Adr alone in increasing concentrations for 2 hr (black bars) or with 48 hr 
of 0.03 µM RAD pretreatment prior to initiating a 2 h Adr treatment (grey bars). Cells were 
harvested at 2 d (A) or 4 d (B) post-treatment and counted in triplicate. MCF7 cells that were not 
treated or only treated with RAD served as the control for Adr only or RAD + Adr, respectively. 
These PDs were set to a value of 1, to which all other PDs were normalized. Results 
representative of at least 3 experiments. Asterisks denote significant reduction (p < 0.05) in PD 
as compared to untreated or RAD only cells. 
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Figure 27: Greater decline in population doubling with RAD and Adr combination 
treatment. Breast cancer MCF7 cells were either acutely treated with increasing concentrations 
of Adr ranging from 0.0075 µM to 0.75 µM (black bars) or pretreated with 0.03 µM RAD for 48 
hrs followed by acute Adr treatment in the same range (grey bars).  Cells were harvested at 2 d 
(A) or 4 d (B) post-treatment, counted in triplicate and population doubling (PD) calculated. 
MCF7 cells that were not treated or only treated with RAD served as the control for Adr only or 
RAD + Adr, respectively. These PDs were set to a value of 1, to which all other PDs were 
normalized. Results representative of at least 3 experiments. Asterisks denote significant 
reduction (p < 0.05) in PD as compared to untreated or RAD only cells. 
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(Figure 27, grey bars). At 2 d, mean PD declines by 30%, 37%, and 55% when sequentially 
treated with RAD and Adr at 0.0075 µM, 0.025 µM, and 0.075 µM Adr, respectively, although 
these averages are not statistically different from Adr only treated cells (Figure 27A). However, 
RAD pretreatment followed by exposure to higher concentrations of Adr at 0.25 µM and 0.75 
µM does significantly reduce cell growth by 91% and over 100%, respectively. At 4 d, RAD 
with all Adr combinations except 0.25 µM induces a significant reduction in population doubling 
compared to Adr alone (Figure 27B). It is notable that for both 2 d and 4 d post-treatment, 
pretreatment with RAD followed by higher Adr concentrations leads to a more than additive 
diminution of cell growth. Collectively, these cell count and population doubling data suggest 
that a more than additive, perhaps, synergistic effect may exist since growth is affected 
significantly more with RAD pretreatment than with either Adr or RAD alone.  
 
4.2.3 RAD and Adr in combination affects cell fate and the expression of cell cycle-associated 
proteins and HSPs.  
The transcription factor, p53, is so intimately linked to carcinogenesis that its role in 
modulating tumorigenic potential and the cellular response to DNA damage is indisputable. 
Because of its ability to regulate the cell cycle, we wanted to determine whether the observed 
growth alterations coincide with changes in p53 expression. MCF7 cells were again either treated 
with Adr alone using the same range of concentrations for 2 hrs or pretreated with RAD for 48 h. 
Acute treatment with Adr induces an appreciable upregulation of p53 total protein expression 
and a corresponding increase in the total protein levels of its downstream effector, p21Waf1/Cip1 
(Figure 28A). Pretreatment with RAD prior to Adr exposure also stimulates overexpression of 
p53 and p21Waf1/Cip1, although the response is not as robust as in singly treated cells (Figure 28B). 
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Figure 28: Induction of p53 and p21 upon single agent and combination treatments. MCF7 
cells were either acutely treated with various concentrations of Adr (A), ranging from 0.0075 µM 
to 0.75 µM, or pretreated with 0.03 µM RAD for 48 hrs followed by acute Adr treatment in the 
same range (B). Cells were harvested at 4 d post-treatment and western analysis performed on 50 
µg of total protein lysate. Immunblot was probed with anti-p53 and anti-p21 antibodies. β-actin 
served as the loading control.  For both blots, lane 1 represents untreated normal fibroblasts and 
lane 2 is untreated MCF7 cells. In blot B, lane 3 represents RAD only treated MCF7 cells.  
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Upon closer inspection, single agent-treated cells display an elevation in p21Waf1/Cip1 protein 
levels that is more dramatic with increasing Adr dose than the upregulation of p53 levels (Figure 
29-30, black bars). Namely, p53 levels on average increase 23% with each successive increase in 
Adr dose, while p21Waf1/Cip1 levels increase by 43%. A similar trend exists for RAD and Adr 
combination treated cells, as p53 levels increase by 31% and p21Waf1/Cip1 levels increase by 37% 
with increasing Adr dose (Figure 29-30, blue bars).  
Based on the finding that p53 and p21 protein levels increase in response to Hsp90 
inhibition and that these changes coincide with growth aberrations, it was necessary to identify 
any corresponding effects on cell cycle regulatory proteins. Of these proteins, the cyclin-
dependent kinase, Cdk4, in concert with cyclin D, controls the G1 to S phase transition, which is 
commonly deregulated in cancer (Deshpande et al., 2005). Adr singly treated MCF7 cells display 
reduced Cdk4 protein levels at 0.25 µM and an even greater decrease at 0.75 µM, compared to 
untreated cells (Figure 31). Pretreatment with 0.03 µM RAD followed by acute Adr treatment 
also results in a downregulation of Cdk4 protein expression (Figure 32). Compared to untreated 
MCF7 cells, treatment with RAD only induces a slight decrease in Cdk4 expression, which 
remains constant in MCF7 cells treated in combination with 0.0075 µM, 0.025 µM, and 0.075 
µM. However, upon treatment with relatively higher Adr doses, 0.25 µM and 0.75 µM, there is 
an even greater reduction in Cdk4 protein levels. Furthermore, regardless of treatment, MCF7 
cells consistently display enhanced Cdk4 levels when compared to normal BJ fibroblasts, which 
have an almost undetectable level of Cdk4. Thus, the overexpression of the cell cycle inhibitory 
proteins, p53 and p21, corresponds to a downregulation of the cell cycle stimulating factor, 
Cdk4, although this is likely unaffected by Hsp90 inhibition.  
Since the Hsp90 chaperone machinery exists as a multiprotein complex, the next step was 
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Figure 29: Greater induction of p53 upon Adr alone treatment.  Quantitation of p53 levels in 
MCF7 cells treated with Adr alone (black bars) or in combination with RAD (blue bars). 
Western blots for p53 were ran three times and the average value calculated, designating 
untreated cells as the control. This p53 value was set to 1, to which all other values were 
normalized. The protein level of p53 is consistently higher in Adr only treated cells than in Adr 
and RAD treated cells at each specific Adr concentration. 
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Figure 30: Greater induction of p21 levels upon Adr alone treatment. Quantitation of p21 
levels in MCF7 cells treated with Adr alone (black bars) or in combination with RAD (blue 
bars). Western blots for p21 were ran three times and the average value calculated, designating 
untreated cells as the control. This p21 value was set to 1, to which all other values were 
normalized. The protein level of p21 is consistently higher in Adr only treated cells than in Adr 
and RAD treated cells at each specific Adr concentration. The levels of p21 are appreciably 
lower in Adr and RAD treated cells than in Adr alone cells. This differential expression is more 
dramatic than for p53. 
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Figure 31: Expression of cochaperones and a cell cycle-regulatory protein in Adr treated 
cancer cells. Breast cancer cells were acutely treated with 0.0075 µM, 0.025 µM, 0.075 µM, 
0.25 µM, and 0.75 µM Adr for 2 hrs. Cells were harvested at 4 d post-treatment and 50 µg of 
total protein lysate was subjected to western analysis. Immunoblot was probed with antibodies 
against Hsp90, Hsp70, Cdk4, and Hsp27. β-actin served as the loading control. Lane 1 represents 
untreated normal fibroblasts (BJ), lane 2 is untreated MCF7 cells, and lanes 3-7 are treated 
MCF7 cells. 
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Figure 32: Expression of cochaperones and a cell cycle-regulatory protein in RAD and Adr 
treated cancer cells. Breast cancer cells were pretreated with 0.03 µM RAD for 48 hrs followed 
by treatment with 0.0075 µM, 0.025 µM, 0.075 µM, 0.25 µM, and 0.75 µM Adr for 2 hrs. Cells 
were harvested at 4 d post-treatment and 50 µg of total protein lysate was subjected to western 
analysis. Immunoblot was probed with antibodies against Hsp90, Hsp70, Cdk4, Hsp27, and p23. 
β-actin served as the loading control. Lane 1 represents untreated normal fibroblasts, lane 2 is 
untreated MCF7 cells, lane 3 represents RAD only treatment in MCF7 cells, and lanes 4-8 are 
RAD and Adr treated MCF7 cells. 
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to determine the effect of Hsp90 inhibition on the expression of these cofactors. As shown in 
Figures 31-32, Hsp90 is abundant in both normal and breast cancer cells and its protein 
expression is not affected by Adr or RAD treatments. However, expression of Hsp70 does appear 
to be affected with both single agent and combinational drugs. Treatment with Adr only leads to 
an appreciable downregulation of Hsp70 at 0.25 µM and 0.75 µM (Figure 31). Similarly, RAD 
pretreatment is also associated with a reduction in Hsp70 protein in combination with 0.25 µM 
and 0.75 µM Adr, although this reduction is not as robust (Figure 32). Although Hsp27 is not a 
component of the Hsp90 chaperone complex, its expression was also assessed because of its role 
as a major responder to cell stress. We show here that Hsp27 levels do not change greatly in 
either singly treated or combinationally treated cells. Taken together, protein levels of the Hsp90 
co-chaperones, Hsp70 and p23, are moderately affected, but the level of the Hsp90 
independently-acting chaperone, Hsp27, are not affected by Hsp90 inhibition. 
 
4.2.4 Radicicol pretreatment elicits a stronger senescence response but no apoptotic response. 
Because of the negative effect of RAD treatment on telomerase activity, we wanted to 
determine whether telomere length was also affected by Hsp90 inhibition. Genomic DNA was 
isolated from treated and untreated cells, thoroughly digested, and telomere fragments resolved 
on an agarose gel. The heterogeneity in length of telomere fragments is reflected in the smeared 
appearance of the TRF gel. According to the distribution of bands within each lane, there is no 
apparent difference in the range of telomere lengths between Adr treated and RAD pretreated 
cells (Figure 33). The telomere length in both treatment groups ranges between about 2.0 kb and 
less than 4.3 kb. However, it is important to recognize that this assay only assesses global
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Figure 33: No change in overall telomere length upon drug treatment. Telomere length was 
assessed in MCF7 cells treated with Adr alone in a range of 0.0075 µM to 0.75 µM or in 
combination with 0.03 µM RAD.  Genomic DNA from each sample was isolated, of which, 8-10 
µg was digested and subjected to a TRF assay, which radiolabels telomeric ends using a G-rich 
telomere specific (TTAGGG)4 probe. The Adr concentration of 0.75 µM was not able to be 
assessed due to lack of substantial DNA. The characteristic smeared appearance of the bands are 
a reflection of the heterogeneity in telomere length. The average range of telomere length is 
demarcated by yellow bars in each lane.  
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telomere length, accounting for the average telomere length in the cell, which does not exclude 
the possibility that chromosome-specific telomere length alterations may exist.  
 Although there were no changes in telomere length in both singly treated and 
combinationally treated cells compared to untreated cells, we wanted to assess whether a 
senescent phenotype existed in these cells. Due to the observed decrease in cell growth and 
population doubling, as well as the reduction in Cdk4 expression, it is possible that these cells 
are undergoing irreversible growth arrest in the absence of telomere shortening. Indeed, MCF7 
cells treated with 0.075 µM and 0.75 µM Adr stain positively for senescence-associated β-
galactosidase (SA-β-gal) activity (Figure 34C, E). Although many cells appear to be reactive to 
β-gal substrate (blue colored cells), they are not necessarily senescent. The criteria thus used are 
two-fold; cells must both be positively stained as well as display morphologic changes associated 
with the senescent phenotype. As denoted by the arrows, senescent cells assume a flattened 
appearance with a large nucleus to cytoplasm ratio. Proliferating MCF7 cells, in contrast, are 
much smaller and display a characteristic “cobblestone” shape. Based on these criteria, 
pretreatment with 0.03 µM RAD prior to Adr exposure similarly induces morphological changes 
and produces more SA-β-gal positive cells than with Adr alone (Figure 34D, F). Untreated cells 
also contain β-gal substrate reactive cells, but the morphology of these cells is not consistent with 
a senescent phenotype (Figure 34A). Quantitation of SA-β-gal activity shows an increase in the 
number of senescent cells with Adr as compared to untreated cells (Figure 35). At 0.075 µM Adr, 
there are approximately 1.5x more senescent cells, and at 0.75 µM, there is 3.35x more, when the 
number of untreated senescent cells is set to a value of 1. RAD only exposure induces 2.5x more 
senescent cells than untreated cells and this number increases when Adr is also added to the 
series, with 0.75 µM Adr eliciting more than 4x more positive cells. Furthermore, at 0.075 
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Figure 34: Drug treated cells exhibit positive senescence-associated β-gal staining. Breast 
cancer MCF7 cells were either acutely treated with 0.075 µM and 0.75 µM Adr for 2 hrs or 
pretreated with 0.03 µM RAD for 48 hrs followed by acute Adr treatment.  At 2 d post-treatment, 
cells were fixed and stained for β-galactosidase activity, as a marker for senescence. Although 
untreated cells contain β-gal positive cells (A), the morphology of these cells is not consistent 
with senescence. Treatment with Adr (C, E) induces the appearance of senescent cells, as does 
treatment with RAD alone (B) and RAD + Adr (D, F). Arrows identify senescent cells based on 
positive staining and morphology.  All images obtained at 40x. 
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Figure 35: Increase in senescent cells upon treatment with RAD and Adr. Quantitation of β-
gal activity in MCF7 cells acutely treated with Adr or pretreated with RAD. At 2 d post-
treatment, cells were assessed for senescence-associated β-galactosidase expression based on 
both morphologic changes and positive staining. Three fields were counted for each treatment 
group. MCF7 cells not exposed to any drug served as the control to which all other counts were 
normalized. Asterisk (*) denotes significant change between Adr only treated and RAD 
pretreated cells (p < 0.05). 
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µM Adr, but not at 0.75 µM Adr, there is a significant difference in the number of senescent cells 
between Adr alone treated cells and RAD pretreated cells (p < 0.0001). Thus, Hsp90 inhibition 
appears to induce more moderate growth arrest when combined with a standard 
chemotherapeutic.   
 Because we observed a steady decline in cell growth as well as an upregulation of the 
cell-fate mediator, p53, with RAD and Adr treatments, we wanted to assess whether the increase 
in senescence was also associated with apoptosis. Apoptotic cells as measured by the TUNEL 
assay were largely undetectable with both Adr and RAD treatments, both singly and in 
combination (Figure 36). Representative images show only a basal level of activity, with only a 
few sporadic fields expressing TUNEL-positive cells. Specifically, treatment with 0.75 µM Adr 
alone is associated with the production of a few apoptotic cells, but this was a rare occurrence. 
 
4.2.5 No change in p53 or p21 expression in MDA-MB231 cells. 
 Thus far, all experiments were performed using MCF7 breast cancer cells that, despite its 
abnormal karyotype, contain wild-type p53. As these cells show alterations in cell fate related 
proteins and Hsp90-related chaperone expression upon treatment, we wanted to determine 
whether these changes were dependent upon functional p53. In order to address this query, the 
highly metastatic MDA-MB 231 cell line, which expresses mutant p53 that possesses a missense 
mutation in the core DNA binding domain (van Slooten et al., 1999), was treated in an identical 
manner with Adr and RAD as MCF7 cells. 
 MDA cells treated acutely with Adr at any concentration (0.0075 µM, 0.025 µM, 0.075 
µM, 0.25 µM, or 0.75 µM) do not show appreciable differences in p53 or p21 levels compared to 
untreated cells (Figure 37A). Similarly, pretreatment with 0.03 µM RAD followed by Adr 
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Figure 36: Apoptotic cells are undetectable upon RAD + Adr treatment.  MCF7 cells were 
either acutely treated with 0.075 µM (C) and 0.75 µM (E) Adr for 2 hrs or pretreated with 0.03 
µM RAD for 48 hrs followed by acute Adr treatment (D, F). Untreated cells are shown in (A) 
and RAD only cells in (B). Upon completion of the treatment series, cells were fixed and 
cytospun onto slides. The amount of apoptotic cells was assessed via the TUNEL assay, which 
detects DNA fragmentation by fluorescently labeling the nicked ends of nucleic acids. Inset in 
(E) shows nuclear localization of DNA fragments in apoptotic cells. All images taken at 40x. 
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Figure 37: No change in p53 or p21 levels in single agent or combination treated MDA-
MB231 cells. The mutant p53 containing MDA-MB 231 cell line was treated with either Adr 
alone in the range of 0.0075 µM to 0.75 µM for 2 hrs or pretreated with 0.03 µM RAD for 48 hrs 
followed by acute Adr treatment in the same range. At 4 d post-treatment, cells were harvested 
and 50 µg of total protein lysate was subjected to western analysis. Immunblots were probed 
with antibodies against total p53 and p21. β-actin served as the loading control.  
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treatment does not induce changes in total p53 or p21 protein levels (Figure 37B). Furthermore, 
both singly and combinationally treated cells do not display altered overall Hsp70 expression, as 
 was evident in MCF7 cells. Unlike treated MCF7 cells, Hsp70 in treated MDA cells resolved as 
a doublet corresponding to 69 kDa and 72 kDa, of which the smaller isoform was more 
predominant in all cases. The expression of both the smaller and larger isoforms does not change 
with Adr treatment at any concentration as compared to untreated cells (Figure 38A).  RAD 
pretreatment with Adr follow-up at various concentrations is also associated with consistently 
more expression of the smaller isoform (Figure 38B). Although it appears as though the larger 
isoform varies when RAD is present, this change is not appear to be significant. Finally, as 
expected, single and combination drug options do not affect Hsp90 protein expression. 
Collectively, these data suggest that the effects of Hsp90 inhibition on expression of cell fate 
related proteins and Hsp90 cycle co-chaperones are dependent upon the presence of functional 
p53. 
 
4.2.6 CIS and TAX are associated with differential expression of cell fate proteins and HSPs. 
In order to elucidate whether the alterations in cell fate related proteins, p53 and p21, and 
the Hsp90-associated co-chaperone, Hsp70, were dependent upon the mechanism of Adr, we 
sought to assesss the effect of other chemotherapeutics, including cisplatin and taxol. CIS, like 
Adr, is also a DNA damaging agent in that it forms unrepairable DNA cross-links. The 
mechanism of action of TAX, however, differs from that of Adr and CIS, since it acts as a 
microtubule-stabilizing agent.  MCF7 cells were treated with either 0.1 µM CIS or 100 nM TAX 
for 24 hrs or pretreated with 0.03 µM RAD for 48 hrs followed sequentially by CIS or TAX 
treatment, respectively. At 4 hr, 24 hr, and 48 hr of treatment, cells were harvested and analyzed 
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Figure 38: No change in chaperone expression in MDA-MB 231 cells upon Adr or RAD + 
Adr treatment. The MDA-MB 231 cell line was treated with either Adr alone in the range of 
0.0075 µM to 0.75 µM for 2 hrs or pretreated with 0.03 µM RAD for 48 hrs followed by acute 
Adr treatment in the same range. Cells were harvested at 4 d post-treatment and 50 µg of total 
protein lysate was subjected to western analysis. Immunblots were probed with antibodies 
against Hsp90 and Hsp70. β-actin served as the loading control.   
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for Hsp90 client and co-chaperone expression. 
Treatment with either drug alone or in combination with RAD has no effect on total 
Hsp90 protein levels (Figure 39). Cells in the CIS treatment group do not appear to be 
significantly different in p53 protein levels at any time point post-treatment (Figure 39A). As 
such, CIS singly treated cells at 4 hr, 24 hr, and 48 hr display p53 at levels similar to that of 
untreated MCF7 cells. Likewise, RAD pretreated cells with CIS follow-up present p53 levels 
comparable to that of RAD only treatment. The lack of change in protein expression between 
untreated, CIS only, RAD only, and RAD and CIS treated cells suggest that cisplatin does not 
exert its antitumor effects through p53. Despite the consistent p53 expression, levels of p21 do  
exhibit an appreciable alteration (Figure 39A). At 48 hr CIS treatment, p21 appears to be 
upregulated as compared to untreated cells and 4 hr or 24 hr harvest points. Pretreatment with 
RAD also induces a noticeable increase in p21 at 4 hr, 24 hr, and 48 hr as compared to both 
untreated and RAD only treated cells. These observations are clearly distinct from that seen with 
RAD and Adr treatment, which shows a corresponding increase in p21 with p53 upregulation. 
The data presented here thus suggest that CIS at 48 hr and RAD plus CIS in combination 
stimulates p21 induction independent of p53 activity. 
TAX treatment with and without RAD elicits a similar response in terms of p53 and p21 
expression as does treatment with Adr with and without RAD. However, although the concurrent 
increase p53 and p21 is parallel to that in Adr studies, the upregulation is much more robust with 
TAX treatment. Specifically, treatment with TAX alone elicits a large increase in p53 expression 
at 24 hr post-treatment, and this increase is even greater at 48 hr (Figure 39B).  The level of p53 
at 4 hr is comparable to that in untreated cells, so it appears that the amount of p53 induction is 
time-dependent. Likewise, RAD pretreatment followed by TAX also displays a time-dependent 
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Figure 39: Differential expression of cell fate related proteins and the Hsp90-related co-
chaperone after CIS or TAX treatment. MCF7 cells were treated in two different groups. In 
the CIS group (A), cells were either treated with 0.1 µM CIS for 24 hrs or pretreated with 0.3 µM 
RAD for 48 hrs followed by 24 hr of CIS. For the TAX group (B), cells were either treated with 
100 nM TAX for 24 hrs or pretreated with 0.3 µM RAD followed by 24 hrs of TAX. Cells were 
harvested at 4 hr, 24 hr, and 48 hr of treatment and 50 µg total protein lysate subjected to western 
analysis. Immunoblot was probed with antibodies against Hsp90, Hsp70, p53, and p21. β-actin 
served as the loading control.  For both blots, lane 1 represents untreated normal BJ fibroblasts, 
lane 2 is untreated MCF7 cancer cells, and lane 6 is 48 hr RAD only treated MCF7 cells. 
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upregulation of p53, though this increase is more dramatic at each time point compared to TAX 
only. Specifically, we observe an increase in p53 as early as 4 hr post initiation of treatment, and 
this upregulation gets progressively stronger over 24 hr and 48 hr. In addition to p53 changes, 
there are also clear differences in p21 expression. Namely, p21 levels increase according to p53 
levels in both singly TAX treated and RAD pretreated cells (Figure 39B). While it is relatively 
low at 4 hr and 24 hr, p21 upregulation appears maximal at 48 hr post TAX alone treatment. 
Pretreatment with RAD also induces a p21 increase, but this increase is more robust since it is 
evident as early as 4 hr and is maintained at 24 hr. Again, the greatest induction occurs at 48 hr, 
and the level at this time point is generally equivalent to that seen at 48 hr in singly TAX treated 
cells. These TAX data indicate that the damage response triggered by TAX is mediated in a p53-
dependent manner. 
Because Hsp70 was shown to be relatively down-regulated in Adr treated cells, it was 
necessary to assess whether this decrease was drug specific. Unlike Adr treatment in MCF7 cells 
but akin to Adr exposure in MDA cells, CIS and TAX treatments produced a doublet band 
corresponding to Hsp70 when resolved. It is evident that the smaller 69 kDa isoform is 
constitutively present, as it is detectable in both normal BJ fibroblasts and untreated breast 
cancer cells (Figure 39). In the CIS only group, the larger 72 kDa isoform is strongly induced at 
48 hr post-treatment, while its expression at 4 hr and 24 hr is nearly identical to untreated cells 
(Figure 39A). Pretreatment with RAD at all time points elicits a similarly strong induction of the 
larger isoform, which is also seen in RAD only cells. For the TAX only group, the larger Hsp70 
form is minimally detectable, while the smaller constitutive form is predominant. RAD 
pretreatment again triggers a robust upregulation of the large Hsp70 form at all time points 
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(Figure 39B). Thus, CIS and TAX also affect expression of Hsp70, although this change was 
reflected in differential expression of its isoforms.  
 
4.2.7 CIS and TAX affect Hsp90 client protein expression. 
Since p53 upregulation was observed in CIS and TAX treated cells, we wanted to 
determine whether expression of Hsp90 client proteins involved in mediating a damage response 
was altered. The ubiquitous tyrosine kinase, c-Abl, was a logical query due to its role in both cell 
cycle arrest and apoptosis, and its implication in breast cancer aggressiveness (Lin and 
Arlinghaus, 2008). A comparison of CIS and TAX treated cells at 24 hr and 48 hr of treatment 
shows different expression of c-Abl depending on the drug used (Figure 40). Treatment with CIS 
only is associated with almost nonexistent c-Abl expression, as is treatment with RAD and CIS 
at 24 hr. However, at 48 hr, RAD and CIS combination treated cells display an increase in c-Abl 
expression. This finding is consistent with the role of c-Abl in responding specifically to DNA 
damage, which is produced as a consequence of CIS presence. Expression of c-Abl in cells 
treated with the microtubule damaging agent TAX is undetectable, which also supports the 
selectivity of response of this tyrosine kinase. Thus, only CIS upregulates c-Abl due to their 
compatibility in mediating and sensing DNA damage.  
In addition to c-Abl, the expression of Cdk4 was also examined to determine whether cell 
cycle aberrations also exist with CIS and TAX treatments. Treatment with CIS alone or in 
combination with RAD does not appear to alter Cdk4 protein expression (Figure 40, lanes 3-5). 
The level of Cdk4 in these cases is comparable to that in RAD only treated and untreated MCF7 
cells, suggesting that Hsp90 inhibition is not predisposing the cell to undergo growth arrest in 
response to CIS. On the other hand, TAX treatment does noticeably alter Cdk4 expression, such 
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Figure 40: Altered expression of Hsp90 client proteins post CIS or TAX treatment.  MCF7 
cells were treated in two different groups. In the CIS group (A), cells were either treated with 0.1 
µM CIS for 24 hrs or pretreated with 0.3 µM RAD for 48 hrs followed by 24 hr of CIS. For the 
TAX group (B), cells were either treated with 100 nM TAX for 24 hrs or pretreated with 0.3 µM 
RAD followed by 24 hrs of TAX. Upon completion of treatment, cells were harvested at 24 hr or 
48 hr and 50 µg total protein lysate subjected to western analysis. Immunoblot was probed with 
antibodies against c-Abl and cdk4. β-actin served as the loading control.  Lane 1 represents 
untreated MCF7 cancer cells, lane 2 is 48 hr RAD only treated MCF7 cells, lane 3 is 48 hr CIS 
only treated MCF7 cells, and lane 6 is 48 hr TAX only treated MCF7 cells. 
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that there is a reduced level with TAX alone (Figure 40, lanes 6-8). RAD pretreatment at 24 hr 
post-treatment is also associated with a reduction in Cdk4 as compared to RAD only cells. 
However, at 48 hr with RAD and TAX, the level of Cdk4 is similar to that of RAD only, 
suggesting that TAX increases Hsp90-induced Cdk4 degradation which is alleviated by RAD 
treatment.  
 
4.2.8 CIS and TAX induce apoptotic cell death. 
In order to determine whether the mechanism of action of CIS and TAX affects cellular 
fate, we assessed the amount of cell death in drug treated cells. In particular, we wanted to 
determine whether CIS elicits a response similar to Adr since they are both DNA damaging 
agents and whether TAX sends the cell down a different path. MCF7 cells were treated with 0.03 
µM RAD, 0.1 µM CIS, or in combination and cell growth analyzed at 4, 24, and 48 hr post 
initiation of treatment. Treated cells in these groups generally retain the morphology of untreated  
cells, displaying the characteristic cobblestone shape (Figure 41). However, RAD pretreatment 
leads to the appearance of detached cells, albeit at a low frequency, represented by rounded, 
“glowing” structures. The emergence of a small population of senescent cells is also present, as 
denoted by the large, flattened, and irregular shape of these cells. When quantified, the extent of 
CIS-induced cell death does not apparently differ when cells are pretreated with RAD (compare 
CIS only versus RAD plus CIS at each time point), since there is no appreciable difference in the 
number of detached cells (Figure 42).  For CIS only treated cells, while 4 hr is associated with 
negligible cell detachment, both 24 hr and 48 hr post-treatment induces about 1.4% cell death, as 
compared to untreated cells, which also show negligible cell detachment.  While RAD alone 
produces about 0.96% cell death, pretreated cells in combination with CIS are associated with 
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Figure 41: Small percentage of morphological cell death in response to treatment with 
Cisplatin. Breast cancer MCF7 cells were treated with either 0.03 µM RAD (B), 0.1 µM CIS 
(C), or with a combination of RAD and CIS (D, E). Phase contrast images of adherent and non-
adherent cells were taken at 24 hr and 48 hr post initiation of combination treatment. CIS induces 
detachment in a small percentage of cells at 24 hr and this amount increases by 48 hrs. Untreated 
(A) and the majority of RAD singly-treated cells remain adherent. Red arrows and blue 
arrowheads denote examples of senescent cells and dead cells, respectively. All images taken at 
40x. 
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Figure 42: Cell death upon CIS treatment. MCF7 cells were either treated with 0.1 µM CIS 
alone or pretreated for 48 hrs with 0.03 µM RAD prior to CIS treatment. Cells were harvested at 
4 h, 24 h, and 48 h of treatment and both adherent and non-adherent cells collected and counted 
in triplicate. Percentage of detached (floating) cells were calculated using non-treated cells as the 
control to which all other counts were normalized. A percentage of 0% represents a negligible 
number of dead cells. Significant difference (p < 0.05) between RAD only and RAD + CIS at 48 
hr is denoted by the asterisk (*). 
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detectable cell death at 4 hr. At this time point, there are about 1.1% dead cells and this 
percentage increases over time, to 2.6% at 48 hr. The only significant difference in percentage of 
dead cells occurs between RAD only treated cells and RAD + CIS treated cells at 48 hr (p = 
0.007), which produces a more than additive effect on the production dead cells. The lack of 
difference between CIS treatment alone and in combination with RAD is supported by TUNEL 
data, which shows no major change in the amount of apoptotic cells between CIS alone and 
RAD + CIS (Figure 43). Thus, RAD pretreatment with 0.1 µM CIS follow-up does not induce 
significantly more cell death than CIS singly treated cells. 
In contrast, treatment with TAX alone and in combination with RAD induces widespread 
cell death in the form of cell detachment (Figure 44). MCF7 cells were treated with 0.03 µM 
RAD, 100 nM TAX, or in combination and cell growth analyzed at 4, 24, and 48 hr post 
initiation of treatment. It is evident that the majority of cells that are treated with TAX alone 
undergo considerable detachment from each other and the surface of the plate. Similarly, RAD 
pretreatment also massively induces the appearance of non-adherent cells, while the vast 
majority of those cells that remain adherent display altered morphology reminiscent of senescent 
cells. Although these morphologically distinct cells are also present with CIS treatment, TAX is 
associated with a great increase in incidence of these cells. When quantified, TAX single 
treatment leads to 12.2% cell death in the form of detached cells at 24 hr and 23.6% cell death at 
48 hr, which is almost a two-fold increase over 24 hr (Figure 45). Pretreatment with RAD leads 
to the emergence of a minute fraction of dead cells at 4 hr, but this percentage increases by 14-
times to 8.4% at 24 hr and by 39-times to 23.6% at 48 hr. These fold increases may be initially 
misleading in that a comparison of TAX alone and RAD/TAX at either 24 hr or 48 hr does not 
produce significant differences in the number of non-adherent cells, as supported by evidence
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Figure 43: Indiscernible change in apoptotic cells between CIS alone or with RAD 
pretreatment. MCF7 cells were treated with 0.1 µM CIS alone for 24 hr (C) or in combination 
with 48 hr pretreatment with 0.03 µM RAD (D). Upon completion of treatment series, cells were 
fixed and processed for the TUNEL assay. Apoptotic cells are represented by the visibly green 
nuclear staining. Untreated cells (A) and RAD only treated cells (B) have only a background 
level of activity, while CIS and RAD/CIS have detectable apoptotic cells. All images taken at 
40x. 
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Figure 44: Massive morphological cell death occurs in response to treatment with Taxol. 
Breast cancer MCF7 cells were treated with either 0.03 µM RAD (B), 100 nM TAX (C), or with 
a combination of RAD and TAX (D, E). Phase contrast images of adherent and non-adherent 
cells were taken at 24 hr and 48 hr post initiation of combination treatment. TAX alone and in 
combination with RAD induces the detachment of the majority of cells at 24 and 48 hrs. 
Untreated (A) and the majority of RAD singly-treated cells remain adherent. Red arrows and 
blue arrowheads denote examples of senescent cells and dead cells, respectively. All images 
taken at 40x. 
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Figure 45: Greater cell death upon TAX treatment.  MCF7 cells were either treated with 100 
nM TAX alone or pretreated for 48 hrs with 0.03 µM RAD prior to TAX treatment. Cells were 
harvested at 4 h, 24 h, and 48 h of treatment and both adherent and non-adherent cells collected 
and counted in triplicate. Percentage of detached (floating) cells were calculated using non-
treated cells as the control to which all other counts were normalized. A percentage of 0% 
represents a negligible number of dead cells. Significant differences (p < 0.05) between RAD 
only and TAX only at 48 hr and between RAD only and RAD + TAX at 48 hr are denoted by 
asterisks (*). 
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from the TUNEL stain (Figure 46). The only significant differences that do emerge exist 
between RAD only and RAD/TAX at 48 hr (p < 0.001) and between RAD only and TAX only at 
48 hr (p = 0.003), which only suggests that TAX sensitizes MCF7 cells to RAD. These data 
indicate that RAD pretreatment does not appreciably affect the emergence of dead cells upon 100 
nM TAX treatment such that the appearance of non-adherent cells is mainly due to the response 
to TAX. 
 
4.2.9 TAM treatment affects cellular proliferation and p53/p21 expression. 
 As shown in previous sections, RAD treatment alone and as a pretreatment in 
combination with Adr evokes a significant reduction in cell proliferation. This decline in cell 
growth was also shown to be associated with an upregulation of p53 and p21. These changes in 
cell fate related proteins were evident in wild-type p53 MCF7 cells but were not recapitulated in 
mutant p53-containing MDA-MB 231 cells. In addition to possessing a different p53 status, 
MCF7 and MDA cells also differ in the status of other factors, including ER and PR, and so may 
elicit cellular responses due to their inherently distinct genotypes. In order to investigate the 
significance of the association of high Hsp90 levels and ER negative breast cancer, we wanted to 
compare MCF7 cells against an appropriate cognate cell. 
 TAM, as an ER antagonist, was used at a concentration of 1 µM to block ER activity in 
ER (+) MCF7 cells. TAM treated and untreated cells were then acutely treated with Adr alone or 
in combination with RAD.  When compared against untreated cells, treatment with TAM alone 
elicits a 43% decrease in cell growth, which is even less than that observed with Adr single 
treatment at 0.75 µM at 2 d (see Figure 27). TAM in combination with Adr at increasing 
concentrations shows a trend towards decreased cell growth, which is significantly different than  
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Figure 46: Apoptotic cell emergence not affected by RAD pretreatment with TAX. MCF7 
cells were treated with 100 nM TAX alone for 24 hr (C) or in combination with 48 hr 
pretreatment with 0.03 µM RAD (D). Upon completion of treatment series, cells were fixed and 
processed for the TUNEL assay. Apoptotic cells are represented by the visibly green nuclear 
staining. Untreated cells (A) and RAD only treated cells (B) have only a background level of 
activity, while TAX and RAD/TAX have detectable apoptotic cells. All images taken at 40x. 
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untreated cell growth at all Adr doses (Figure 47, compare blue bar against black bars). RAD 
pretreatment with TAM alone follow-up leads to a 44% reduction in growth compared to RAD 
only (Figure 47, compare green bar against first grey bar). When Adr is added to this series, the 
decline in population doubling is even more apparent with increasing Adr dose. More notably, 
significant proliferation differences emerge between the TAM + Adr and TAM + RAD + Adr 
series. At Adr concentrations of 0.025 µM, 0.25 µM, and 0.75 µM, RAD pretreated cells have 
undergone significantly fewer PDs than TAM alone, suggesting that inhibition of Hsp90 acts in 
concert with ER antagonism. Taken together, these data indicate that blocking ER signaling does 
negatively affect cellular proliferation, although it appears to be more additive than synergistic. 
Since we observe a decline in cell growth upon TAM treatment with RAD and Adr, we 
wanted to determine whether expression of p53 and p21 were also affected as they are by RAD 
and Adr together. ER antagonism by TAM apparently drastically diminishes p53 protein 
expression, regardless of whether Adr is present or not (compare lane 3 to lanes 4-8, Figure 
48A), and TAM suppresses the Adr-induced p53 stabilization. However, expression of p21 does 
not seem to be affected since its protein levels remain constant throughout the TAM/Adr series 
and is comparable to that of untreated MCF7 cells. Despite the lack of change in p21, which 
mediates inhibition of Cdk4-dependent cell cycle progression, the protein level of Cdk4 is 
nevertheless markedly reduced. Likewise, TAM in combination with both RAD and Adr 
produces a considerable decrease in p53 expression compared to untreated and RAD alone 
treated cells (Figure 48B). The expression of p21 remains unchanged in this treatment series at 
0.0075 µM and 0.025 µM Adr since levels are equivalent to that of TAM/RAD, RAD only, and 
untreated. However, at 0.075 µM, 0.25 µM, and 0.75 µM Adr, p21 substantially decreases. There 
is also an observable reduction in Cdk4 expression, similar to that of the TAM/Adr series.
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Figure 47: Cell growth declines in response to tamoxifen treatment.  MCF7 cells were 
treated with 1 µM TAM for 24 hr. Cells were then either acutely treated with Adr alone (“TAM 
+ Adr”, black bars) at various concentrations, ranging from 0.0075 µM to 0.75 µM, or pretreated 
for 48 hrs with 0.03 µM RAD followed by Adr treatment at the same range (“TAM + RAD + 
Adr”, grey bars). Upon completion of drug treatments, cells were harvested and counted in 
triplicate. MCF7 cells without drug exposure (blue bar) and RAD only treated cells (green bar) 
served as controls to which all other population doublings for TAM + Adr or TAM + RAD + 
Adr, respectively, were normalized.  Asterisks (*) denote significant changes (p < 0.05) between 
TAM + Adr and TAM + RAD + Adr at the indicated Adr concentration. 
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Figure 48: Decreased expression of cell fate related proteins with TAM treatment. MCF7 
cells were treated with 1 µM TAM for 24 hr. Cells were then either acutely treated with Adr 
alone (“TAM + Adr”, A) at various concentrations, ranging from 0.0075 µM to 0.75 µM, or 
pretreated for 48 hrs with 0.03 µM RAD followed by Adr treatment at the same range (“TAM + 
RAD + Adr”, B). Upon completion of treatment, cells were harvested and 50 µg of total lysate 
was subjected to western analysis. Immunoblot was probed with antibodies against Hsp90, 
Hsp70, p53, Cdk4, and p21. β-actin served as the loading control. Normal fibroblasts are 
represented by “BJ” and untreated MCF7 cells by “Ø”.   
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Unexpectedly, it appears that 0.75 µM Adr in conjuction with TAM and RAD is associated with 
an upregulation of Cdk4, but this could be a spurious finding. 
Furthermore, expression of the Hsp90 cycle-associated co-chaperone, Hsp70 was 
assessed to identify consequences of ER antagonism on other heat shock proteins. Within each 
treatment series, TAM/Adr or TAM/RAD/Adr, Hsp70 expression does not greatly differ with 
increasing Adr concentration (Figure 48). Both the smaller 69 kDa and the larger 72 kDa forms 
abundantly exist. Initial assessment of Hsp70 in the TAM/RAD/Adr series suggests relatively 
lower expression of the larger form, but this is in fact due to reduced protein content, as shown 
by β-actin levels. Finally, TAM treatment is does not appear to be associated with any affect on 
Hsp90 expression in any case. Collectively, TAM data imply that blockade of ER signaling 
negatively affects p53 and Cdk4 expression and that the presence of RAD causes a decrease in 
p21 levels and a stabilization of Cdk4 with TAM and high Adr concentration.  
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Chapter 5 
Discussion 
 
5.1 Preface 
 Since the war on cancer was declared by President Nixon in 1971, many advances have 
been made in understanding breast cancer biology mechanisms and developing practical 
treatments. Although a wide array of therapeutic options are currently available and 
improvements continually made, cancer prevalence is on the rise and drug resistance remains a 
major challenge in successful disease elimination. Targeted therapies directed at specific 
molecules or signaling pathways have become increasingly prominent, but cancer cells 
nevertheless manage to evade complete eradication by utilizing alternative mechanisms of 
survival. These properties highlight the inherent genomic instability and adaptiveness of cancer 
cells. In order to address the deregulation of multiple routes of tumorigenesis, Hsp90 inhibition 
has evolved as an attractive method of simultaneously targeting a variety of pathways. Hence, 
indirect targeting of client proteins for degradation or inactivation via Hsp90 inhibition has a 
promising future in the treatment of cancer.   
 
5.2 Differential expression of Hsp90 and p23 in breast cancer 
The results presented in the immunostaining study offer considerable insight into the 
importance of chaperones in breast cancer and demonstrate the utility of tissue arrays. The use of 
CBCTR tissue arrays with both benign and malignant breast tissues embedded on individual 
slides provides a powerful tool with great analytical and statistical power, allowing for the 
simultaneous examination of disease stages from a variety of specimens relevant to the breast. 
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Notably, their experimentally uniform nature allows for reliable data analysis and less variability, 
both of which are advantages for any study. Each tissue microarray contained hundreds of cores 
including 23 normal breast specimens, 10-11 DCIS, 79-80 invasive cores, and 9 duplicate cell 
lines representing the breast, prostate, kidney, colon, and endometrium. The robustness of this 
study is certain, since normal and DCIS tissues were analyzed alongside invasive carcinomas. 
Additionally, the use of breast tissue specimens as an initial means of analysis allows for a more 
applicable translation into a clinical setting. Furthermore, the method of collection of 
immunoreactivity scores prevents any bias from forming, thus eliminating the possibility of data 
skewing. This is evident for Hsp90 and p23 immunostaining since inter-rater agreement was high 
in both cases.  
 Since Hsp90 exists as an abundant and ubiquitous cellular protein, it is not surprising that 
Hsp90 protein expression is highly detectable in normal mammary epithelial cell strains, 
immortal cells, and breast cancer cell lines. We found a significant increase in total cellular 
levels of Hsp90 in tumor cell lines as compared to mortal, non-tumorigenic lines. Tissue array 
data supports this finding as evident by an increase in the average immunostaining score for 
cytoplasmic Hsp90. Overall, normal breast tissue express less total Hsp90 in the cytoplasm than 
DCIS and invasive carcinomas. These findings are in line with previous reports of increased 
expression of both total Hsp90 and Hsp90α in tumor cells compared to normal cells (Pick et al., 
2007; Yano et al., 1996, 1999). In addition to breast cancer, overexpression of Hsp90 mRNA or 
protein has also been reported in leukemia, gliomas, and ovarian, endometrial, and pancreatic 
cancers (Xiao et al., 1996; Strik et al., 2000; Nanbu et al., 1996; Mileo et al., 1990; Ogata et al., 
2000). Although the mechanism driving this Hsp90 upregulation needs clarification, it is possible 
that the inherently “stressful” conditions of the tumor microenvironment, including low glucose, 
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low intra- and extra-cellular pH, and hypoxia (Laderoute et al., 2006; Lee et al., 2008; Qing and 
Simon, 2009) are favorable for Hsp90 induction. Furthermore, the accumulation of mutant 
oncoproteins during cancer establishment may trigger Hsp90 upregulation in response to the 
presence of these misfolded or conformationally altered proteins.  Thus, the increase in Hsp90 in 
cancer cells is likely related to the induction of the heat shock response, mediated by heat shock 
transcription factors such as HSF1 (Shamovsky and Nudler, 2008). The HSF1 protein is 
normally sequestered by Hsp70/Hsp40 in an inactive state, but upon heat shock, it is released 
from this complex and trimerizes to gain activity. These actions cause the subsequent binding of 
HSF1 to DNA elements that promote the transcription of HSPs. In the context of this study, it is 
possible that the tumor environment is triggering a heat shock response involving the activation 
of HSF1, which then stimulates Hsp90 upregulation.  
Expression of Hsp90 in the nucleus, however, is lower for all disease types and does not 
significantly vary between the three disease states. This predominantly cytoplasmic localization 
has also been similarly reported in lobular neoplasia of the breast (Zagouri et al., 2008). Despite 
the generally weak nuclear Hsp90 expression, it is notable that only invasive carcinomas contain 
a subset of specimens that stain intensely in the nucleus. Nevertheless, the dual localization of 
Hsp90 is consistent with previous studies that report localization of Hsp90 in both the nucleus 
and cytoplasm of breast cancer tissue (Yano et al., 1996). Future breast cancer therapy could be 
designed to take advantage of this nuclear localization of Hsp90. In fact, many Hsp90 targets 
require its association for entry into the nucleus, including mutant steroid receptors (Kang et al., 
1994) and fibroblast growth factors (Wesche et al., 2006). Thus, treatments that exploit a 
nucleus-targeted approach to blocking Hsp90 function could potentially be more effective in 
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both delivery and eliciting a response in advanced breast cancers that are more difficult to treat 
with conventional therapies.  
Although p23 total protein expression was shown to increase in cell culture as pre-
immortal HME cells progressed toward immortality and also in breast cancer cell lines, this 
observation was not reproducible in clinical specimens. In fact, p23 expression decreases when 
comparing normal versus DCIS versus invasive breast carcinomas, suggesting an inverse 
relationship between p23 expression and breast cancer progression. Thus, it appears that as 
malignancy increases, p23 expression decreases. The significance of this observation is unclear, 
since studies involving p23 function in cancer mostly focus on its role in estrogen receptor 
signaling. It is known that p23 preferentially interacts with Hsp90 in the ATP-bound state 
(Sullivan et al., 2002), but the mechanism of action of this co-chaperone remains to be 
elucidated. One report suggests that mutant p23 (which affects ER signaling, but still binds 
Hsp90) antagonizes Hsp90 function under heat shock conditions, suggesting that Hsp90 is 
actually sequestered by p23 under cellular stress (Oxelmark et al., 2003).  
The opposing results found in our cultured systems and clinical specimens related to p23 
expression reflect the presence of inherent differences between these two models, highlighting 
the fact that in vitro data is not always a true representation of nature. Based on this idea, we find 
that nuclear Hsp90 is greater in established cell lines than nuclear expression in DCIS and 
invasive breast tissue. Similarly, cytoplasmic Hsp90 is also greater in cancer cell lines than 
cytoplasmic Hsp90 in the same tissue specimens. These findings also extend to p23 nuclear and 
cytoplasmic locations, indicating that chaperone expression is innately higher in artificial 
systems. These differences reflect the dissimilarity of cell lines and in vivo tumors (Lerescu et 
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al., 2008) and may be indicative of the accumulation of alterations due to continuous culture and 
growth in an isolated environment.  
Since invasive carcinomas displayed highly variable Hsp90 and p23 immunostaining, we 
explored the possibility that chaperone expression in these heterogeneous cores may correlate 
with other breast cancer-associated factors. In order to describe the extent or severity of a 
particular breast cancer, the TNM system has delineated specific criteria for grouping cancers 
and has been a standard method of uniformly grading breast cancers to allow meaningful 
comparisons (Escobar et al., 2006). This system takes into account the tumor-node-metastasis 
stage of a particular cancer by assigning categorical numbers describing the size of the tumor 
(TX, Tis, T0-T4), the involvement of lymph nodes (NX, N0-N4), and the presence of metastases 
(MX, M0-M1).5 Using these guidelines, a higher T, N, and M number signifies a more advanced 
tumor. The TNM score also serves as a predictive marker for response to therapy and as such, 
provides prognostic information. Accordingly, we discovered that a positive correlation exists 
between nuclear Hsp90 and TNM stage, such that higher Hsp90 in invasive breast carcinomas 
was associated with a higher TNM grade. This finding suggests that elevated nuclear Hsp90 may 
be an indicator or marker of severity and may identify those cancers that are more likely to 
metastasize. 
Since the majority of breast cancers are estrogen-dependent (Bai and Gust, 2009), it was 
necessary to address whether chaperones were associated with the presence or absence of steroid 
hormone receptors, specifically the estrogen and progesterone receptors. Additionally, since ER 
and PR use the Hsp90 machinery for maturation, it would be logical to address whether the 
status of these receptors is altered upon Hsp90 and/or p23 upregulation. As a summary of 
receptor status, less than a third and less than half of all invasive carcinomas included in our 
                                                 
5 http://ccm.ucdavis.edu/bcancercd/311/tnm_staging.html
 
 
145
tissue arrays are ER or PR negative, respectively, which is in line with the general observation 
that ER and PR are present in the majority of breast cancers. Of note is the fact that more 
advanced and/or recurrent breast cancers that are originally ER positive eventually lose ER 
expression through various mechanisms, including epigenetic ones, thus obviating any response 
to endocrine therapy (Kuukasjärvi et al. 1996; Jensen and Jordan, 2003; Schiff et al., 2003; Leu 
et al., 2004). Similar observations have been reported for PR, which is positively regulated by 
ER, in that loss of PR expression coincides with the onset of tamoxifen resistance (Gross et al., 
1984) together with an increase in tumor aggressiveness and a decrease in survival rate (Balleine 
et al., 1999). The mechanisms for loss of PR are also variable and include the presence of 
nonfunctional ER and hypermethylation of the PR promoter (Horwitz and McGuire, 1978; 
Lapidus et al., 1996). 
Breast cancer progression studies involving Hsp90 and ER are less defined, but we find 
here that higher Hsp90 expression is tightly associated with ER negativity. In identifying a 
negative correlation between cytoplasmic Hsp90 and ER status, it appears that higher chaperone 
levels are associated with the loss of ER expression and the development of more aggressive 
breast cancers. Because ER is also a key prognostic marker for early breast cancer outcome 
(Martín, 2006; Rhee et al., 2008), as opposed to advanced stages where ER is weakly 
informative, it is indicative that high Hsp90 is associated with those cancers that have a poorer 
prognosis. Furthermore, since ER is a client protein of Hsp90, it may be possible that the 
upregulation of Hsp90 in invasive carcinomas is hyperactively reducing ER stability by targeting 
it for degradation, which contributes to loss of receptor expression. The finding presented here is 
contrary to a previous study, which reported the lack of any correlation between Hsp90 and ER; 
however, this previous study only examined lobular neoplasia in situ and adjacent normal tissue 
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(Zagouri et al., 2008). Indeed, it has been found that higher Hsp90 expression is significantly 
associated with decreased survival over 10 years in breast cancer patients (Pick et al., 2007), 
implying that increased Hsp90 levels may affect response to treatment. In our study, although no 
significant correlation emerged between Hsp90 and PR, which is also a prognostic marker in 
breast cancer, it has been shown that PR requires more Hsp90 for stabilization and activity than 
ER, which would suggest that elevated Hsp90 may lead to hyperactive PR rather than 
degradation (Felts et al., 2007). As an extension of our hormone receptor analysis, we sought to 
determine whether any relationship exists between TNM score and ER/PR status. Consistent 
with previous reviews (Cui et al., 2005), we found that those cancers that are ER or PR negative 
also exist at a higher TNM stage. It is evident that a change in hormone receptor status over the 
natural course of the disease corresponds to more advanced cancers. 
Despite the lack of a significant relationship between p23 and TNM stage, there was a 
positive correlation with ER and PR. The significant correlation to ER in malignant cancers 
supports other reports proposing that upregulation of p23 in an ER-positive tumor setting may 
impart a greater invasive potential (Oxelmark et al., 2006). The co-chaperone p23 may act as a 
positive regulator of ER signaling in the presence of Hsp90 and thus affect ligand binding and 
subsequently, the transcriptional activity of this receptor (Oxelmark et al., 2003). Our results 
showing that p23 positively correlates with ER presence support these previous studies. In fact, a 
decline in p23’s association with the ER complex during progression increases the likelihood 
that ER is targeted for Hsp90-mediated proteasomal degradation. Thus, the development of more 
aggressive cancers may be influenced by p23 in ER positive cancers, while ER negative cancers 
may be less affected by p23 upregulation. In terms of PR, we observed a significant positive 
correlation between p23 expression and PR presence, which is supported by the dependence of 
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PR stability and maturation on Hsp90 co-chaperones, such as p23 (Felts et al., 2007). Thus, high 
p23 expression positively regulates ER signaling, which in turn upregulates PR expression. 
Taken together, there appears to be a differential association of chaperones with clinical 
parameters that seemingly influences the prognosis of disease. 
The HER2/neu receptor, which is a member of the epidermal growth factor family, 
mediates signaling of growth and differentiation, and is thus also highly implicated in 
establishing or maintaining the pathogenesis of breast cancer. It is overexpressed in 20-30% of 
all breast cancers, and as such, is useful as a prognostic marker since its expression is associated 
with poorly differentiated and more aggressive breast cancers (Slamon et al., 1987). Indeed, 
HER2/neu positive lymph node-negative patients show significantly decreased disease-free and 
overall survival over 10 years (Choi et al., 2009). Due to various study limitations, we were not 
able to assess correlative HER2/neu protein expression with Hsp90 or p23 in our tissue arrays. It 
is possible that since HER2/neu overexpression is significantly associated with ER and PR 
negativity (Choi et al., 2009), Hsp90 expression may be higher while p23 may be reduced in 
these tumors. 
 
5.3 Client-bound and free forms of Hsp90 co-exist in cancer cells. 
The upregulation of Hsp90 expression has been reported to be associated with functional 
or mechanistic differences between normal and transformed cells. One published study reported 
that Hsp90 in cancer cells has been found predominantly in an activated form bound to its client 
proteins, while most normal cells have uncomplexed Hsp90 (Kamal et al., 2003). Furthermore, 
they show that Hsp90 in cancer cells has a higher affinity for Hsp90 inhibitors compared to 
normal cells, thus providing tumor selectivity via an unknown mechanism (Kamal et al., 2003). 
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These observations suggest that Hsp90 in stressful conditions (as in tumor cells) exists in a 
highly activated state as a multiprotein complex capable of supporting the transformed 
phenotype (Chiosis and Neckers, 2006). Normal cells must then maintain Hsp90 in an inactive 
state that undergoes more dynamic interactions with client partners. Thus, the balance between 
activated and latent Hsp90 must be tipped in favor of multichaperone assembly in order for 
transformation to occur or progress. 
Together, these data have provided a global rationale for Hsp90 inhibition; yet, our 
highly reproducible results contradict those previous observations, showing that Hsp90, while 
increased in high grade breast tumors over normal cells, is maintained in both a free and a bound 
state in normal, immortal, and tumor cells. Thus, based on both in vivo observations and in vitro  
data, it appears that while cancer cells exhibit upregulated Hsp90 expression, the heightened 
formation of client-bound complexes may not be exclusive for tumor cells and may therefore be 
dependent on increased Hsp90 levels, which could in turn drive the observed increased 
detectable association with clientele. Given this finding, the significance of Hsp90 inhibition is 
more importantly related to its localization and increased expression, rather than its client-bound 
or -unbound state. Hence, Hsp90 inhibition remains a promising field of research, with analogs 
of geldanamicin already in later phases of clinical trials. 
The results of this study have provided a framework on which to study the biological 
significance of Hsp90 and p23 in breast cancer progression and the utility of chaperone 
inhibition as a breast cancer therapy. In summary, chaperone protein levels are differentially 
expressed in normal breast cells versus invasive breast carcinomas, and that this differential 
expression is based on cancer staging, rather than alterations in the Hsp90/client protein binding 
status. To our knowledge, this is the first comprehensive study examining Hsp90 and p23 
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proteins in terms of both expression and cellular compartmentalization. Examination of the role 
of p23 has determined that this co-chaperone has minimal correlation to breast cancer 
progression per se, but rather acts to influence ER signaling in established cancers. More 
importantly, we find that Hsp90 levels increase significantly in the nucleus of metastatic breast 
tumors, correlating with a higher TNM stage and ER negativity. Because of this relationship, it is 
feasible then that future breast cancer therapy could be designed to exploit a nucleus-targeted 
approach to blocking Hsp90 function and thus improve both delivery and response. These results 
have not only confirmed the upregulation of Hsp90 protein levels in cancer cells but have also 
implicated a relationship between this chaperone and prognostic parameters in breast cancer. 
Thus, Hsp90 is certainly an important regulator during breast cancer progression, and based on 
our results, its role in chaperoning oncogenic client proteins coupled to its linkage with clinical 
markers is clear.  
 
5. 4 Radicicol, alone and in combination, affects cellular proliferation  
The chaperone Hsp90 is designated as a member of a new GHKL superfamily of proteins 
that are ATP-dependent. This family of proteins varies in their functions and primary sequence, 
but do share a unique ATP-binding motif, termed the Bergerat fold (Dutta and Inouye, 2000). 
Since radicicol directly interacts with Hsp90 via this fold, this inhibitor is able is modulate the 
chaperoning activities of Hsp90. In fact, RAD has a higher affinity for Hsp90, competes with GA 
for binding in the N-terminal domain (Schulte et al., 1998a), and is effective in GA-resistant 
cells (Chiosis et al., 2003). Furthermore, RAD is not associated with hepatotoxicity as seen with 
GA treatment, is more potent in terms of blocking ATPase activity, and prevents the association 
of the co-chaperone p23 with Hsp90 (Yamamoto et al., 2003; Roe et al., 1999). In cancer cells, 
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RAD has been shown to affect the level of Hsp90 client proteins involved in cell signaling 
(Schulte et al., 1998a). The major drawback for RAD is its lack of in vivo efficacy, which could 
be overcome with appropriate delivery mechanisms. 
Since Hsp90 affects the maturation of client proteins that are involved in the cell cycle, 
examining cell growth was a logical start to delving into the cellular response to RAD. We have 
shown here that RAD does elicit a robust decline in proliferation and this effect is noticeable 
even at lower RAD concentrations. It is possible that RAD is acting on key factors that modulate 
progression through the cell cycle. Studies have shown that RAD inhibits the activity of human 
topoisomerase II, which aids in unwinding DNA during replication (Gadelle et al., 2006). 
Because MCF7 cells respond to RAD at a lower concentration, it is possible that breast cancer 
cells are more sensitive to Hsp90 inhibition than prostate cancer cells (Compton et al., 2006), 
which show responsiveness at a much higher (10-fold) RAD concentration. 
RAD pretreatment in combination with Adr elicits an even greater reduction in cell 
growth when compared to Adr singly treated cells. At each Adr concentration, the decrease in 
population doubling with RAD pretreatment is more than the combined effects of RAD alone 
and Adr alone. These results indicate that RAD plus Adr produces a greater than additive effect 
on cell growth, rather, it suggests a more synergistic response. As such, RAD pretreatment 
appears to be sensitizing breast cancer cells to the damaging effects of Adr, culminating in a 
more potent growth inhibition. Substantiating this finding, RAD has been shown to induce 
radiosensitization as evidenced by an increase in cell death and the degradation of Her2/neu, 
which is responsible for mediating cell growth signaling (Harashima et al., 2005). Additionally 
important is the finding that since low Adr concentrations in combination with RAD is able to 
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significantly reduce cell growth, it is possible to treat breast cancer using a less toxic 
chemotherapeutic dosage when combined with a pretreatment agent. 
Unlike RAD plus Adr treatment, which was associated with negligible cell death, RAD 
plus CIS or TAX did cause an increase in cell death. As assessed by the number of non-adherent 
cells, treatment with RAD plus CIS caused a significant increase in dead cells as compared to 
treatment with RAD alone at the longest treatment period. The average number of CIS induced 
dead cells was also less than combination treatment but it was not statistically significant. 
Considering average numbers, the combination of RAD and CIS (2.6%) is associated with 
slightly more dead cells than the simple addition of RAD only (0.96%) and CIS only (1.4%) 
treated cells (0.96% + 1.4% = 2.4%). It is necessary to point out that although non-adherent cells 
appear upon RAD and CIS combination treatment, the percentages of dead cells are still 
considerably low. RAD pretreatment with TAX greatly induces the appearance of non-adherent 
cells, displaying percentages more than nine times that of RAD plus CIS at the longest treatment 
time, but this increase is comparable to that of TAX alone. Again, the number of dead cells with 
RAD plus TAX was significantly different than with RAD alone. Thus, Hsp90 inhibition does 
not appear to be sensitizing CIS or TAX treated cells to cell death. 
Tamoxifen acts as an ER antagonist, such that it recognizes and binds at the same site as 
the normal ligand, estradiol, but is believed to prohibit functional signaling beyond this receptor. 
At a concentration of 1 µM, TAM was shown to negatively affect cellular proliferation in ER-
positive MCF7 cells. When compared to MCF7 with intact ER activity (RAD plus Adr), TAM 
plus RAD plus Adr treated cells display even more reduced cell growth at lower Adr 
concentrations. It is apparent that blocking ER activity is eliciting a stronger negative 
proliferative response in breast cancer cells. Furthermore, since the estrogen receptor is also a 
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client protein of Hsp90 whose activity triggers proliferation signals (Björnström and Sjöberg, 
2005), inhibition of Hsp90 may be leading to ER degradation. Indeed, RAD represses ER 
activation of ERE-responsive target genes and contributes to a ubiquitination and subsequent 
degradation of ERα (Lee et al., 2002). Thus, prior blockade of ER activity combined with 
inhibition of Hsp90 chaperoning activities on ER may collectively contribute to decreased cell 
growth.  
 
5.5 Telomerase activity decreases in response to RAD  
As an Hsp90 client protein that is involved in immortalization and conversion to the 
transformed phenotype, telomerase is upregulated in the majority of human cancers and is 
associated with more aggressive breast cancers (Bieche et al., 2000). Minimally composed of the 
catalytic hTERT subunit and the internal RNA template, hTR, telomerase maintains telomere 
length and provides for an unlimited replication potential. The stable association of Hsp90 and 
p23 with the functional telomerase enzyme is an uncommon occurrence for chaperones (Forsythe 
et al., 2001), since chaperones generally interact dynamically with their clientele (Banerji, 2009). 
The interaction between Hsp90 and its client protein telomerase, in this case, is more than a 
transient process and may provide functional insight into this reverse transcriptase.  
It has been proposed that the continued association of Hsp90 and p23 is required to 
maintain the proper conformation of telomerase during translocation of the enzyme as hTR binds 
and unbinds telomeric sequence (Forsythe et al., 2001). We present here that Hsp90 inhibition 
effectively reduces telomerase activity in a time-dependent manner. It is possible that RAD is 
blocking the chaperoning function of Hsp90 on telomerase, which may lead to reduced assembly 
or less stability and thus less activity. This decrease in telomerase activity has been reported in 
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other studies involving both RAD and other Hsp90 inhibitor classes (Nakai et al., 2006; 
Donnelly and Blagg, 2008). It is notable that 0.03 µM RAD alone induces a decline in 
telomerase activity that coincides with a reduction in cell proliferation, such that RAD only 
treated cells display a 70% reduction in cell growth at 2 d and a 35% reduction at 4 d compared 
to untreated cells. In this respect, the decrease in telomerase activity may be alleviating telomere 
maintenance in these cancer cells, leading to the lack of proliferation. As supporting evidence, 
inhibition of telomerase activity is associated with growth inhibition and reduction in telomere 
length in myeloma cells (Shammas et al., 2004).  
In this respect, the decline in telomerase activity upon Hsp90 inhibition could be due to a 
lack of telomerase assembly, a lack of telomere binding, the absence of catalytic hTERT activity, 
or telomerase degradation. Firstly, inhibition of Hsp90 may prevent the association of the 
catalytic subunit with the internal RNA subunit, and thus prevent proper assembly of telomerase. 
Alternatively, it is possible that Hsp90 inhibition exerts its effect on telomerase activity by 
preventing the reassembly of hTERT and hTR following translocation to the next telomeric tract. 
Secondly, Hsp90 could aid in substrate recognition by telomerase, such that inhibition of Hsp90 
activity subsequently leads to an inability of telomerase to bind telomeres. Thirdly, it may be 
possible that hTERT and hTR are able to associate, but inhibition of Hsp90 prevents functional 
activity of the assembled complex. Finally, telomerase degradation via the proteasomal pathway 
has been observed in lung carcinoma cells treated with GA in a time- and dose-dependent 
manner (Kim et al., 2005). Our lab has corroborated this finding in prostate cancer cells, 
showing that cells transfected with GFPhTERT show a time- and dose-dependent decline in 
fluorescence upon RAD treatment that is able to be blocked by a proteasome inhibitor (Nguyen 
and Holt, unpublished observations). 
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5.6 p53, p21, and cell cycle regulation 
 The tumor suppressor protein, p53, has been associated with malignant transformation 
since it is frequently mutated in cancer. Long considered the guardian of the genome, p53’s 
essential role in mediating cell cycle arrest, senescence, and apoptosis in response to DNA 
damage is well documented (Vasquez et al., 2008). Mutant p53 is dependent upon the 
chaperoning ability of the Hsp90 machinery in order to remain in a stable conformation, 
supported by structural studies that reveal the presence of the unfolded form of p53 in 
association with Hsp90 (Rudiger et al., 2002). Abrogation of functional Hsp90 by geldanamycin 
leads to a reduction in mutant p53 most likely through destabilization of the improperly folded 
form of p53 (Blagosklonny et al., 1996). 
Deregulation of the cell cycle is a fundamental factor contributing to the persistence of 
the cancer phenotype. By gaining the ability to continuously proliferate, tumor cells can proceed 
through the cell cycle unchecked due to their insensitivity to inhibitory signals and regulatory 
controls (Deshpande et al., 2005). As explained in detail in the introduction, upon DNA damage, 
wild-type p53 primarily signals via the cyclin-dependent kinase inhibitor, p21Waf1/Cip1, which 
triggers G1/S phase cell cycle arrest (Cadwell and Zambetti¸ 2001). p21 physically associates 
with and is able to inhibit the activity of cyclin D-Cdk4 complexes, which normally guide 
progression through the G1/S restriction point upon stimulation by mitogenic signals (LaBaer et 
al., 1997).  
Although it acts as the standard breast cancer cell line in basic research, MCF7 cells (here 
obtained from ATCC) carry a highly complex karyotype, containing between 64-83 
chromosomes with various chromosome-specific duplications and deletions (Wenger et al., 
2004). For most studies, proliferating (young) BJ foreskin fibroblasts were included as the 
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standard “normal” cell line to which breast cancer cells were compared. These fibroblasts were 
maintained and used at population doublings in the range of approximately PD 30 to PD 45, 
which is well below the onset of senescence in the range of PD 80-100 (Keys et al., 2004; Sitte 
et al., 2001). Of note, the levels of p53 and p21 in normal BJ fibroblasts are consistently very 
low to undetectable by western blotting at low protein concentration, suggesting that under 
normal conditions, the tumor suppressor protein p53 and its downstream target p21 remain in a 
latent state.  Hence, normal cells are subject to growth regulatory controls, while cancer cells 
display enhanced cell cycle progression and hyperactivation of cyclin-Cdk complexes (Ortega et 
al., 2002). This cell cycle deregulation exists in sporadic breast carcinomas, in which Cdk4 gene 
amplification and high Cdk4 protein expression has been associated with an increase in 
proliferative index (An et al., 1999). 
 The decline in cell growth with the concurrent upregulation of p53 and p21 upon 
treatment with Adr alone and with RAD plus Adr support the role of these proteins in negative 
regulation of the cell cycle. RAD plus Adr induces p53 and p21 to a lesser extent than Adr alone, 
indicating that MCF7 cells are being sensitized by Hsp90 inhibition. In other words, the 
combination of RAD plus Adr evokes a pronounced decline in cell growth (more so than with 
Adr alone) but elicits less DNA damage. The less severe damage response could then be 
interpreted as a clinical advantage since it would be associated with less cytotoxicity. 
Additionally, both Adr alone and RAD with acute Adr treatment leads to a decrease in Cdk4 
levels, such that the highest Adr concentration corresponds to the greatest induction of p53 and 
p21 and the lowest reduction of Cdk4. The notable decline in Cdk4 is indicative of a blockade in 
cell cycle progression, which leads to growth arrest manifested as decreased cell growth.  Indeed, 
it has been established that in cells with wild-type p53, Cdk4 down regulation in the presence of 
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TGF-β coincides with G1 growth arrest (Ewen, 1996). Furthermore, since Cdk4 is also a client 
protein of Hsp90, the observed Cdk4 reduction could also reflect the consequence of Hsp90 
inhibition. In this manner, RAD may cause the degradation of Hsp90-associated Cdk4. Finally, 
mutant p53 MDA-MB231 cells do not display alterations in p53 or p21 protein expression upon 
Adr or RAD plus Adr treatments, suggesting that the results noted in MCF7 cells may be p53-
dependent. Taken together, cell growth aberrations are likely the culmination of both p53- and 
p21-induced arrest at the transition point between G1 and S phases, as well as the potential 
degradation of cell cycle regulatory proteins upon RAD and Adr treatment. 
In order to elucidate whether the alterations in cell fate-related proteins, p53 and p21, 
were dependent upon the mechanism of action related to Adr, we sought to assess the effect of 
other chemotherapeutics, including cisplatin and taxol. CIS, like Adr, is also a DNA damaging 
agent in that it forms unrepairable DNA cross-links. While Adr inhibits DNA unwinding by 
topoisomerase II, CIS acts by prohibiting further progression by RNA polymerase II, creating 
stalled complexes that are ineffectively resolved. The mechanism of action of TAX, however, 
differs from that of Adr and CIS, since it acts as a microtubule-stabilizing agent.  In this manner, 
the metaphase to anaphase transition is blocked due to the absence of the required microtubule 
depolymerization. Despite the different mechanisms, CIS and TAX both typically influence cell 
fate by sending cells down an apoptotic pathway. 
 In our study, treatment with CIS over 48 hr results in a slight upregulation of p21 without 
a concurrent increase in p53 upon CIS treatment alone and more evidently, in conjunction with 
RAD. Although no detectable change occurs in p53 protein levels over this time period, it may 
be possible that p53 is transiently induced early (< 4 hr) upon CIS treatment. Nevertheless, these 
data indicate that p53-independent mechanisms exist to stimulate p21 activation or expression in 
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response to CIS. It is notable that CIS alone at 48 hr induces a similar level of p21 expression as 
does RAD and CIS at 4 hr. Unlike RAD and Adr combination treatments, treatments with CIS do 
not induce any significant changes in Cdk4 expression. It may be possible that p21 levels must 
reach a threshold level not attained in our CIS studies in order to exert an inhibitory effect on 
Cdk4. Nevertheless, it is possible that inhibition of Hsp90 is sensitizing cells to be more 
responsive to CIS in terms of cell fate mediator expression. In other words, RAD pretreatment 
could be eliciting a damage response earlier than with CIS alone, which may have therapeutic 
implications. Breast cancer cells could be treated for a shorter period of time if first applied with 
RAD, thus limiting off target effects while maximizing antitumor responses.  
 Treatment with TAX alone or with RAD plus TAX produces an extreme upregulation of 
p53 protein levels, potentially reflecting increased protein stability, and a corresponding increase 
in p21 that appears to be time-dependent. A closer inspection shows that RAD pretreatment 
elicits an increase in p53 and p21 earlier than with TAX alone. Similar to CIS treated cells, RAD 
may be sensitizing cells to be more responsive to TAX in terms of cell fate protein induction. 
TAX, as a microtubule stabilizing agent, blocks the G2 to M phase transition but is also 
associated with a down regulation of Cdk4 (Yoo et al., 1998). This decrease subsequently leads 
to a blockade in the G1 to S phase transition, thus inducing cell cycle arrest at this stage. Our 
observation that Cdk4 is reduced upon treatment with TAX alone is consistent with this previous 
finding, yet the significance of why RAD pretreatment subsequently increases Cdk4 expression 
remains unclear.  
 Treatment with TAM in conjunction with Adr leads to a marked decrease in p53, without 
a concurrent decrease in p21. Similarly TAM + RAD + Adr (TRA) treated cells also display 
decreased p53 comparable to that of TAM + Adr (TA) treated cells, suggesting that TAM is the 
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key factor driving p53 reduction. It has been reported that ER activity is regulated by wild-type 
p53, signifying concordance between ER and p53 expression (Shirley et al., 2009), but it is 
unclear whether abolition of ER activity in turn affects p53 expression. Unlike that of TA cells, 
TRA cells exhibit reductions in p21 at the highest Adr concentrations, indicating that RAD 
pretreatment may only be effective at higher doses of Adr, and thus would not be a good method 
of sensitization. Both TA and TRA treated cells display reduced Cdk4 protein levels in the 
absence of p21 upregulation, suggesting that TAM is modulating Cdk4 inhibition via a different 
cyclin-dependent kinase inhibitor, such as p16. 
 
5.7 Radicicol affects co-chaperones of the Hsp90 cycle   
 Upon proteotoxic damage, the main responders, Hsp70 and Hsp27, are strongly induced. 
The ATP-dependent chaperone Hsp70 is able to act both independently of and in concert with 
Hsp90. When utilized for the Hsp90 machinery, Hsp70 acts as a co-chaperone to recruit client 
proteins for the Hsp90 cycle (Morishima et al., 2000). This co-chaperone has been shown to 
include various isoforms, otherwise considered different members of the Hsp70 family. Our data 
suggest that a constitutive and inducible form exist and that they are differentially expressed 
depending upon the type of drug treatment. The smaller 69 kDa form is seen in all cells, treated 
or not, and so appears to represent constitutive Hsp70 found under basal conditions, while the 
larger 72 kDa form seems to be inducible. The ATP-independent chaperone, Hsp27, exerts its 
protective function autonomously since it is not a component of the Hsp90 cycle.  
 Adr single treatment induces an appreciable reduction in Hsp70 while RAD plus Adr 
only produces a slight decrease. This observation further supports the presence of sensitization 
since the heat shock response is less stimulated due to less stress on the cell upon RAD 
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pretreatment.  Although treatment with AdR and RAD plus Adr did not affect total protein levels 
of Hsp27, this chaperone has also been implicated in cell survival (Landry et al., 1989). For 
instance, overexpression of Hsp27 blocks apoptosis by preventing caspase activation in leukemic 
cells treated with etoposide, an inhibitor of topoisomerase II (Garrido et al., 1999). Thus, the 
Hsp90-related chaperone, Hsp70, is affected by RAD, but not the Hsp90-independent chaperone, 
Hsp27. 
 RAD pretreatment with Adr follow-up also led to an appreciable decrease in p23 levels at 
the highest Adr concentration (0.75 µM). This decline may be related to the role of p23 as both a 
member of the Hsp90 machinery and as an independent chaperone. Since p23 stabilizes the 
ATP-bound form of Hsp90, it is likely that treatment with radicicol prevents this association, as 
reported with GA treatment. In support of this notion, p23 was found to be cleaved by caspase 3 
and 7 upon GA treatment in cancer cells (Gausdal et al., 2004), and in apoptotic cells, this 
cleavage occurred at the C-terminal end creating a truncated p23 that was then directed towards 
degradation in a proteasome-dependent manner (Mollerup and Berchtold, 2005). RAD 
pretreatment may be eliciting the same effect and causing the degradation of p23 via the 
proteasomal pathway. Since p23 also has chaperoning activity independent of Hsp90 (Freeman 
et al., 1996), RAD and Adr in combination may be blocking this additional function. 
Furthermore, overexpression of p23 has been shown to be associated with the development of 
resistance to Hsp90 inhibitors. In corroborating studies, p23 overexpression reduced the 
inhibitory activity of RAD (Cox and Miller, 2003), while p23 reduction increased susceptibility 
to Hsp90 inhibition (Forafonov et al., 2008). Extended to our data, RAD pretreatment may lead 
to a p23 decrease when treated in combination with 0.75 µM Adr, causing destabilization of the 
ATP-bound form of Hsp90, which consequently negatively affects Hp90 activity on clientele.   
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 Inhibition of Hsp90 prior to CIS or TAX treatment, as well as CIS alone at 48 hr, is 
associated with an upregulation of the inducible 72 kDa form of Hsp70. Likewise, RAD plus 
TAX treated cells also induce the larger Hsp70 form. Since this form is only barely detectable at 
earlier CIS only time points and at all TAX only time points, it may be that Hsp90 inhibition is 
stimulating a more robust heat shock response from other chaperones. In other words, Hsp70 
may be upregulated in response to the lack of Hsp90 activity. This is supported by the finding 
that RAD alone treatment elicits the same upregulation of the inducible Hsp70 form, suggesting 
that RAD is not sensitizing cells to CIS or TAX treatments in terms of co-chaperone expression. 
Treatment with the TAM plus Adr series does not considerably affect Hsp70 expression, while 
the TRA series does seem to show a small increase in the inducible Hsp70 form when compared 
against RAD only, again suggesting that RAD may be provoking the stress response of other 
chaperones in the context of Hsp90 inactivity. 
 
5.8 Expression of c-Abl is altered in response to CIS but not TAX 
 The c-Abl tyrosine kinase is an Hsp90 client protein that is ubiquitously expressed in all 
tissues and aids in the regulation of cellular proliferation, cell survival, cell migration, and 
influences cell fate decisions (Lin and Arlinghaus, 2008). Nuclear c-Abl is activated by DNA 
damage, which in turn initiates an apoptotic response, while cytoplasmic c-Abl is involved in 
signal transduction and is thus believed to be the oncogenic form (Wang, 2000). Although 
mostly known for its role as part of the bcr-abl fusion protein found in chronic myeloid 
leukemia, c-Abl activation also exists in solid tumors, including breast cancer. Previous studies 
have reported that c-Abl can be stimulated by ErbB2 signaling, which has been shown to be 
constitutively active in breast cancer (Plattner et al., 1999). Activated c-Abl can promote  
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invasion in breast cancer cells, such that treatment with imatinib mesylate (Gleevec), a c-Abl 
kinase inhibitor, in a highly metastatic breast cancer cell line reduces the size and incidence of 
colony formation (Srinivasan and Plattner, 2006; Srinivasan et al., 2008).  
We present here that RAD plus TAX does not stimulate c-Abl production, while RAD in 
combination with CIS only modestly induces an increase in protein levels. This suggests that the 
difference in c-Abl expression is likely due to the presence of either CIS, a DNA damaging 
agent, or TAX, a microtubule stabilization agent, but not RAD. It would be interesting to assess 
the activity of this tyrosine kinase in terms of its ability to interact with and activate signaling 
molecules and apoptotic mediators. In this respect, CIS may be activating the kinase function in 
MCF7 cells while c-abl remains dormant in TAX treated cells. 
 
5.9 Induction of senescence or apoptosis  
 The observed increase in senescence in RAD pretreated cells corresponds to the decrease 
in telomerase activity over time. It is believed that overcoming proliferative boundaries involves 
the upregulation of telomerase and the subsequent maintenance of telomere length (Shay and 
Wright, 1996). Through inhibition of Hsp90, we were not only able to reduce telomerase activity 
but also induce a senescent phenotype. However, no observable changes in telomere length were 
noted, which contradicts the idea that replicative senescence is universally associated with 
telomere shortening. Rather, the range of telomere length is consistently between 2.0 kb and 
about 4.0 kb, regardless of treatment or no treatment, with is in line with previous findings 
reporting an average telomere length of 3.5 kb in MCF7 cells (Elmore et al., 2002). As such, the 
change in telomerase activity may not be associated with telomere length, since a previous study 
has shown that telomerase activity does not foretell telomere length (Savre-Train et al., 2000).  
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The lack of telomere length changes may also point to the limitation of the TRF assay, 
which assesses global length alterations such that chromosome-specific changes are not readily 
detectable. It is possible that telomere length regulation and restriction of proliferative capacity is 
mediated by alterations at specific chromosome ends rather than by the overall shortening of all 
telomeres. In theory, because human telomere length varies greatly, the shortest telomere should 
govern proliferative life span (Lansdorp et al., 1996). In support of the chromosome-specific 
proliferation restriction, the Xp chromosome reportedly maintains its length while all other 
telomeres shorten, and the active Xp undergoes shortening at a slower rate than inactive Xp (Hao 
and Tan, 2001; Marten et al., 2000; Surralles et al., 1999). Similarly, the telomeres of 
chromosome 17q are shorter than global telomere lengths in DCIS and breast carcinoma tissue, 
while chromosome 9p telomere length is shorter in breast cancer patients than unaffected 
controls (Rashid-Kolvear et al., 2007; Zheng et al., 2009). 
 Despite the lack of replicative senescence, accelerated senescence induced in response to 
chemotherapeutics may exist. Cells undergoing this type of senescence share morphological and 
biochemical similarities to those undergoing replicative senescence (Gewirtz et al., 2008). 
Senescence in RAD and Adr treated cells was assessed by β-galactosidase staining which works 
optimally at pH 6.0. Initially believed to be an isoform of the lysosomal β-galactosidase, recent 
studies report that this enzyme is in fact lysosomal β-galactosidase, and its accumulation is a 
reflection of increased lysosomal mass, which is present in senescent cells (Kurz et al., 2000).  
Although the β-gal enzyme is not directly related to senescence, cells undergoing growth arrest 
uniformly express its activity, while proliferating or young cells do not contain detectable 
activity. Despite its seemingly arbitrary designation, it is an accepted and widely used marker of 
the senescence phenotype in the absence of an alternative method of detection (Coates, 2002; 
 
 
163
Dimri et al., 1995). As a cautionary statement, normal cells also display positive SA-β-gal 
activity depending on the temperature and incubation time with β-gal substrate, so additional 
parameters must be applied to assess a genuine senescence response.  
Our observation that the population of senescent cells increases upon drug treatment is 
consistent with the upregulation of p53, which has been reported in other studies (Wynford-
Thomas, 1999). The increase in p53 and p21 expression after both Adr treatment and Hsp90 
inhibition triggers the cell to cease cell division and may in turn lead to growth arrest. However, 
p53 and p21 are not exclusive to growth arrest induction since they also participate in 
quiescence, differentiation, and apoptosis. Indeed, activation of senescence and apoptotic 
programs via p53 are critical tumor suppressor mechanisms that prevent malignant 
transformation (Rodier et al., 2007). 
As p53 is also intricately involved in transducing an apoptotic signal in response to DNA 
damage, apoptotic cell death was assessed upon RAD pretreatment. We observe no outstanding 
differences between Adr singly treated cells and RAD pretreated cells, suggesting that Hsp90 
inhibition does not predispose MCF7 breast cancer cells to apoptosis. The lack of apoptotic cells 
may be related to the unchanged expression of Hsp27, which has the ability to abrogate apoptosis 
(Garrido et al., 2006). Taken together with the cell growth data, it appears that RAD 
pretreatment with Adr follow-up does not primarily stimulate an apoptotic response. However, it 
is also important to recognize that MCF7 cells lack functional caspase 3, which is a key effector 
of the apoptotic response and a valid biochemical marker of apoptosis (Abu-Qare et al., 2001). In 
support of this role of caspase 3, MCF7 cells are reportedly resistant to radiation-induced 
apoptosis in the absence of caspase 3, but are observed to activate caspase 9 and undergo 
apoptosis upon reintroduction of caspase 3 (Essmann et al., 2004). Thus, in our study, 
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undetectable apoptosis in RAD plus Adr treated MCF7 cells may in part be attributed to the 
absence of activated caspase 3.  
On the other hand, RAD in combination with 0.1 µM CIS or 100 nM TAX does lead to 
the emergence of apoptotic cells. CIS and TAX exert their actions through both the 
mitochondrial (intrinsic) and death receptor mediated (extrinsic) apoptotic pathways (Fulda and 
Debatin, 2006). We show here that RAD plus CIS is associated with more apoptotic cells than 
RAD alone, as supported by the difference in the number of non-adherent cells. However, the 
percentage of non-adherent cells between RAD plus CIS and CIS alone treated cells do not 
significantly differ at either 24 hr or 48 hr, which is also shown by the lack of difference in the 
amount of apoptotic cells. Similar observations were found for TAX studies, in that RAD plus 
TAX induced apoptotic cell death to the same extent as TAX only treated cells. Based on this 
data, it appears that Hsp90 inhibition is not sensitizing cells to be more responsive to CIS or 
TAX sequential treatment in terms of apoptotic death induction. Perhaps lower drug 
concentrations may produce more sensitivity to RAD pretreatment and lead to synergistic effects 
on apoptosis. As such, non-apoptotic cell death (necrosis, autophagy, mitotic catastrophe) may 
be present, but undetectable, since drug dosage may affect the type of cell death (Fulda and 
Debatin, 2006). 
 
5.10 Perspective 
 In summary, the results presented herein highlight the utility of Hsp90 inhibition on 
abrogation of cellular proliferation, a key aspect of any cancer. Expression of cell fate related 
proteins and those involved in regulation of the cell cycle, as well as co-chaperones and Hsp90 
client proteins, are differentially affected depending on the drug used. In conclusion, the overall 
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study has presented both descriptive and informative data suggestive of mechanistic differences 
regarding the role of Hsp90 in breast cancer progression. Higher Hsp90 expression is present in 
invasive breast carcinomas as compared to normal breast tissue, and this upregulation 
corresponds to loss of ER expression and advanced disease stage. Inhibition of Hsp90 through 
the action of radicicol appears to be a valid method to combat breast cancer, especially in terms 
of cellular proliferation and expression of Hsp90-related oncogenic proteins. Thus, Hsp90 clearly 
plays an active role in breast cancer progression and maintenance such that inhibition of Hsp90 
elicts a robust response to certain chemotherapies more so than others. The future will surely 
reveal exciting advances in the comprehension of Hsp90 inhibition and advantages of its use in 
cancer therapy.  
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Appendix 
Telomere-associated TRF2 Expression during Breast Cancer Progression 
 
A.1 Introduction and Rationale 
Telomeres are specialized structures found at the ends of linear chromosomes that 
contain non-coding DNA distinguished by a 5’-TTAGGG-3’ sequence (Blackburn, 1991). The 
end replication problem produces a stretch of unreplicated DNA between the final RNA 
priming event and the terminus. To counteract this problem, the processive ribonucleoprotein 
enzyme, telomerase, extends these continuously shortened ends. An internal RNA template (in 
humans, hTR) recognizes the single stranded overhang produced as a result of normal 
replication, and a catalytic reverse transcriptase (hTERT) uses the hTR template to add on 
telomeric DNA (Nugent and Lundblad, 1998). Telomerase maintains telomeres in the vast 
majority of tumor cells thus providing for unlimited proliferative potential (Holt and Shay, 
1999; Shay and Bacchetti, 1997). However, despite high levels of telomerase activity in cancer 
cells, telomeres are nevertheless maintained at a relatively short length. In fact, telomere length 
abnormalities are seen as early events in the initiation of epithelial carcinogenesis, including 
ductal carcinoma in situ (DCIS) of the breast (Meeker et al., 2004a; 2004b). 
In light of these abnormalities, a host of telomere binding proteins are critical for 
assuring that telomeres do not trigger a DNA damage response, since an unfolded telomere 
could be sensed as a double strand DNA break (Deng and Chang, 2007). Some of the telomere 
binding proteins that provide this capping function include telomeric repeat binding protein 
factor 1 and 2 (TRF1 and 2), TIN2, POT1, RAP1, MRE11 complex, PTOP/PIP1, and tankyrase 
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1/2 (Shay and Bacchetti, 1997). These proteins cooperatively establish the t-loop, in which the 
single-stranded 3’overhang folds back onto itself and invades duplex DNA (de Lange, 2005; 
Kanoh and Ishikawa, 2003). The region of invasion is referred to as the D-loop (Neidle and 
Parkinson, 2003). Without a capping mechanism, the ends of chromosomes are eroded to such 
a critically short length that telomere dysfunction ensues. 
Shelterin is a complex consisting of six integral telomere binding proteins, TRF1, 
TRF2, TIN2, Rap1, TPP1, and POT1. Unlike other telomere-associated proteins, this complex 
is abundant only at chromosome ends and remains associated at the telomere throughout the 
cell cycle (de Lange, 2005). Two of the shelterin components, TRF1 and TRF2, are necessary 
for the proper formation of the T/D-loop. Both proteins contain DNA-binding domains and 
form homodimers and higher order oligomers (de Lange, 2005). TRF2 has emerged as the 
major protective factor at chromosome ends, acting as a positive regulator of telomere length 
(Karlseder, 2003). In support of this role, overexpression of TRF2 results in increased telomere 
shortening, without an associated increase in replicative senescence rate (Karlseder, 2002). This 
finding indicates that TRF2 acts to stabilize and protect shortened telomeres and prevents the 
induction of senescence. Functional inactivation of TRF2 results in a loss of t-loop invasion, 
leading to non-homologous end joining-mediated formation of end-to-end fusions. These 
fusions arise from the cells’ inability to distinguish natural ends and broken DNA. In addition 
to fusions, normal cells without a capping mechanism may also undergo recombination due to 
their highly repetitive sequence (Baykal et al., 2004). Other downstream chromosomal 
instabilities may occur at later rounds of cell division, including translocations, non-disjunction, 
and aneuploidy, which all likely contribute to tumorigenesis. Thus, maintaining telomere 
integrity and avoiding dysfunction are critical for genomic stability.  
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Previous data indicate that TRF2 may also assume additional (non-telomeric) cellular 
roles. For instance, TRF2 has been implicated in sensing and responding to irradiation-induced 
non-telomeric interstitial DNA damage (Bradshaw et al., 2005). Currently very little is known 
about the involvement of TRF2 in mammary carcinogenesis. One study has reported that TRF2 
is upregulated in ductal carcinoma in situ (DCIS) and invasive breast cancer (Nijjar et al., 
2005). However, this analysis only included six clinical specimens and mainly served as 
confirmatory data for in vitro cell culture findings, suggesting that TRF2 is upregulated during 
mammary cancer progression. The present study seeks to examine TRF2 expression in full 
scale microarrays of normal, DCIS, and invasive breast cancer tissue. It may be possible that 
breast cancer cells overexpress TRF2 to protect short telomeres, thus allowing for continued 
cell proliferation. TRF2 expression in normal, DCIS, and malignant breast tissues in 
immunohistochemically stained sections were compared in terms of reactivity, intensity, and 
cellular localization. Telomere length in these tissues was assessed using telomere-specific 
FISH analysis. Finally, we determined whether there was any correlation between TRF2 
expression and progression of disease stage and between telomere length and advancement of 
breast cancer. 
 
A.2 Results 
A.2.1 Invasive breast carcinomas express less nuclear TRF2. 
Based on the immunostaining results, cellular distribution of TRF2 was almost 
exclusively localized in the nucleus in normal, DCIS, and malignant cores. Cores in which no 
primary TRF2 antibody was applied do not show any positive staining (Figure 49A, C, E). 
Normal breast ductal epithelial cells exhibit moderately high levels of TRF2 staining in the 
nucleus (Figure 49B). Out of all the normal breast cores examined, the majority (73.35% ± 
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Figure 49: TRF2 expression in normal, DCIS, and invasive breast carcinomas from tissue 
arrays. Representative images of PBS treated sections of normal (A), DCIS (C), and invasive 
(E) cores. Immunostaining with an antibody against TRF2 shows that it is localized to the 
nucleus of normal (B), and DCIS (D) cores and shows variability in expression in invasive 
cores (F, G). Total numbers of cores stained was n = 113 for normal, n = 56 for DCIS, and n = 
459 for invasive carcinomas. Overall weighted kappa value is 0.5495. All representative 
images shown are at 40x. 
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3.55%) were scored as 2, corresponding to moderate intensity (Table 10). Similarly, the 
greatest proportion of DCIS cores (66.8% ± 4.2%) was also moderately stained in intensity 
(Figure 49D, Table 10). The remainder of the cores for both normal and DCIS tissues could be 
categorized into weakly and strongly staining, but these fractions were considerably smaller 
and thus may represent outliers in the data. 
Unlike normal and DCIS cores, invasive carcinomas show a greater variability in TRF2 
staining, ranging from very low intensity or negative immunoreactivity to strongly reactive 
(Figure 49F, G). Again, the majority of invasive cores were given a score of 2 for moderate 
staining (59% ± 3.65%) (Table 10). It is interesting to note that although moderately intense 
TRF2 expression was seen in the largest proportion of each disease type, this proportion 
decreased with increasing malignancy. Specifically, a smaller fraction of invasive breast 
carcinomas stained moderately intense than normal breast, with DCIS scores falling in the 
middle. Furthermore, out of the three disease types, invasive cores had a greater proportion of 
very weakly expressing TRF2 cores (5.35% ± 1.35%) than both normal (3.45% ± 0.7%) and 
DCIS (0.95% ± 0.4%) specimens. However, invasive cores also had the largest proportion of 
strongly expressing TRF2 cores (12.2% ± 2.85%) relative to normal (9.25% ± 2.3%) and DCIS 
(5.4% ± 1.6%) tissues.  
 
A.2.2 Consistently high levels of nuclear TRF2 in breast and non-breast cell lines.  
In addition to breast tissue, immortalized and cancer cell lines were assessed for TRF2 
expression. Included in duplicate in this array were the breast cancer cell lines MCF7 and 
T47D, the immortalized non-tumorigenic epithelial cell line MCF-10A, prostate cancer cell line 
PC3, and the colon adenocarcinoma HT-29 cell lines. Unlike the variability observed in 
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Table 10: TRF2 nuclear immunostaining 
 Nuclear Score % (stdev) 
Intensity Normal DCIS Invasive Cell Lines 
0 3.45 (0.70) 0.95 (0.40) 5.35 (1.35) 0 
1 14.05 (2.45) 26.8 (3.0) 23.45 (3.85) 0 
2 73.35 (3.55) 66.8 (4.20) 59.0 (3.65) 26.65 (4.45) 
3 9.25 (2.30) 5.4 (1.60) 12.2 (2.85) 73.35 (4.45) 
 
 
 202
invasive breast carcinomas, established cell lines consistently exhibit very intense TRF2  
immunostaining, that is primarily localized in the nucleus (Figure 50). Specifically, the great 
majority of cell lines stains strongly (73.35% ± 4.45%), while only a fraction stain moderately 
intense (26.65% ± 4.45%) (Table 10). Additionally, the frequency of strong TRF2 staining in 
established cell lines is noticeably higher than normal, DCIS, and invasive breast tissue. It is 
striking that none of the cell lines have weak TRF2 expression, indicating that TRF2 may be an 
important growth regulator in established cancer cell lines.  
 
A.2.3 Highly variable FISH signal indicative of nonhomogeneous telomere length. 
 TRF2 has emerged as a major protective protein at the telomere. In pursuance of the 
variability in TRF2 immunostaining, we wanted to determine whether the differences in TRF2 
intensity within breast carcinomas were influenced by telomere length. Fluorescence in situ 
hybridization (FISH) was performed on breast tissue arrays to assess telomere length in normal, 
DCIS, and invasive carcinoma cores. The pantelomeric PNA probe specific for telomeric 
sequences produces multiple, punctate, nuclear hybridization signals. In general, normal cores 
generally had brighter telomeric signal, corresponding to longer telomeres (data not shown). 
Representative results indicate that invasive breast carcinomas displayed a range of telomeric 
signal intensities, with some cores showing intense fluorescence signal and other cores showing 
very weak, but still readily detectable signal, corresponding to short telomeres (Figure 51). 
These invasive carcinomas were found to include both weak (shorter) telomeric signals as well 
as strong (longer) telomeric signals. Telomere length as noted in the surrounding normal 
architecture was generally longer, since FISH signals were consistently larger (Figure 52). 
DCIS cases also seemingly displayed some variability in telomeric signal, but there were fewer  
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Figure 50: Established cell lines consistently express high levels of nuclear TRF2. Control 
cores in each array included breast cancer cell lines MCF7 and T-47D; immortalized epithelial 
cell line MCF-10A; prostate cancer cell line PC-3 (not shown); and colon cancer cell line HT-
29 (not shown). These cores display significantly strong nuclear staining, more so than normal, 
DCIS, or invasive breast carcinomas. Representative images of MCF10A (B) and breast cancer 
cell lines MCF7 (D) and T47D (F) are shown stained with an antibody against TRF2. PBS-
treated MCF10A (A), MCF7 (C), and T47D (E) served as negative controls (no primary 
antibody). Total numbers of cell line cores stained was n = 108. Overall weighted kappa value 
is 0.5495. All images shown are at 40x. 
 204
 
 
A CB D
strong weak DAPImoderate
 
 
Figure 51: Variability in telomeric signal in invasive cores. Invasive breast carcinoma cores 
display varied telomere length, as can be seen by the diversity in intensity of the telomeric 
signal. Since tissues are three-dimensional, there are multiple planes of telomeric signal. (A) 
Representative images of tissue with telomeres longer than normal show strong telomeric 
signal. (B) Tissue with telomeres comparable in size to that of normal cores have moderate 
signal intensity. (C) Tissue with telomeres shorter than that of normal tissue, but are still 
detectable. (D) Low power image of core with DAPI staining. 
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Figure 52: Tumor and surrounding normal tissue express varying telomeric intensity. 
Pantelomeric FISH detects varying telomeric signal between tumor cells and the surrounding 
normal cells within an invasive breast carcinoma core. Representative images show 
undetectable signal in tumor cells with strong signal in normal cells (A); weak signal in tumor 
cells and moderate signal in normal cells (B); moderate signal in tumor cells (C); and strong 
signal in both tumor and normal cells (D).  
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cores staining brightly (data not shown). Taken together with the TRF2 finding, the variability 
of FISH signals in invasive cores is in accordance with the wide distribution of TRF2 intensity 
that was observed with immunostaining. Thus, malignant breast cancers display variable TRF2 
protein expression as well as telomere length.  
  
A.2.4 No difference in TRF2 score, but considerable difference in FISH score. 
  As a group in terms of TRF2 immunostaining, normal cores on average score at 1.8967 
± 0.5897 while DCIS cores score at 1.7685 ± 0.5767 and invasive cores at 1.7806 ± 0.7235 
(Table 11). Based on these observed means, there is no significant difference between the three 
disease types when examining TRF2 expression in the nucleus (p = 0.0810). This finding 
suggests that invasive breast carcinomas more frequently express both very low and very high 
TRF2 levels than normal and DCIS tissues, highlighting the inherent variability of malignant 
breast tissue. Although proportions of weakly, moderately, and strongly staining cores appear 
to appreciably differ between the disease types, there is a lack of any real difference as a 
disease group. 
Although no significant differences emerged between the disease types in terms of 
TRF2 expression, telomeric signal is considerably different as assessed by FISH. Normal breast 
tissue generally displays moderately strong FISH signal (2.2111 ± 0.1981), corresponding to 
telomere lengths characteristically found in normal stroma and mammary epithelial cells (Table 
11). DCIS and invasive carcinomas express relatively weaker telomeric signal, 1.1915 ± 0.47 
and 1.3786 ± 0.2942, respectively, reflecting shorter telomeres. Thus, normal breast tissue 
contains significantly longer telomeres than pre-invasive and malignant breast specimens 
(p<0.0001). 
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Table 11: Average TRF2 immunostaining and FISH scores 
Observed means (s.e.)  
 Normal (n = 113) DCIS (n = 56) Invasive (n = 459) p-value* 
TRF2 1.8967 (0.5897) 1.7685 (0.5737) 1.7806 (0.7235) 0.0810 
FISH 2.2111 (0.1981) 1.1915 (0.4700) 1.3786 (0.2942) <0.0001 
*p<0.05 are significant 
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A.2.5 Age influences TRF2 expression.   
Despite the lack of significant difference in TRF2 expression between all disease types, 
we nevertheless observed great variability in invasive breast carcinomas. Since TRF2 is a tight 
regulator of telomere maintenance, it may be possible that the TRF2 variability in malignant 
tissue reflects alterations in telomere length. In order to address this finding, we wanted to 
determine if TRF2 protein is influenced by chronologic age, which is closely associated with 
telomeric length. As shown in Table 12, no significant correlations emerge between 
chronologic age and TRF2 intensity in invasive breast carcinomas. However, TRF2 expression 
in both normal breast tissue (p<0.0001) and pre-invasive DCIS tissue (p = 0.0017) reveals 
significant positive correlations with age. Additionally, we wanted to determine if the 
variability in invasive cores was impacted by breast cancer stage as designated by TNM 
grading. We do not observe significant correlations between TNM and TRF2 score (p = 
0.7052), suggesting that the degree of malignancy is not associated with TRF2 expression 
(Table 12). 
 
A.2.6 Association of TRF2 and telomere length.   
Although chronologic age at diagnosis does not appear to be a driving factor in TRF2 
expression in invasive cores, physiologic age as assessed by measuring telomere length may 
possibly be more influential. We find that TRF2 negatively correlates with FISH intensity, 
indicating that greater TRF2 expression is associated with weaker FISH signals in invasive 
carcinomas (p = 0.0491, Table 13). As an extension of this finding, we determined that a 
greater FISH signal also significantly correlates with a lower TNM grade (p = 0.0250, Table 
13). When examining chronologic age, no apparent correlations emerge with FISH signal. 
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Table 12: Correlations between chronologic age or TNM stage and 
average TRF2 score  
 Tissue Type Correlation p-value* 
Normal + <0.0001 
DCIS + 0.0017 
Age 
Invasive None 0.8766 
TNM Invasive None 0.7052 
*p<0.05 are significant 
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Table 13: Correlations between TRF2 score or clinical parameters and FISH  
Parameter Tissue Type Correlation p-value* 
TRF2 Invasive - 0.04913 
TNM Invasive - 0.02496 
Normal None 0.6069 
DCIS None 0.254 
Age 
Invasive None 0.6411 
*p<0.05 are significant 
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Thus, telomere length is mainly associated with TRF2 expression and influenced by the cancer 
stage in invasive carcinomas. 
 
A.3 Discussion 
Many telomere-binding proteins are required at the telomere to avoid triggering a DNA 
damage response, since an unfolded telomere could be interpreted as a double strand break. 
TRF2 is part of the shelterin complex and implicated in assisting in the formation of the 
protective t-loop. To study the role of TRF2 in breast cancer progression, tissue microarrays 
were used since they allow for the simultaneous investigation of a large number of tissue 
specimens on a single slide. Although normal, DCIS, and invasive subdivisions are by no 
means an exhaustive grouping of breast cancer types, they closely represent the natural 
progression of this disease. 
The present study confirms that TRF2 is almost exclusively localized in the nucleus. In 
addition to its protective role, the nuclear localization of TRF2 suggests that it may also be 
involved in non-telomeric functions. Bradshaw, et al., 2005 have shown that TRF2 associates 
with irradiation-induced double strand breaks, forming transient foci in these regions. Also, 
Ning, et al, 2006 published data indicating that adriamycin or etoposide treatment had no effect 
on telomere length, but did upregulate TRF2 in gastric cancer cells. 
 Similar to the study by Nijjar, et al., 2005, our study also showed marked nuclear 
staining in normal, DCIS, and invasive breast tissue. However, contrary to their study, the 
results presented here show that TRF2 is not significantly upregulated in DCIS and invasive 
breast carcinomas compared to normal breast tissue. These differences may be due to 
experimental power, since only a few clinical specimens were analyzed and no statistical 
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analyses were included in their study. Our study examined hundreds of cores simultaneously 
and included internal controls within each slide.  
Presently, we found that the majority of normal cores stained moderately intense for 
TRF2, implying that normal breast tissue is associated with more TRF2 protein bound to 
telomeres. The presence of this protein protects telomeres by promoting t-loop formation at 
chromosome ends, thereby avoiding the cellular growth arrest that accompanies a critically 
short telomere. So although normally dividing cells have longer telomeres, it is the telomere 
state that actually regulates senescence onset (Karlseder, 2003). 
A comparison of normal and invasive tissues showed that there were fewer normal 
cores but more invasive cores that exhibited weak TRF2 expression. In other words, invasive 
breast tissue expressed less TRF2 levels relative to normal breast tissue. This finding may be 
reflective of the inherently shorter telomere length in cancer cells. The vast majority of cancer 
cells, including breast cancer, display elevated levels of telomerase due to reactivation of this 
enzyme. Due to this phenomenon, telomeres are maintained in cancer cells, although at shorter 
lengths than normal (Shay and Bacchetti, 1997). Applied to the data presented here, it is 
possible that shorter telomeres provide fewer repeat sequence (TTAGGG) sites for TRF2, and 
so less TRF2 can stably bind in the malignant state (Nijjar, et al., 2005). This working model is 
supported by chromatin immunoprecipitation studies performed in our lab showing less TRF2 
bound at the telomere in cancer cells without exogenous telomerase expression. 
Unlike clinical breast tissue, immortalized and cancer cell lines consistently displayed 
elevated levels of nuclear TRF2 expression. This finding was also observed previously in our 
lab, which showed that immortalized and breast cancer cell lines have increased TRF2 levels as 
analyzed by immunoblotting. The elevated TRF2 expression in this case may reflect an artifact 
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of cultured cell lines. These cells may need to upregulate TRF2 as a protective mechanism to 
ensure continued proliferation under the selective pressures of growing in culture, which breast 
tissue specimens do not experience. 
Since TRF2 is a tight regulator of telomere maintenance, it may be possible that the 
TRF2 variability in malignant tissue reflects alterations in telomere length. Since aging and 
alterations in telomere length are closely related (Aubert and Lansdorp, 2008), we assessed the 
association of TRF2 with chronologic age. We found that TRF2 expression in both normal and 
pre-invasive breast tissue significantly correlates with age. These positive correlations indicate 
that greater TRF2 expression is associated with greater age at diagnosis in benign tissue or less 
aggressive cancers. It is possible that in normal breast cells, more TRF2 is recruited to impart 
telomeric protection in older individuals. In invasive carcinomas, we do not observe any 
significant correlation to chronologic age. However, the observed variability in TRF2 intensity 
in invasive cores could also be due to the heterogeneous nature of malignant breast tissue in 
terms of telomeric or physiologic age. FISH data indicated that normal breast tissue show 
longer telomeres, while invasive carcinomas have generally shorter and varied telomere length. 
This is in agreement with a previous study (Meeker, et al., 2004a) in which invasive and DCIS 
breast tissues displayed variable telomere length. The presence of stronger telomeric signal in 
normal breast tissue and weaker signal in malignant breast tissue is supported by studies 
reporting telomere shortening occurring as part of tumorigenic conversion (Meeker, et al., 
2004a; 2004b).  Our finding that longer telomere lengths in invasive carcinomas as assessed by 
FISH correlates with weaker TRF2 expression suggests that these larger lengths may require 
less stabilization by TRF2. Thus, the weaker TRF2 intensity in this subset of invasive tissue 
may reflect a less protected telomere state, allowing the cell to become more genetically 
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unstable. Furthermore, since TNM stage does not correlate with TRF2 expression, it is possible 
that TRF2 only provides a growth potential or advantage to premalignant and malignant cells 
without imparting any tumorigenic potential. However, we did show that a significant negative 
association exists between TNM stage and FISH signal, such that a greater telomeric signal is 
indicative of a lesser degree of malignancy. 
Collectively, the results presented reflect a model in which TRF2 behaves in a 
differential manner depending on the presence or absence of malignancy. In normal cells or in 
“young” cells, telomeres are generally longer and thus require less TRF2 association for 
protection of the t-loop. However, in invasive carcinomas, TRF2 acts in a bimodal capacity. 
For those cancers that contain longer lengths, less TRF2 is localized to the telomere and may 
provide less protection, predisposing the cell to a malignant state. In contrast, in those cancers 
with shorter telomeres, we find higher TRF2 expression, suggesting that TRF2 may be heavily 
recruited to these sites. These short telomeres may be inducing a damage response such that 
TRF2 attempts to impart more protection. Indeed, telomere-binding proteins, in forming a 
protective cap on telomeres, aid in length regulation and stabilization of the t-loop structure (De 
Boeck et al., 2009).  
In summary, there are clear trends in the data based on degree of malignancy, which 
may ultimately serve as the basis for mechanistic studies of breast cancer progression and the 
role of telomere binding proteins in this process. The importance of telomere-binding proteins 
at the telomere in imparting protection and avoidance of activating a DNA damage response is 
clearly evident, as telomere dysfunction leads to genomic instability and/or transformation. 
Thus, maintenance of telomeric structure and function in part by TRF2 is critically essential in 
cell homeostasis and the evasion of tumorigenesis.  
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